


**CUMULATIVE
SUPPLEMENT 12
December 2011**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 12

December 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	viii
1.7 Cumulative Supplement Legend	ix
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 12
December 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON LABORATORIES INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON RESEARCH LTD (ALCON RES)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
JOHNSON AND JOHNSON PHARMACEUTICAL (JOHNSON AND JOHNSON)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
MCNEIL PEDIATRICS (MCNEIL PED)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)
ORTHO BIOTECH PRODUCTS LP (ORTHO BIOTECH)	JANSSEN PHARMACEUTICALS INC (JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN
PHARMACEUTICAL INC
(ORTHO MCNEIL JANSSEN)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

ORTHO MCNEIL JANSSEN
PHARMACEUTICAL INC
(ORTHO MCNEIL JANSSEN)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

JANSSEN PHARMACEUTICALS INC
(JANSSEN PHARMS)

PADDOCK LABORATORIES INC
(PADDOCK LABS)

PADDOCK LABORATORIES LLC
(PADDOCK LLC)

SHIONOGI PHARMA INC
(SHIONOGI PHARMA)

SHIONOGI INC
(SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001

LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029	14309	14271	14480
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)	2452 (17.2%)	2451 (16.9%)
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)	11743 (82.3%)	11953 (82.5%)
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)	11573 (81.1%)	11792 (81.4%)
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)	170 (1.2%)	161 (1.1%)
EXCEPTIONS ¹	89 (0.6%)	89 (0.6%)	89 (0.6%)	76 (0.5%)	76 (0.5%)
NEW MOLECULAR ENTITIES					
APPROVED	8	6	8	6	6
NUMBER OF APPLICANTS	752	768	784	801	810

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

1-1

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Apr	NEWA
+	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Aug	CAHN

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	STRIDES ARCOLAB LTD	25MG	A090912	001	Jul 27, 2011	Jul	NEWA
AB		50MG	A090912	002	Jul 27, 2011	Jul	NEWA
AB		100MG	A090912	003	Jul 27, 2011	Jul	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

	NEXGEN PHARMA	300MG;50MG	A090956	001	Aug 23, 2011	Aug	NEWA
--	---------------	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
AA		500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB	+	WATSON LABS INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Oct	CAHN
----	---	-----------------	----------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN
----	-------------------	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	@ WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006	Aug	DISC
--	------------------------	-------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001		Aug	DISC
AA	VINTAGE PHARMS	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011	Oct	NEWA

SUSPENSION; ORAL

CAPITAL AND CODEINE

	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001		Aug	DISC
--	------------------------	--------------------	---------	-----	--	-----	------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	+	DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997	Dec	DISC
>A>			@	300MG;15MG	A040223	001	Nov 18, 1997	Dec	DISC
>D>	AA			300MG;30MG	A040223	002	Nov 18, 1997	Dec	DISC
>A>			@	300MG;30MG	A040223	002	Nov 18, 1997	Dec	DISC
>D>	AA			300MG;60MG	A040223	003	Nov 18, 1997	Dec	DISC
>A>			@	300MG;60MG	A040223	003	Nov 18, 1997	Dec	DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	AA	MALLINCKRODT	300MG;15MG	A040419	001	May 31, 2001	Dec	CRLD
>A>	AA	+ MALLINCKRODT INC	300MG;15MG	A040419	001	May 31, 2001	Dec	CRLD
		@ WATSON LABS	300MG;15MG	A089997	001	Dec 28, 1994	Aug	DISC
		@	300MG;30MG	A089998	001	Dec 28, 1994	Aug	DISC
		@	300MG;60MG	A089999	001	Dec 28, 1994	Aug	DISC
		@ WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003	Jul	DISC
		@	300MG;30MG	A040443	002	Jan 22, 2003	Jul	DISC
		@	300MG;60MG	A040443	003	Jan 22, 2003	Jul	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		BOCA PHARMA	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Jul	NEWA
		@ MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003	Nov	DISC
AA	+	MIKART	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Jul	CTEC
AA		NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002	Nov	CAHN

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
AB			300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA
AA			300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
AB			300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA
AA			300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
AB			300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA
AA	+	MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD
AA			300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
AA	+		300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
AA	+		300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC
		@ RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007	May	DISC
		@	500MG;10MG	A040824	001	Aug 16, 2007	May	DISC
		@ RANBAXY LABS LTD	325MG;10MG	A040826	001	Aug 16, 2007	May	DISC
		@	750MG;7.5MG	A040822	001	Aug 16, 2007	May	DISC
		@ WATSON LABS	325MG;10MG	A040248	002	Apr 28, 2000	Nov	DISC
		@	500MG;2.5MG	A040123	003	Mar 04, 1996	Aug	DISC
		@	500MG;7.5MG	A040123	004	Mar 04, 1996	Aug	DISC
		@	650MG;7.5MG	A040123	001	Mar 04, 1996	Aug	DISC
		@	650MG;10MG	A040123	002	Mar 04, 1996	Aug	DISC
		@ WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003	Jul	DISC
		@	750MG;7.5MG	A040494	001	May 28, 2003	Jul	DISC
		LORTAB						
AA		UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

		@ ACTAVIS TOTOWA	500MG;5MG	A040199	001	Dec 30, 1998	Jul	DISC
--	--	------------------	-----------	---------	-----	--------------	-----	------

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

		@ MALLINCKRODT INC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Nov	DISC
--	--	--------------------	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

		@ ACTAVIS TOTOWA	325MG;5MG	A040203	001	Mar 15, 1999	Jul	DISC
--	--	------------------	-----------	---------	-----	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@ MYLAN	650MG;65MG	A083978 001		Aug	DISC
@ VINTAGE PHARMS	650MG;65MG	A040507 001	Jul 30, 2003	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

@ XANODYNE PHARM	650MG;100MG	N017122 002		Jan	DISC
------------------	-------------	-------------	--	-----	------

DARVOCET-N 50

@ XANODYNE PHARM	325MG;50MG	N017122 001		Jan	DISC
------------------	------------	-------------	--	-----	------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@ CORNERSTONE	325MG;100MG	A076743 001	May 07, 2004	Mar	DISC
---------------	-------------	-------------	--------------	-----	------

@	500MG;100MG	A076750 001	Jun 28, 2004	Mar	DISC
---	-------------	-------------	--------------	-----	------

@ MIRROR PHARMS	650MG;100MG	A077821 001	Feb 11, 2008	Apr	DISC
-----------------	-------------	-------------	--------------	-----	------

AB			650MG;100MG	A077821 001	Feb 11, 2008	Mar	CAHN
----	--	--	-------------	-------------	--------------	-----	------

>D>	+	MYLAN	650MG;100MG	A070145 001	Jun 12, 1985	Dec	DISC
-----	---	-------	-------------	-------------	--------------	-----	------

	+		650MG;100MG	A070145 001	Jun 12, 1985	Aug	CRLD
--	---	--	-------------	-------------	--------------	-----	------

>A>		@ MYLAN PHARMS INC	650MG;100MG	A070145 001	Jun 12, 1985	Dec	DISC
-----	--	--------------------	-------------	-------------	--------------	-----	------

		@ TEVA	650MG;100MG	A074119 001	Dec 19, 1994	Mar	DISC
--	--	--------	-------------	-------------	--------------	-----	------

		@ VINTAGE PHARMS	325MG;50MG	A074843 002	Feb 15, 2001	Mar	DISC
--	--	------------------	------------	-------------	--------------	-----	------

		@	650MG;100MG	A074843 001	Feb 12, 1997	Mar	DISC
--	--	---	-------------	-------------	--------------	-----	------

		@ WOCKHARDT LTD	325MG;50MG	A077677 001	Mar 16, 2007	Aug	DISC
--	--	-----------------	------------	-------------	--------------	-----	------

		@	650MG;100MG	A077677 002	Mar 16, 2007	Aug	DISC
--	--	---	-------------	-------------	--------------	-----	------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB		HERITAGE PHARMS INC	500MG	A090779 001	Jul 14, 2011	Oct	CAHN
----	--	---------------------	-------	-------------	--------------	-----	------

AB		INDICUS PHARMA	500MG	A090779 001	Jul 14, 2011	Jul	NEWA
----	--	----------------	-------	-------------	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

@ ACTAVIS MID ATLANTIC	2%	A087146 001		Aug	DISC
------------------------	----	-------------	--	-----	------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+	BAUSCH AND LOMB	20MG/VIAL	N020213 001	Sep 22, 1993	Jun	CAHN
---	-----------------	-----------	-------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ ACTAVIS ELIZABETH	200MG	A074906 001	Aug 26, 1997	Aug	DISC
---------------------	-------	-------------	--------------	-----	------

AB		MYLAN	200MG	A074977 001	Apr 13, 1998	Feb	CAHN
----	--	-------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

ZOVIRAX

+	VALEANT INTL	5%	N021478 001	Dec 30, 2002	Jul	CAHN
---	--------------	----	-------------	--------------	-----	------

OINTMENT; TOPICAL

ZOVIRAX

+	VALEANT INTL	5%	N018604 001	Mar 29, 1982	Jul	CAHN
---	--------------	----	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

	@ ACTAVIS ELIZABETH	400MG	A074870 001	Jun 05, 1997	Aug	DISC
	@	800MG	A074870 002	Jun 05, 1997	Aug	DISC
AB	MYLAN	400MG	A074976 001	Apr 13, 1998	Feb	CAHN
AB		800MG	A074976 002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	+	APP PHARMS	EQ 500MG BASE/VIAL	A075015 001	Apr 30, 1998	Aug	CRLD
		@ HOSPIRA	EQ 25MG BASE/ML	A074720 001	Apr 22, 1997	Aug	DISC
		@	EQ 50MG BASE/ML	A075065 001	Feb 25, 1999	Feb	DISC
>D>	AP	TEVA PARENTERAL	EQ 50MG BASE/ML	A075627 001	Mar 28, 2001	Dec	DISC
>A>		@	EQ 50MG BASE/ML	A075627 001	Mar 28, 2001	Dec	DISC
>D>	AP		EQ 500MG BASE/VIAL	A074969 001	Aug 26, 1997	Dec	DISC
>A>		@	EQ 500MG BASE/VIAL	A074969 001	Aug 26, 1997	Dec	DISC
>D>	AP		EQ 1GM BASE/VIAL	A074969 002	Aug 26, 1997	Dec	DISC
>A>		@	EQ 1GM BASE/VIAL	A074969 002	Aug 26, 1997	Dec	DISC
		ZOVIRAX					
		@ GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N018603 001	Oct 22, 1982	Aug	DISC
		@	EQ 1GM BASE/VIAL	N018603 002	Jun 29, 1989	Aug	DISC

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	MEDA PHARMS	5%;1%	N022436 001	Jul 31, 2009	May	CTNA
+	VALEANT INTL	5%;1%	N022436 001	Jul 31, 2009	Aug	CAHN

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@	BAXTER HLTHCARE	3MG/ML	A076501 001	Jun 16, 2004	Sep	DISC
---	-----------------	--------	-------------	--------------	-----	------

ALBENDAZOLE

TABLET; ORAL

ALBENZA

+	COREPHARMA	200MG	N020666 001	Jun 11, 1996	Jun	CAHN
---	------------	-------	-------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

@	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533 001	Sep 26, 1995	Aug	DISC
AN	RTEDOSE CORP	EQ 0.083% BASE	A077839 001	Dec 16, 2008	Jul	CAHN
AN	WATSON LABS INC	EQ 0.083% BASE	A076370 001	Nov 24, 2003	Aug	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747 001	Oct 07, 2011	Oct	NEWA
---	----------------------	------------------------------	-------------	--------------	-----	------

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+	ALLERGAN	0.25%	N022134 001	Jul 28, 2010	Jun	CAHN
---	----------	-------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

>A>	AB	+	FOUGERA PHARMS	0.05%	N018707 001	Dec 14, 1982	Dec	CAHN
>D>	AB	+	NYCOMED US	0.05%	N018707 001	Dec 14, 1982	Dec	CAHN

OINTMENT; TOPICAL

ACLOVATE

	AB	+	FOUGERA PHARMS	0.05%	N018702 001	Dec 14, 1982	Nov	CAHN
	AB	+	NYCOMED US	0.05%	N018702 001	Dec 14, 1982	Mar	CAHN

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

@ HOSPIRA

5ML/100ML; 5GM/100ML

A083263 001

Aug DISC

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	MYLAN		EQ 35MG BASE	A078638 001	Aug 04, 2008	Feb	CAHN
AB			EQ 70MG BASE	A078638 002	Aug 04, 2008	Feb	CAHN
	@ SANDOZ		EQ 5MG BASE	A075871 001	Apr 22, 2009	Mar	DISC
	@		EQ 10MG BASE	A075871 002	Apr 22, 2009	Mar	DISC
	@		EQ 35MG BASE	A075871 004	Apr 22, 2009	Mar	DISC
	@		EQ 40MG BASE	A075871 003	Apr 22, 2009	Mar	DISC
	@		EQ 70MG BASE	A075871 005	Apr 22, 2009	Mar	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC		10MG	A079013 001	Jul 18, 2011	Jul	NEWA
AB	MYLAN		10MG	A079014 001	Jul 18, 2011	Jul	NEWA
AB	SUN PHARMA GLOBAL		10MG	A079057 001	Jul 18, 2011	Jul	NEWA
AB	TEVA PHARMS		10MG	A079056 001	Jul 18, 2011	Jul	NEWA
AB	TORRENT PHARMS		10MG	A079054 001	Jul 18, 2011	Jul	NEWA
	UROXATRAL						
AB	+	SANOFI AVENTIS US	10MG	N021287 001	Jun 12, 2003	Jul	CFTG

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD		100MG	A090637 001	Mar 16, 2011	Feb	NEWA
AB			300MG	A090637 002	Mar 16, 2011	Feb	NEWA

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

AP	+	MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	N020298 001	May 17, 1996	Jul	CAHN
----	---	---------------------	--------------------	-------------	--------------	-----	------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	ANCHEN PHARMS		0.5MG	A078469 001	Sep 29, 2011	Sep	NEWA
AB			1MG	A078469 002	Sep 29, 2011	Sep	NEWA
AB			2MG	A078469 003	Sep 29, 2011	Sep	NEWA
AB			3MG	A078469 004	Sep 29, 2011	Sep	NEWA

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	AUROBINDO PHARMA USA	0.5MG	A090871 001	Jun 07, 2011	May	NEWA
AB		1MG	A090871 002	Jun 07, 2011	May	NEWA
AB		2MG	A090871 003	Jun 07, 2011	May	NEWA
AB		3MG	A090871 004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

	MEDA PHARMS	0.125MG	N020700 001	Nov 19, 1996	May	CAHN
		0.25MG	N020700 002	Nov 19, 1996	May	CAHN
		0.5MG	N020700 003	Nov 19, 1996	May	CAHN
+		1MG	N020700 004	Nov 19, 1996	May	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A077659 001	Feb 23, 2006	Jul	DISC
---	----------------	-------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	HOSPIRA	EQ 500MG BASE/100ML	A064146 001	Apr 02, 1997	Aug	DISC
---	---------	---------------------	-------------	--------------	-----	------

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 11.4%

@	HOSPIRA	11.4% (11.4GM/100ML)	N017957 003	Aug 09, 1982	Aug	DISC
---	---------	----------------------	-------------	--------------	-----	------

NOVAMINE 15%

@	HOSPIRA	15% (15GM/100ML)	N017957 004	Nov 28, 1986	Aug	DISC
---	---------	------------------	-------------	--------------	-----	------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@	HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;2 05MG/100ML	N019683 001	Nov 07, 1988	Aug	DISC
---	---------	--	-------------	--------------	-----	------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

@	HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N019683 002	Nov 07, 1988	Aug	DISC
---	---------	---	-------------	--------------	-----	------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@	HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N019683 003	Nov 07, 1988	Aug	DISC
---	---------	---	-------------	--------------	-----	------

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

@	HOSPIRA	3.5%;25GM/100ML	N019681 001	Nov 01, 1988	Aug	DISC
---	---------	-----------------	-------------	--------------	-----	------

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	3.5%;5GM/100ML	N019681 002	Nov 01, 1988	Aug	DISC
---	---------	----------------	-------------	--------------	-----	------

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

@	HOSPIRA	4.25%;10GM/100ML	N019681 004	Nov 01, 1988	Aug	DISC
---	---------	------------------	-------------	--------------	-----	------

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

@	HOSPIRA	4.25%;20GM/100ML	N019681 005	Nov 01, 1988	Aug	DISC
---	---------	------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01, 1988	Aug	DISC
-----------	------------------	-------------	--------------	-----	------

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

@ HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988	Aug	DISC
-----------	---------------	-------------	--------------	-----	------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988	Aug	DISC
-----------	---	-------------	--------------	-----	------

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988	Aug	DISC
-----------	--	-------------	--------------	-----	------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

>D>	AP	TEVA PARENTERAL	25MG/ML	A081142 001	Sep 25, 1991	Dec	DISC
>A>		@	25MG/ML	A081142 001	Sep 25, 1991	Dec	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

NEXTERONE

AP	BAXTER HLTHCARE	50MG/ML	N022325 001	Dec 24, 2008	Oct	CAHN
+		150MG/100ML (1.5MG/ML)	N022325 002	Nov 16, 2010	Oct	CAHN
+		360MG/200ML (1.8MG/ML)	N022325 003	Nov 16, 2010	Oct	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552 001	Apr 08, 2009	Apr	CAHN
AB		EQ 5MG BASE	A078552 002	Apr 08, 2009	Apr	CAHN
AB		EQ 10MG BASE	A078552 003	Apr 08, 2009	Apr	CAHN
	@ GEDEON RICHTER USA	EQ 2.5MG BASE	A077333 001	Jul 17, 2007	Jul	DISC
	@	EQ 5MG BASE	A077333 002	Jul 17, 2007	Jul	DISC
	@	EQ 10MG BASE	A077333 003	Jul 17, 2007	Jul	DISC
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007	May	CAHN
AB		EQ 5MG BASE	A078131 002	Sep 04, 2007	May	CAHN
AB		EQ 10MG BASE	A078131 003	Sep 04, 2007	May	CAHN
AB	SECAN PHARMS	EQ 5MG BASE	A090752 001	Apr 15, 2011	Apr	NEWA
AB		EQ 10MG BASE	A090752 002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090149 002	Jul 05, 2011	Jun	NEWA
AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A078466 006	Jul 05, 2011	Jun	NEWA
AB	MYLAN	EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011	Jun	NEWA
AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011	Jun	NEWA

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	TEVA PHARMS	EQ 10MG BASE;40MG	A077179 006	Jul 05, 2011	Jun	NEWA
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090364 002	Jul 05, 2011	Jun	NEWA
LOTREL						
AB	NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
AB	+	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB		500MG	A062058 002		Feb	CDFR

AMOXIL

>A>	AB	DR REDDYS LABS INC	250MG	A062216 001		Dec	CMFD
>A>	AB		500MG	A062216 004		Dec	CMFD
>D>		@ GLAXOSMITHKLINE	250MG	A062216 001		Dec	CMFD
>D>		@	500MG	A062216 004		Dec	CMFD

FOR SUSPENSION; ORAL

AMOXIL

>A>	AB	DR REDDYS LABS INC	50MG/ML	A062226 005		Dec	CMFD
>A>	AB		125MG/5ML	A062226 001		Dec	CMFD
	AB		200MG/5ML	N050760 001	Apr 15, 1999	Sep	CMFD
>A>	AB		250MG/5ML	A062226 002		Dec	CMFD
	AB		400MG/5ML	N050760 002	Apr 15, 1999	Sep	CMFD
>D>		@ GLAXOSMITHKLINE	50MG/ML	A062226 005		Dec	CMFD
>D>		@	125MG/5ML	A062226 001		Dec	CMFD
>D>		@	250MG/5ML	A062226 002		Dec	CMFD

LAROTID

>A>	AB	DR REDDYS LABS INC	250MG/5ML	A062226 004		Dec	CMFD
>D>	AB	GLAXOSMITHKLINE	250MG/5ML	A062226 004		Dec	CMFD

TABLET; ORAL

AMOXIL

AB	DR REDDYS LABS INC	500MG	N050754 002	Jul 10, 1998	Sep	CMFD
AB		875MG	N050754 001	Jul 10, 1998	Sep	CMFD

TABLET, CHEWABLE; ORAL

AMOXIL

AB	DR REDDYS LABS INC	125MG	N050542 002		Sep	CMFD
AB		200MG	N050761 001	Apr 15, 1999	Sep	CMFD
AB		250MG	N050542 001		Sep	CMFD
AB		400MG	N050761 002	Apr 15, 1999	Sep	CMFD

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	SHIONOGI INC	775MG	N050813 001	Jan 23, 2008	Aug	CAHN
---	--------------	-------	-------------	--------------	-----	------

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@ RANBAXY LABS LTD	200MG	A065080 002	Aug 11, 2003	Aug	DISC
	@	400MG	A065080 001	Aug 11, 2003	Aug	DISC

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Feb	NEWA
---	-----------------	--	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '125'

AB	DR REDDYS LABS INC	125MG/5ML;EQ 31.25MG BASE/5ML	N050575 001	Aug 06, 1984	Sep	CAHN
----	--------------------	-------------------------------	-------------	--------------	-----	------

AUGMENTIN '200'

AB	DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725 001	May 31, 1996	Sep	CMFD
----	--------------------	------------------------------	-------------	--------------	-----	------

AUGMENTIN '250'

AB	+ DR REDDYS LABS INC	250MG/5ML;EQ 62.5MG BASE/5ML	N050575 002	Aug 06, 1984	Sep	CAHN
----	----------------------	------------------------------	-------------	--------------	-----	------

AUGMENTIN '400'

AB	DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725 002	May 31, 1996	Sep	CMFD
----	--------------------	----------------------------	-------------	--------------	-----	------

AUGMENTIN ES-600

AB	DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755 001	Jun 22, 2001	Sep	CMFD
----	--------------------	------------------------------	-------------	--------------	-----	------

SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090 001	Dec 20, 2011	Dec	NEWA
-----	----	----------------------	------------------------------	-------------	--------------	-----	------

>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	A201090 002	Dec 20, 2011	Dec	NEWA
-----	----	--	----------------------------	-------------	--------------	-----	------

>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091 001	Dec 20, 2011	Dec	NEWA
-----	----	--	------------------------------	-------------	--------------	-----	------

TABLET; ORAL

AUGMENTIN '250'

AB	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564 001	Aug 06, 1984	Sep	CAHN
----	--------------------	---------------------	-------------	--------------	-----	------

AUGMENTIN '500'

AB	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564 002	Aug 06, 1984	Sep	CAHN
----	--------------------	---------------------	-------------	--------------	-----	------

AUGMENTIN '875'

AB	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996	Sep	CAHN
----	--------------------	---------------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

AB	DR REDDYS LABS INC	125MG;EQ 31.25MG BASE	N050597 001	Jul 22, 1985	Sep	CMFD
----	--------------------	-----------------------	-------------	--------------	-----	------

AUGMENTIN '200'

AB	DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726 001	May 31, 1996	Sep	CMFD
----	--------------------	----------------------	-------------	--------------	-----	------

AUGMENTIN '250'

AB	DR REDDYS LABS INC	250MG;EQ 62.5MG BASE	N050597 002	Jul 22, 1985	Sep	CMFD
----	--------------------	----------------------	-------------	--------------	-----	------

AUGMENTIN '400'

AB	DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726 002	May 31, 1996	Sep	CMFD
----	--------------------	--------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

AB	+ DR REDDYS LABS INC	1GM;EQ 62.5MG BASE	N050785 001	Sep 25, 2002	Sep	CAHN
----	----------------------	--------------------	-------------	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440 001	Oct 07, 2003	Sep	DISC
---	------------------	-----------------------------	-------------	--------------	-----	------

@		1.875MG;1.875MG;1.875MG;1.875MG	A040440 002	Oct 07, 2003	Sep	DISC
---	--	---------------------------------	-------------	--------------	-----	------

@		2.5MG;2.5MG;2.5MG;2.5MG	A040440 003	Oct 07, 2003	Sep	DISC
---	--	-------------------------	-------------	--------------	-----	------

@		3.125MG;3.125MG;3.125MG;3.125MG	A040440 004	Oct 07, 2003	Sep	DISC
---	--	---------------------------------	-------------	--------------	-----	------

@		3.75MG;3.75MG;3.75MG;3.75MG	A040440 005	Oct 07, 2003	Sep	DISC
---	--	-----------------------------	-------------	--------------	-----	------

@		5MG;5MG;5MG;5MG	A040440 006	Oct 07, 2003	Sep	DISC
---	--	-----------------	-------------	--------------	-----	------

@		7.5MG;7.5MG;7.5MG;7.5MG	A040440 007	Oct 07, 2003	Sep	DISC
---	--	-------------------------	-------------	--------------	-----	------

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

>D>	AP	TEVA PARENTERAL	50MG/VIAL	A064062 001	Mar 31, 1995	Dec	DISC
-----	----	-----------------	-----------	-------------	--------------	-----	------

>A>		@	50MG/VIAL	A064062 001	Mar 31, 1995	Dec	DISC
-----	--	---	-----------	-------------	--------------	-----	------

AP	+ X GEN PHARMS	50MG/VIAL	A063206 001	Apr 29, 1992	Jun	CRLD
----	----------------	-----------	-------------	--------------	-----	------

INJECTABLE; INJECTION

FUNGIZONE

@ APOTHECON

50MG/VIAL

A060517 001

Jun DISC

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+ ALDOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996 Jul CAHN

+

100MG/VIAL

N050729 002 Nov 22, 1996 Jul CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP AUROBINDO PHARMA

EQ 1GM BASE/VIAL;EQ 500MG
BASE/VIAL

A090340 001 Sep 20, 2010 Apr CAIN

AP

EQ 1GM BASE/VIAL;EQ 500MG
BASE/VIAL

A090349 001 Sep 20, 2010 Apr CAIN

AP

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

A090340 002 Sep 20, 2010 Apr CAIN

AP

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

A090349 002 Sep 20, 2010 Apr CAIN

AP

EQ 10GM BASE/VIAL;EQ 5GM
BASE/VIAL

A090339 001 Sep 20, 2010 Apr CAIN

>A> AP

HOSPIRA INC

EQ 1GM BASE/VIAL;EQ 500MG
BASE/VIAL

A090653 001 Dec 21, 2011 Dec NEWA

>A> AP

EQ 1GM BASE/VIAL;EQ 500MG
BASE/VIAL

A090375 001 Dec 21, 2011 Dec NEWA

>A> AP

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

A090653 002 Dec 21, 2011 Dec NEWA

>A> AP

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

A090375 002 Dec 21, 2011 Dec NEWA

>A> AP

EQ 10GM BASE/VIAL;EQ 5GM
BASE/VIAL

A090646 001 Dec 21, 2011 Dec NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

DAVA PHARMS INC

EQ 125MG BASE/5ML

A062982 001 Feb 10, 1989 Jul CTEC

PRINCIPEN

@ APOTHECON

EQ 125MG BASE/5ML

A061394 002

Jul DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB SANTOS BIOTECH

1MG

A078944 001 Jun 28, 2010 Feb CAHN

AB

SUN PHARM INDS LTD

1MG

A091177 001 Jul 15, 2011 Jul NEWA

@ SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010 Jul DISC

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+ US WORLDMEDS

30MG/3ML (10MG/ML)

N021264 002 Apr 20, 2004 Nov CAHN

@

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004 Nov CAHN

ARGATROBAN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

+ EAGLE PHARMS

50MG/50ML (1MG/ML)

N022434 001 Jun 29, 2011 Jun NEWA

+ SANDOZ

125MG/125ML (1MG/ML)

N022485 001 May 09, 2011 May NEWA

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

@ SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011 May DISC

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

+	MERCK SHARP DOHME	EQ 10MG BASE	N022117 002	Aug 13, 2009	Aug	CAHN
+	ORGANON USA INC	EQ 10MG BASE	N022117 002	Aug 13, 2009	Nov	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+	WATSON LABS INC	325MG;50MG;40MG	N017534 005	Apr 16, 1986	Oct	CAHN
----	---	-----------------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@	ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710 002	Aug 23, 1983	Aug	DISC
---	-------------------	-----------------	-------------	--------------	-----	------

@	PURACAP PHARM	325MG;50MG;40MG	A087048 002	Dec 09, 1983	Jun	CAHN
---	---------------	-----------------	-------------	--------------	-----	------

FIORINAL

@	WATSON LABS INC	325MG;50MG;40MG	N017534 003	Apr 16, 1986	Oct	CAHN
---	-----------------	-----------------	-------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE

AB	+	WATSON LABS INC	325MG;50MG;40MG;30MG	N019429 003	Oct 26, 1990	Oct	CAHN
----	---	-----------------	----------------------	-------------	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

NORGESIC

>D>	AB	GRACEWAY	385MG;30MG;25MG	N013416 003	Oct 27, 1982	Dec	CAHN
-----	----	----------	-----------------	-------------	--------------	-----	------

>A>	AB	MEDICIS	385MG;30MG;25MG	N013416 003	Oct 27, 1982	Dec	CAHN
-----	----	---------	-----------------	-------------	--------------	-----	------

NORGESIC FORTE

>D>	AB	+	GRACEWAY	770MG;60MG;50MG	N013416 004	Oct 27, 1982	Dec	CAHN
-----	----	---	----------	-----------------	-------------	--------------	-----	------

>A>	AB	+	MEDICIS	770MG;60MG;50MG	N013416 004	Oct 27, 1982	Dec	CAHN
-----	----	---	---------	-----------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	MIRROR PHARMS	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
----	---------------	-------------	-------------	--------------	-----	------

AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN
----	-------------	-------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	MIRROR PHARMS	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
----	---------------	------------------	-------------	--------------	-----	------

AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	-------------	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670 001	Mar 16, 2011	Feb	NEWA
----	----------------	----------------	-------------	--------------	-----	------

AA	WATSON LABS	325MG;4.8355MG	A090084 001	Mar 22, 2011	Mar	NEWA
----	-------------	----------------	-------------	--------------	-----	------

PERCODAN

AA	+	ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005	Feb	CFTG
----	---	-------------	----------------	-------------	--------------	-----	------

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126 003	Aug 26, 1998	Feb	CAHN
----	-------	------	-------------	--------------	-----	------

TABLET; ORAL

ATENOLOL

AB	MYLAN	50MG	A074126 001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126 002	Mar 23, 1994	Feb	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	10MG	A078940 001	Aug 30, 2010	Aug	DISC
@		18MG	A078940 002	Aug 30, 2010	Aug	DISC
@		25MG	A078940 003	Aug 30, 2010	Aug	DISC
@		40MG	A078940 004	Aug 30, 2010	Aug	DISC
@		60MG	A078940 005	Aug 30, 2010	Aug	DISC
@		80MG	A078940 006	Aug 30, 2010	Aug	DISC
@		100MG	A078940 007	Aug 30, 2010	Aug	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	RANBAXY LABS LTD	EQ 10MG BASE	A076477 001	Nov 30, 2011	Nov	NEWA
AB		EQ 20MG BASE	A076477 002	Nov 30, 2011	Nov	NEWA
AB		EQ 40MG BASE	A076477 003	Nov 30, 2011	Nov	NEWA
AB		EQ 80MG BASE	A076477 004	Nov 30, 2011	Nov	NEWA

LIPITOR

AB	PFIZER	EQ 10MG BASE	N020702 001	Dec 17, 1996	Nov	CFTG
AB		EQ 20MG BASE	N020702 002	Dec 17, 1996	Nov	CFTG
AB		EQ 40MG BASE	N020702 003	Dec 17, 1996	Nov	CFTG
AB	+	EQ 80MG BASE	N020702 004	Apr 07, 2000	Nov	CFTG

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA	
	MALARONE						
AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000	Jan	CFTG

ATROPINE

INJECTABLE; INJECTION

ATROPINE

@	SOLVAY	EQ 2MG SULFATE/0.7ML	A071295 001	Jan 30, 1987	Jul	CAHN
---	--------	----------------------	-------------	--------------	-----	------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

@	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677 001	Nov 06, 1991	Oct	DISC
+		0.14MG/ML;10MG/ML	N019678 001	Nov 06, 1991	Oct	CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

@	MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203 001	Oct 15, 2008	Aug	DISC
---	-------------	-----------------------	-------------	--------------	-----	------

>A> AZILSARTAN KAMEDOXOMIL

>A> TABLET; ORAL

>A> EDARBI

>A>	TAKEDA PHARMS	EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011	Dec	CAIN
-----	---------------	-------------------	-------------	--------------	-----	------

>A>	TABLET; ORAL								
>A>	EDARBI								
>A>	+ TAKEDA PHARMS	EQ 80MG MEDOXOMIL		N200796 002	Feb 25, 2011	Dec	CAIN		
>A>	<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE</u>								
>A>	TABLET; ORAL								
>A>	EDARBYCLOR								
>A>	TAKEDA PHARMS	EQ 40MG MEDOXOMIL;12.5MG		N202331 001	Dec 20, 2011	Dec	NEWA		
>A>	+	EQ 40MG MEDOXOMIL;25MG		N202331 002	Dec 20, 2011	Dec	NEWA		
>D>	<u>AZILSARTAN MEDOXOMIL</u>								
>D>	TABLET; ORAL								
>D>	EDARBI								
>D>	TAKEDA PHARMS	40MG		N200796 001	Feb 25, 2011	Dec	CAIN		
		40MG		N200796 001	Feb 25, 2011	Feb	NEWA		
>D>	+	80MG		N200796 002	Feb 25, 2011	Dec	CAIN		
	+	80MG		N200796 002	Feb 25, 2011	Feb	NEWA		
	<u>AZITHROMYCIN</u>								
	TABLET; ORAL								
	AZITHROMYCIN								
AB	APOTEX CORP	EQ 250MG BASE		A065507 001	Jul 13, 2011	Jul	NEWA		
AB		EQ 500MG BASE		A065509 001	Jul 13, 2011	Jul	NEWA		
AB		EQ 600MG BASE		A065508 001	Jul 13, 2011	Jul	NEWA		
	<u>AZTREONAM</u>								
	INJECTABLE; INJECTION								
	AZTREONAM								
AP	BEDFORD	1GM/VIAL		A065286 001	Mar 23, 2011	Mar	NEWA		
AP		2GM/VIAL		A065286 002	Mar 23, 2011	Mar	NEWA		
	<u>BACITRACIN</u>								
	OINTMENT; OPHTHALMIC								
	BACITRACIN								
	+ FERA PHARMS	500 UNITS/GM		A061212 001		Feb	CAHN		
	+ NYCOMED US	500 UNITS/GM		A061212 001		Jan	CAHN		
	<u>BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
	OINTMENT; OPHTHALMIC								
	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC								
AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A060764 002		Feb	CAHN		
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A060764 002		Jan	CAHN		
	<u>BACITRACIN ZINC; POLYMYXIN B SULFATE</u>								
	OINTMENT; OPHTHALMIC								
	BACITRACIN ZINC AND POLYMYXIN B SULFATE								
AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM		A065022 001	Feb 27, 2002	Feb	CAHN		
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM		A065022 001	Feb 27, 2002	Jan	CAHN		
	<u>BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
	OINTMENT; OPHTHALMIC								
	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE								
	+ FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		A062166 002		Feb	CAHN		

ointment; ophthalmic

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jan	CAHN
---	------------	---	-------------	--	-----	------

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	PRINSTON INC	5MG	A076118 001	Feb 11, 2004	Aug	CAHN
AB		10MG	A076118 002	Feb 11, 2004	Aug	CAHN
AB		20MG	A076118 003	Feb 11, 2004	Aug	CAHN
AB		40MG	A076118 004	Feb 11, 2004	Aug	CAHN
AB	PRINSTON PHARM LLC	5MG	A076118 001	Feb 11, 2004	May	CAHN
AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
AB		40MG	A076118 004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007	Nov	CAHN
AA		200MG	A040795 002	Oct 31, 2007	Nov	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>A>	AA	MALLINCKRODT INC	50MG	A040773 001	Apr 25, 2007	Dec	CAHN
>D>	AA	TYCO HLTHCARE	50MG	A040773 001	Apr 25, 2007	Dec	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ ACTAVIS TOTOWA 0.5MG
 @ 1MG
 @ 2MG

A040699 001 Feb 14, 2008 Jul DISC
 A040705 001 Feb 14, 2008 Jul DISC
 A040706 001 Feb 14, 2008 Jul DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB STI PHARMA LLC EQ 0.1% BASE

A070052 001 Jul 31, 1985 Apr CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ ACTAVIS TOTOWA 5MG
 @ 10MG
 @ 25MG

A040552 001 Oct 28, 2004 Jul DISC
 A040553 001 Oct 28, 2004 Jul DISC
 A040554 001 Oct 28, 2004 Jul DISC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB ROXANE 50MG

A078285 001 Mar 24, 2011 Mar NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+ APTALIS PHARMA US 140MG;125MG;125MG
 + AXCAN 140MG;125MG;125MG

N050786 001 Sep 28, 2006 Oct CAHN
 N050786 001 Sep 28, 2006 Jun CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@ ACTAVIS ELIZABETH 2.5MG;6.25MG
 @ 5MG;6.25MG
 @ 10MG;6.25MG

A075672 001 Sep 25, 2000 Oct DISC
 A075672 002 Sep 25, 2000 Oct DISC
 A075672 003 Sep 25, 2000 Oct DISC

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ SCHERING 200MG

N202258 001 May 13, 2011 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ HOSPIRA 50MG/ML

N019030 001 Apr 29, 1986 Jun DISC

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 200MG/100ML
 + 400MG/100ML
 @ HOSPIRA 200MG/100ML
 @ 400MG/100ML

N019121 002 Apr 29, 1986 Aug CTEC
 N019121 003 Apr 29, 1986 Aug CTEC
 N019008 002 Apr 29, 1986 Aug DISC
 N019008 003 Apr 29, 1986 Aug DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

@ TEVA PARENTERAL 0.2%

A076372 001 Sep 10, 2004 Nov DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+	ISTA PHARMS INC	0.09%	N021664 002	Oct 16, 2010	Mar	CRLD
	BROMFENAC SODIUM					
	COASTAL PHARMS	0.09%	A201211 001	May 11, 2011	Apr	NEWA
	XIBROM					
@	ISTA PHARMS INC	0.09%	N021664 001	Mar 24, 2005	Mar	DISC

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB	MYLAN	3MG	A090410 001	May 16, 2011	May	NEWA
	ENTOCORT EC					
AB	+	ASTRAZENECA	3MG	N021324 001	Oct 02, 2001	May CFTG

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

>D>	AP	TEVA PARENTERAL	0.25MG/ML	A074613 001	Nov 18, 1997	Dec	DISC
>A>		@	0.25MG/ML	A074613 001	Nov 18, 1997	Dec	DISC

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011	Oct	NEWA
+		266MG/20ML (13.3MG/ML)	N022496 002	Oct 28, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	SAGENT STRIDES	0.25%	A091503 001	Oct 18, 2011	Oct	NEWA
AP		0.5%	A091503 002	Oct 18, 2011	Oct	NEWA
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	SAGENT STRIDES	0.25%	A091487 002	Oct 18, 2011	Oct	NEWA
AP		0.5%	A091487 001	Oct 18, 2011	Oct	NEWA
AP		0.75%	A091487 003	Oct 18, 2011	Oct	NEWA

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

@	AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496 001	May 23, 2003	Jun	CAHN
---	----------------------	--	-------------	--------------	-----	------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

	VALEANT INTL	174MG	N022108 001	Apr 23, 2008	Jun	CAHN
+		348MG	N022108 002	Apr 23, 2008	Jun	CAHN
		522MG	N022108 003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	ANCHEN PHARMS	100MG	A091459 001	Jun 09, 2011	May	NEWA
-----	---------------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB2	ANCHEN PHARMS	150MG	A091520 001	Jun 09, 2011	May	NEWA
AB1		150MG	A091459 002	Jun 09, 2011	May	NEWA
AB1		200MG	A091459 003	Jun 09, 2011	May	NEWA
AB1	WATSON LABS FLORIDA	100MG	A079095 001	Mar 24, 2009	May	CAHN
AB1		150MG	A079095 002	Mar 24, 2009	May	CAHN
AB2		150MG	A079094 001	Mar 24, 2009	May	CAHN
AB1		200MG	A079095 003	Mar 24, 2009	May	CAHN
FORFIVO XL						
+	INTELGENX CORP	450MG	N022497 001	Nov 10, 2011	Nov	NEWA
WELLBUTRIN XL						
AB3	+ VALEANT INTL	150MG	N021515 001	Aug 28, 2003	Jul	CAHN
AB3		300MG	N021515 002	Aug 28, 2003	Jul	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

@ BRISTOL MYERS SQUIBB 5MG

N018731 001 Sep 29, 1986 Aug DISC

BUSPIRONE HYDROCHLORIDE

@ ACTAVIS TOTOWA 5MG

A075388 001 May 09, 2002 Jul DISC

@ 10MG

A075388 002 May 09, 2002 Jul DISC

@ 15MG

A075388 003 May 09, 2002 Jul DISC

@ 30MG

A078302 001 Dec 17, 2007 Jul DISC

@ IVAX SUB TEVA PHARMS 5MG

A075385 001 Mar 01, 2002 Nov DISC

@ 10MG

A075385 002 Mar 01, 2002 Nov DISC

@ 15MG

A075385 003 Mar 01, 2002 Nov DISC

AB NESHER PHARMS 5MG

A075572 001 Feb 27, 2002 Nov CAHN

AB 10MG

A075572 002 Feb 27, 2002 Nov CAHN

AB 15MG

A075572 003 Feb 27, 2002 Nov CAHN

AB + TEVA 15MG

A075022 003 Feb 28, 2002 Nov CRLD

BUSULFAN

TABLET; ORAL

MYLERAN

+ ASPEN GLOBAL 2MG

N009386 001 Oct CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT G AND W LABS INC 0.005%

A078468 001 Mar 24, 2011 Mar NEWA

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

>D> AP GENIX THERAP 0.001MG/ML

A077102 001 Feb 08, 2006 Dec CAHN

>D> AP LYNE 0.001MG/ML

A076206 001 Sep 17, 2003 Dec CAHN

>A> AP ROCKWELL MEDCL 0.001MG/ML

A076206 001 Sep 17, 2003 Dec CAHN

>A> AP SAGENT PHARMS 0.001MG/ML

A077102 001 Feb 08, 2006 Dec CAHN

>D> AP TEVA PARENTERAL 0.001MG/ML

A075823 001 Mar 31, 2003 Dec DISC

>A> @ 0.001MG/ML

A075823 001 Mar 31, 2003 Dec DISC

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

+ FRESENIUS MEDCL EQ 169MG CALCIUM/5ML

N022581 001 Apr 18, 2011 Apr NEWA

TABLET; ORAL

CALCIUM ACETATE

AB	PADDOCK LABS	EQ 169MG CALCIUM	A091561 001	Apr 13, 2011	Mar	NEWA
ELIPHOS						
AB	+ CYPRESS PHARM	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008	Mar	CTEC

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	PRINSTON INC	12.5MG	A074477 001	Feb 13, 1996	Aug	CAHN
AB		25MG	A074477 002	Feb 13, 1996	Aug	CAHN
AB		50MG	A074477 003	Feb 13, 1996	Aug	CAHN
AB		100MG	A074477 004	Feb 13, 1996	Aug	CAHN
AB	PRINSTON PHARM LLC	12.5MG	A074477 001	Feb 13, 1996	May	CAHN
AB		25MG	A074477 002	Feb 13, 1996	May	CAHN
AB		50MG	A074477 003	Feb 13, 1996	May	CAHN
AB		100MG	A074477 004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	APOTEX INC	100MG	A078986 001	Nov 25, 2011	Nov	NEWA
AB		200MG	A078986 002	Nov 25, 2011	Nov	NEWA
AB		300MG	A078986 003	Nov 25, 2011	Nov	NEWA
AB	NOSTRUM	100MG	A076697 001	May 20, 2011	May	NEWA
AB		200MG	A076697 002	May 20, 2011	May	NEWA
AB		300MG	A076697 003	May 20, 2011	May	NEWA
CARBATROL						
AB	SHIRE	100MG	N020712 003	Sep 30, 1997	May	CFTG
AB		200MG	N020712 001	Sep 30, 1997	May	CFTG
AB	+	300MG	N020712 002	Sep 30, 1997	May	CFTG

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

@ JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988 Jan CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	10MG;100MG	N017555 001		Jan	CAHN
AB		25MG;100MG	N017555 003		Jan	CAHN
AB	+	25MG;250MG	N017555 002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan	CAHN
AB	+	50MG;200MG	N019856 001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

>A>	AA	LYNROSE LABS	4MG	A090756 001	May 27, 2011	Dec	CAHN
>D>	AA	RIVERS EDGE PHARMS	4MG	A090756 001	May 27, 2011	Dec	CAHN
	AA		4MG	A090756 001	May 27, 2011	May	NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ONCO THERAPIES LTD	50MG/5ML (10MG/ML)	A091063 001	Nov 09, 2011	Oct	NEWA
AP		150MG/15ML (10MG/ML)	A091063 002	Nov 09, 2011	Oct	NEWA
AP		450MG/45ML (10MG/ML)	A091063 003	Nov 09, 2011	Oct	NEWA
AP		600MG/60ML (10MG/ML)	A091063 004	Nov 09, 2011	Oct	NEWA
+		1GM/100ML (10MG/ML)	A091478 001	Nov 23, 2011	Nov	NEWA
	@ SAGENT PHARMS	50MG/5ML (10MG/ML)	A077096 001	Jun 14, 2005	Sep	CAHN
	@	150MG/15ML (10MG/ML)	A077096 002	Jun 14, 2005	Sep	CAHN
	@	450MG/45ML (10MG/ML)	A077096 003	Jun 14, 2005	Sep	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar	CAHN
AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN

CEFACLOR

FOR SUSPENSION; ORAL

CEFACLOR

@	FACTA FARMA	EQ 125MG BASE/5ML	A062206 001		Aug	CAHN
@		EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988	Aug	CAHN
@		EQ 250MG BASE/5ML	A062206 002		Aug	CAHN
@		EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

+	TEVA	EQ 500MG BASE	A065058 002	Sep 04, 2002	Jul	CRLD
@	WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan	CAHN
AP	STERI PHARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	Jul	CMFD
AP		EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	Jul	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan	CAHN
		MAXIPIME					
AP	+	HOSPIRA INC	EQ 500MG BASE/VIAL	N050679 001	Jan 18, 1996	Aug	CAHN
AP	+		EQ 1GM BASE/VIAL	N050679 002	Jan 18, 1996	Aug	CAHN
AP	+		EQ 2GM BASE/VIAL	N050679 003	Jan 18, 1996	Aug	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan	CAHN
----	-------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTIONCEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTIONCEFOTETAN

AP	+ APP PHARMS	EQ 1GM BASE/VIAL	A065374 001	Aug 09, 2007	Oct	CTEC
AP	+	EQ 2GM BASE/VIAL	A065374 002	Aug 09, 2007	Oct	CTEC
AP	+	EQ 10GM BASE/VIAL	A065375 001	Aug 09, 2007	Oct	CTEC
AP	WEST-WARD PHARM CORP	EQ 1GM BASE/VIAL	A091031 001	Oct 26, 2011	Oct	NEWA
AP		EQ 2GM BASE/VIAL	A091031 002	Oct 26, 2011	Oct	NEWA
AP		EQ 10GM BASE/VIAL	A091030 001	Oct 26, 2011	Oct	NEWA

CEFOXITININJECTABLE; INJECTIONCEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Aug	NEWA

CEFOXITIN SODIUMINJECTABLE; INJECTIONCEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN
	MEFOXIN					
	@ MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	N050517 001		Aug	CAHN
	@	EQ 2GM BASE/VIAL	N050517 002		Aug	CAHN
	@	EQ 10GM BASE/VIAL	N050517 003		Aug	CAHN

CEFPODOXIME PROXETILTABLET; ORALCEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
	VANTIN					
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTAZIDIMEINJECTABLE; INJECTIONCEFTAZIDIME IN DEXTROSE CONTAINERB BRAUN

+

EQ 1GM BASE

EQ 2GM BASE

N050823 001	Jun 13, 2011	Jun	NEWA
N050823 002	Jun 13, 2011	Jun	NEWA

CEFTRIAXONE SODIUMINJECTABLE; IM-IVCEFTRIAXONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN

INJECTABLE; IM-IV

CEFTRIAXONE

AP	HOSPIRA INC	EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN
----	-------------	------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM LABS LTD	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN
AB	APOTEX	EQ 250MG BASE	A065069 001	Oct 02, 2002	Jun	CAHN
AB		EQ 500MG BASE	A065069 002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	FACTA FARMA	EQ 250MG BASE	A062118 001		Aug	CAHN
AB		EQ 500MG BASE	A062118 002		Aug	CAHN
	KEFLEX					
AB	SHIONOGI INC	EQ 250MG BASE	N050405 002		Aug	CAHN
	@	EQ 333MG BASE	N050405 004	May 12, 2006	Aug	CAHN
AB		EQ 500MG BASE	N050405 003		Aug	CAHN
	+	EQ 750MG BASE	N050405 005	May 12, 2006	Aug	CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Jan	CAHN
	@ FACTA FARMA	EQ 100MG BASE/ML	A062117 001		Aug	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Aug	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Aug	CAHN

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

	@ RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003	Aug	DISC
	@	EQ 250MG BASE	A065100 001	Sep 11, 2003	Aug	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

	@ ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010	Aug	DISC
--	------------------------	---------	-------------	--------------	-----	------

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	PERRIGO R AND D	5MG/5ML	A078398 001	Jun 17, 2008	Aug	CAHN
----	-----------------	---------	-------------	--------------	-----	------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

AB	APOTEX INC	30MG	A091260 001	Aug 25, 2011	Aug	NEWA
----	------------	------	-------------	--------------	-----	------

EVOXAC

AB	+ DAIICHI SANKYO CO	30MG	N020989 002	Jan 11, 2000	Aug	CFTG
----	---------------------	------	-------------	--------------	-----	------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

>A>	+ PBS	2MG	N010669 002		Dec	CAHN
-----	-------	-----	-------------	--	-----	------

>D>	+ SMITHKLINE BEECHAM	2MG	N010669 002		Dec	CAHN
-----	----------------------	-----	-------------	--	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
----	------------------	---------------	-------------	--------------	-----	------

AA		EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA
----	--	---------------	-------------	--------------	-----	------

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011	Jul	NEWA
----	-------------------	--------------------	-------------	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

ZUTRIPRO

	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439 001	Jun 08, 2011	Jun	NEWA
--	-----------------	----------------------------	-------------	--------------	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

>A>	HI-TECH PHARMA CO	EQ 4MG MALEATE; EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007	Dec	CAHN
-----	-------------------	-----------------------------------	-------------	--------------	-----	------

>A>	+	EQ 8MG MALEATE; EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007	Dec	CAHN
-----	---	------------------------------------	-------------	--------------	-----	------

>D>	TYCO HLTHCARE	EQ 4MG MALEATE; EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007	Dec	CAHN
-----	---------------	-----------------------------------	-------------	--------------	-----	------

>D>	+	EQ 8MG MALEATE; EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007	Dec	CAHN
-----	---	------------------------------------	-------------	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ ACTAVIS TOTOWA

250MG

A088928 001	May 08, 1987	Jul	DISC
-------------	--------------	-----	------

@

500MG

A040113 001	Sep 29, 1995	Jul	DISC
-------------	--------------	-----	------

@ OHM LABS

250MG

A081298 001	Dec 29, 1993	Aug	DISC
-------------	--------------	-----	------

@

500MG

A081299 001	Dec 29, 1993	Aug	DISC
-------------	--------------	-----	------

PARAFON FORTE DSC

>D>	AA	+ JANSSEN PHARMS	500MG	N011529 002	Jun 15, 1987	Dec	CAHN
-----	----	------------------	-------	-------------	--------------	-----	------

>A>	AA	+ JANSSEN R AND D	500MG	N011529 002	Jun 15, 1987	Dec	CAHN
-----	----	-------------------	-------	-------------	--------------	-----	------

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
CHOLESTYRAMINE LIGHT							
AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
QUESTRAN							
		@ BRISTOL MYERS	EQ 4GM RESIN/SCOOPFUL	N016640 003		Apr	DISC
		@	EQ 4GM RESIN/PACKET	N016640 001		Apr	DISC
QUESTRAN LIGHT							
		@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
		@	EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
AB	+		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT		TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	--	------	----	-------------	--------------	-----	------

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

IMIPENEM AND CILASTATIN

>A>	AP	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A090577 001	Dec 21, 2011	Dec	NEWA
>A>	AP		EQ 500MG BASE/VIAL;500MG/VIAL	A090577 002	Dec 21, 2011	Dec	NEWA
	AP	HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825 001	Nov 16, 2011	Nov	NEWA
	AP		EQ 500MG BASE/VIAL;500MG/VIAL	A090825 002	Nov 16, 2011	Nov	NEWA
	AP		EQ 500MG BASE/VIAL;500MG/VIAL	A091007 001	Nov 16, 2011	Nov	NEWA
PRIMAXIN							
>D>		MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756 001	Jan 08, 1987	Dec	CTEC
>A>	AP		EQ 250MG BASE/VIAL;250MG/VIAL	A062756 001	Jan 08, 1987	Dec	CTEC
	AP	+	EQ 250MG BASE/VIAL;250MG/VIAL	N050587 001	Nov 26, 1985	Nov	CFTG
>D>			EQ 500MG BASE/VIAL;500MG/VIAL	N050630 001	Dec 14, 1990	Dec	CTEC
>D>			EQ 500MG BASE/VIAL;500MG/VIAL	A062756 002	Jan 08, 1987	Dec	CTEC
>A>	AP		EQ 500MG BASE/VIAL;500MG/VIAL	N050630 001	Dec 14, 1990	Dec	CTEC
>A>	AP		EQ 500MG BASE/VIAL;500MG/VIAL	A062756 002	Jan 08, 1987	Dec	CTEC
	AP	+	EQ 500MG BASE/VIAL;500MG/VIAL	N050587 002	Nov 26, 1985	Nov	CFTG

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

		@ ACTAVIS TOTOWA	100MG	A077028 002	Nov 26, 2004	Jul	DISC
--	--	------------------	-------	-------------	--------------	-----	------

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

>D>	AP	TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997	Dec	DISC
>A>		@	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997	Dec	DISC
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		@ HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994	Aug	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

		@ TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008	Aug	DISC
		@	400MG/200ML	A077138 002	Mar 18, 2008	Aug	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

@ DEPOMED INC

EQ 500MG BASE

N021744 001 May 19, 2005 May DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE

A078166 002 Nov 27, 2007 Jun CMFD

AB 425.2MG;EQ 574.9MG BASE

A078166 001 Nov 27, 2007 Jun CMFD

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@ BRISTOL MYERS

50MG/VIAL

N018057 002

Jun DISC

@ CORDEN PHARMA

10MG/VIAL

N018057 001

Oct CAHN

@

50MG/VIAL

N018057 002

Oct CAHN

PLATINOL-AQ

@ CORDEN PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984 Oct CAHN

@

1MG/ML

N018057 004 Nov 08, 1988 Oct CAHN

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB MYLAN EQ 10MG BASE

A077042 001 Nov 05, 2004 Apr CAHN

AB EQ 20MG BASE

A077042 002 Nov 05, 2004 Apr CAHN

AB EQ 40MG BASE

A077042 003 Nov 05, 2004 Apr CAHN

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP ONCO THERAPIES LTD 1MG/ML

A200510 001 Oct 06, 2011 Sep NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

@ ACTAVIS MID ATLANTIC EQ 0.5MG BASE/5ML

A074075 001 Oct 31, 1993 Aug DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB MATRIX LABS LTD EQ 75MG BASE

A091225 001 May 31, 2011 May NEWA

AB EQ 150MG BASE

A091225 002 May 31, 2011 May NEWA

AB EQ 300MG BASE

A091225 003 May 31, 2011 May NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT + GALDERMA LABS LP EQ 1% BASE

N050782 001 Nov 27, 2000 Mar CRLD

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP SAGENT STRIDES EQ 150MG BASE/ML

A090108 001 Sep 30, 2011 Sep NEWA

AP EQ 150MG BASE/ML

A090109 001 Sep 30, 2011 Sep NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ ACTAVIS MID ATLANTIC EQ 1% BASE

A062811 001 Sep 01, 1988 Aug DISC

@ COREPHARMA EQ 1% BASE

A064108 001 Sep 27, 1996 Apr CAHN

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK INC

5MG

N202067 001 Oct 21, 2011 Oct NEWA

10MG

N202067 002 Oct 21, 2011 Oct NEWA

+

20MG

N202067 003 Oct 21, 2011 Oct NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX

AB + STIEFEL LABS INC 0.05%

N021142 001 May 26, 2000 May CAHN

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC 0.05%

A074139 001 Aug 03, 1994 Aug DISC

@ COREPHARMA 0.05%

A075338 001 Feb 09, 2001 Apr CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

@ COREPHARMA 0.05%

A075733 001 Aug 22, 2001 Apr CAHN

TEMOVATE

AB1 + NYCOMED US 0.05%

N019322 001 Dec 27, 1985 Aug CAHN

TEMOVATE E

>D> AB2 + ALTANA 0.05%

N020340 001 Jun 17, 1994 Dec CAHN

>A> AB2 + FOUGERA PHARMS 0.05%

N020340 001 Jun 17, 1994 Dec CAHN

GEL; TOPICAL

TEMOVATE

AB + NYCOMED US 0.05%

N020337 001 Apr 29, 1994 Aug CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC 0.05%

A074128 001 Aug 03, 1994 Aug DISC

@ COREPHARMA 0.05%

A075057 001 Aug 12, 1998 Apr CAHN

TEMOVATE

AB + NYCOMED US 0.05%

N019323 001 Dec 27, 1985 Aug CAHN

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB ACTAVIS MID ATLANTIC 0.05%

A078854 001 Jun 07, 2011 May NEWA

CLOBEX

AB + GALDERMA LABS 0.05%

N021644 001 Feb 05, 2004 May CFTG

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

@ ACTAVIS MID ATLANTIC 0.05%

A074331 001 Dec 15, 1995 Aug DISC

AT NYCOMED US 0.05%

A075391 001 Feb 08, 1999 Apr CAHN

TEMOVATE

AT + NYCOMED US 0.05%

N019966 001 Feb 22, 1990 Aug CAHN

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT PADDOCK LABS 0.05%

A090898 001 Jun 16, 2011 May NEWA

CLOBEX

AT + GALDERMA LABS LP 0.05%

N021835 001 Oct 27, 2005 Jun CTEC

+

0.05%

N021835 001 Oct 27, 2005 May CFTG

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+	PROMIUS PHARMA LLC	0.1%	N017765 001			Jun	CAHN
---	--------------------	------	-------------	--	--	-----	------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	MALLINCKRODT LLC	25MG	N019906 001	Dec 29, 1989	Aug	CAHN
AB	+	50MG	N019906 002	Dec 29, 1989	Aug	CAHN
AB		75MG	N019906 003	Dec 29, 1989	Aug	CAHN

CLONIDINE

SUSPENSION, EXTENDED RELEASE; ORAL

CLONIDINE

@	TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499 001	Dec 03, 2009	Sep	DISC
---	-----------------	-------------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE

@	TRIS PHARMA INC	EQ 0.17MG BASE	N022500 001	Dec 03, 2009	Sep	DISC
---	-----------------	----------------	-------------	--------------	-----	------

@		EQ 0.26MG BASE	N022500 002	Dec 03, 2009	Sep	DISC
---	--	----------------	-------------	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	APP PHARMS	1MG/10ML (0.1MG/ML)	A200673 001	Jul 08, 2011	Jun	NEWA
AP		5MG/10ML (0.5MG/ML)	A200673 002	Jul 08, 2011	Jun	NEWA
AP	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300 001	Jan 26, 2011	Jul	CAHN
AP		5MG/10ML (0.5MG/ML)	A200300 002	Jan 26, 2011	Jul	CAHN
AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300 001	Jan 26, 2011	Jan	NEWA
AP		5MG/10ML (0.5MG/ML)	A200300 002	Jan 26, 2011	Jan	NEWA

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	0.1MG	A091368 001	Dec 06, 2011	Nov	NEWA
AB		0.2MG	A091368 002	Dec 06, 2011	Nov	NEWA
AB		0.3MG	A091368 003	Dec 06, 2011	Nov	NEWA

TABLET, EXTENDED RELEASE; ORAL

JENLOGA

@	SHIONOGI INC	0.1MG	N022331 001	Sep 30, 2009	Nov	DISC
---	--------------	-------	-------------	--------------	-----	------

@		0.2MG	N022331 002	May 25, 2010	Nov	DISC
---	--	-------	-------------	--------------	-----	------

KAPVAY

+	SHIONOGI INC	0.1MG	N022331 003	Sep 28, 2010	Nov	CRLD
---	--------------	-------	-------------	--------------	-----	------

@		0.2MG	N022331 004	Sep 28, 2010	Nov	DISC
---	--	-------	-------------	--------------	-----	------

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+	ROXANE	30MG/5ML	N202245 001	Jun 30, 2011	Jun	NEWA
---	--------	----------	-------------	--------------	-----	------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	MIRROR PHARMS	0.5MG;500MG	A040618 001	May 13, 2008	Mar	CAHN
----	---------------	-------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN

AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750 001		Jun	CAHN
----	---	----------------------	-------------	-------------	--	-----	------

CRIZOTINIB

CAPSULE; ORAL
XALKORI

		PFIZER	200MG	N202570 001	Aug 26, 2011	Aug	NEWA
	+		250MG	N202570 002	Aug 26, 2011	Aug	NEWA

CROMOLYN SODIUM

CONCENTRATE; ORAL
CROMOLYN SODIUM

AA		PACK PHARMS LLC	100MG/5ML	A202583 001	Oct 27, 2011	Oct	NEWA
----	--	-----------------	-----------	-------------	--------------	-----	------

AA	+	ASTROPHARMA	100MG/5ML	N020479 001	Feb 29, 1996	Oct	CTEC
----	---	-------------	-----------	-------------	--------------	-----	------

SOLUTION; INHALATION
CROMOLYN SODIUM

	@	ACTAVIS MID ATLANTIC	10MG/ML	A075067 001	Jul 19, 1999	Aug	DISC
--	---	----------------------	---------	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
AMRIX

AB		ANESTA AG	15MG	N021777 001	Feb 01, 2007	Apr	CFTG
AB	+		30MG	N021777 002	Feb 01, 2007	Apr	CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN	15MG	A090738 001	Apr 18, 2011	Apr	NEWA
AB			30MG	A090738 002	Apr 18, 2011	Apr	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		JUBILANT CADISTA	5MG	A077563 001	Apr 19, 2006	Jan	CAHN
AB			10MG	A077563 002	Apr 19, 2006	Jan	CAHN
AB		KVK TECH	5MG	A078048 001	Feb 28, 2011	Feb	NEWA
AB			10MG	A078048 002	Feb 28, 2011	Feb	NEWA
AB		PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209 001	Oct 04, 2005	Feb	CAHN

FLEXERIL

>D>	AB	JANSSEN PHARMS	5MG	N017821 001		Dec	CAHN
>D>	AB	+	10MG	N017821 002		Dec	CAHN
>A>	AB	JANSSEN R AND D	5MG	N017821 001		Dec	CAHN
>A>	AB	+	10MG	N017821 002		Dec	CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

AP	+	BAXTER HLTHCARE	500MG/VIAL	A040745 001	May 21, 2008	Aug	CRLD
AP	+		1GM/VIAL	A040745 002	May 21, 2008	Aug	CRLD
AP	+		2GM/VIAL	A040745 003	May 21, 2008	Aug	CRLD

CYTOXAN

AP		BAXTER HLTHCARE	500MG/VIAL	N012142 003		Aug	CRLD
AP			1GM/VIAL	N012142 004	Aug 30, 1982	Aug	CRLD
AP			2GM/VIAL	N012142 005	Aug 30, 1982	Aug	CRLD

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	ONCO THERAPIES LTD	20MG/ML	A200916 001	Dec 13, 2011	Nov	NEWA
AP		20MG/ML	A200915 001	Dec 13, 2011	Nov	NEWA
AP		20MG/ML	A200914 001	Dec 13, 2011	Nov	NEWA

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

@	ACTAVIS TOTOWA	25MG	A076686 001	Oct 24, 2005	Jul	DISC
@		50MG	A076686 002	Oct 24, 2005	Jul	DISC
@		100MG	A076686 003	Oct 24, 2005	Jul	DISC

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

REV-EYES

@	FERA PHARMS	0.5%	N019849 001	Dec 31, 1990	Oct	CAHN
---	-------------	------	-------------	--------------	-----	------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513 001	Dec 22, 2004	May	CAHN
+		EQ 15MG BASE	N021513 002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

>A> SUSPENSION; ORAL

>A> PREZISTA

>A>	+	TIBOTEC	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011	Dec	NEWA
-----	---	---------	------------------	-------------	--------------	-----	------

TABLET; ORAL

PREZISTA

@	TIBOTEC	EQ 300MG BASE	N021976 001	Jun 23, 2006	May	DISC
---	---------	---------------	-------------	--------------	-----	------

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

+	GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996	Jun	CAHN
---	------------	----------------	-------------	--------------	-----	------

DEFERIPRONE

TABLET; ORAL

FERRIPROX

+	AOPHARMA INC	500MG	N021825 001	Oct 14, 2011	Oct	NEWA
---	--------------	-------	-------------	--------------	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@	COREPHARMA	75MG	N050261 001		May	CAHN
---	------------	------	-------------	--	-----	------

AB		150MG	N050261 002		May	CAHN
----	--	-------	-------------	--	-----	------

AB	+	300MG	N050261 003		May	CAHN
----	---	-------	-------------	--	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

AB	VERSAPHARM	150MG	A065389 001	Dec 01, 2008	May	CAHN
----	------------	-------	-------------	--------------	-----	------

AB		300MG	A065389 002	Dec 01, 2008	May	CAHN
----	--	-------	-------------	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	50MG	A071588	001	Jun 05, 1987	Aug	CAHN
----	----------------	------	---------	-----	--------------	-----	------

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB	DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA
>A> AB	PERRIGO R AND D	5MG	A078361	001	Dec 22, 2011	Dec	NEWA

DESLOMATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG
----	---	----------	-----------	---------	-----	--------------	-----	------

DESLOMATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB	DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA
----	--------------------	-----------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE

	@ CSL BEHRING	0.15MG/SPRAY	N020355	001	Mar 07, 1994	May	DISC
--	---------------	--------------	---------	-----	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA
----	---------	---------------	---------	-----	--------------	-----	------

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA
----	------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

TOPICORT

+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	May	CMFD
---	-------------------	-------	---------	-----	--------------	-----	------

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
----	------	-----------	---------	-----	--------------	-----	------

AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

DEXAMETHASONE

BP	PAR PHARM	0.5MG	A088148	001	Apr 28, 1983	Aug	CMFD
BP		0.75MG	A088160	001	Apr 28, 1983	Aug	CMFD
BP		1.5MG	A088237	001	Apr 28, 1983	Aug	CMFD
BP		4MG	A088238	001	Apr 28, 1983	Aug	CMFD
BP	+	6MG	A088481	001	Nov 28, 1983	Sep	CRLD
BP		6MG	A088481	001	Nov 28, 1983	Aug	CMFD
BP	ROXANE	0.5MG	A084611	001		Aug	CTEC
BP		0.75MG	A084613	001		Aug	CTEC
BP		1MG	A088306	001	Sep 15, 1983	Aug	CTEC
BP		2MG	A087916	001	Aug 26, 1982	Aug	CTEC
BP		4MG	A084612	001		Aug	CTEC
BP	+	6MG	A088316	001	Sep 15, 1983	Aug	CTEC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	PFIZER	EQ 4MG PHOSPHATE/ML	A040803 001	Aug 29, 2008	May	CAHN
AP		EQ 10MG PHOSPHATE/ML	A040802 001	Aug 29, 2008	May	CAHN
	@ TEVA PARENTERAL	EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990	Aug	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989	Jan	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

NOVARTIS

25MG

N021802 008 Apr 21, 2011 May NEWA

35MG

N021802 007 Apr 21, 2011 May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	EQ 250MG BASE/VIAL	A200752 001	Oct 19, 2011	Oct	NEWA
AP		EQ 500MG BASE/VIAL	A200752 002	Oct 19, 2011	Oct	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	COREPHARMA	5MG	N017078 001		Jun	CAHN
AB		10MG	N017078 002		Jun	CAHN
AB	+	15MG	N017078 003		Jun	CAHN

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

MIKART

2.5MG

A090533 001 Oct 25, 2011 Oct NEWA

AA		5MG	A090533 002	Oct 25, 2011	Oct	NEWA
		7.5MG	A090533 003	Oct 25, 2011	Oct	NEWA
AA		10MG	A090533 004	Oct 25, 2011	Oct	NEWA
		15MG	A090533 005	Oct 25, 2011	Oct	NEWA
		20MG	A090533 006	Oct 25, 2011	Oct	NEWA
		30MG	A090533 007	Oct 25, 2011	Oct	NEWA
AA	NESHER PHARMS	5MG	A040365 001	Oct 31, 2002	Nov	CAHN
AA		10MG	A040367 001	Oct 31, 2002	Nov	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575 001	Feb 08, 2011	Jan	NEWA
----	---------------	---------------------	-------------	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634 004		Jun	CAHN
----	-----------------	----------------------	-------------	--	-----	------

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER									
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001					Jun	CAHN
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER									
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003					Jun	CAHN
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER									
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002					Jun	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 5GM/100ML;111MG/100ML;256MG/100ML N019514 001 May 08, 1986 Aug DISC
;146MG/100ML;207MG/100ML

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@ ACTAVIS ELIZABETH 2MG A070781 001 Mar 19, 1986 Aug DISC
@ 5MG A070706 001 Mar 19, 1986 Aug DISC
@ 10MG A070707 001 Mar 19, 1986 Aug DISC

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ FOUGERA PHARMS 3% N021005 001 Oct 16, 2000 Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB VALEANT INTL 100MG A075492 001 Feb 11, 2000 Apr CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

AB + APTALIS PHARMA US 10MG N007409 003 Oct 15, 1984 Oct CAHN

INJECTABLE; INJECTION

BENTYL

AP + APTALIS PHARMA US 10MG/ML N008370 001 Oct 15, 1984 Oct CAHN

BENTYL PRESERVATIVE FREE

AP + APTALIS PHARMA US 10MG/ML N008370 002 Oct 15, 1984 Oct CAHN

SYRUP; ORAL

BENTYL

AA + APTALIS PHARMA US 10MG/5ML N007961 002 Oct 15, 1984 Oct CAHN

TABLET; ORAL

BENTYL

AB + APTALIS PHARMA US 20MG N007409 001 Oct 15, 1984 Oct CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA LANNETT HOLDINGS INC 25MG A200177 001 Jul 18, 2011 Jul NEWA

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

AB LANNETT HOLDINGS INC 75MG A091680 001 Oct 24, 2011 Oct NEWA

TENUATE DOSPAN

AB + WATSON PHARMS 75MG N012546 001 Oct CFTG

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

+	ALCON PHARMS LTD	0.05%	N022212 001	Jun 23, 2008	May	CAHN
---	------------------	-------	-------------	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

LANOXIN

>A>	AP	+	COVIS PHARMA	0.25MG/ML	N009330 002		Dec	CAHN
-----	----	---	--------------	-----------	-------------	--	-----	------

>D>	AP	+	GLAXOSMITHKLINE LLC	0.25MG/ML	N009330 002		Dec	CAHN
-----	----	---	---------------------	-----------	-------------	--	-----	------

LANOXIN PEDIATRIC

>A>		+	COVIS PHARMA	0.1MG/ML	N009330 004		Dec	CAHN
-----	--	---	--------------	----------	-------------	--	-----	------

>D>		+	GLAXOSMITHKLINE LLC	0.1MG/ML	N009330 004		Dec	CAHN
-----	--	---	---------------------	----------	-------------	--	-----	------

TABLET; ORAL

DIGOXIN

@	ACTAVIS TOTOWA	0.125MG	A040282 001	Dec 23, 1999	Jul	DISC
---	----------------	---------	-------------	--------------	-----	------

@		0.25MG	A040282 002	Dec 23, 1999	Jul	DISC
---	--	--------	-------------	--------------	-----	------

LANOXIN

>A>		@	COVIS PHARMA	0.0625MG	N020405 001	Sep 30, 1997	Dec	CAHN
-----	--	---	--------------	----------	-------------	--------------	-----	------

>A>	AB			0.125MG	N020405 002	Sep 30, 1997	Dec	CAHN
-----	----	--	--	---------	-------------	--------------	-----	------

>A>		@		0.1875MG	N020405 003	Sep 30, 1997	Dec	CAHN
-----	--	---	--	----------	-------------	--------------	-----	------

>A>	AB	+		0.25MG	N020405 004	Sep 30, 1997	Dec	CAHN
-----	----	---	--	--------	-------------	--------------	-----	------

>A>		@		0.375MG	N020405 005	Sep 30, 1997	Dec	CAHN
-----	--	---	--	---------	-------------	--------------	-----	------

>A>		@		0.5MG	N020405 006	Sep 30, 1997	Dec	CAHN
-----	--	---	--	-------	-------------	--------------	-----	------

>D>		@	SMITHKLINE BEECHAM	0.0625MG	N020405 001	Sep 30, 1997	Dec	CAHN
-----	--	---	--------------------	----------	-------------	--------------	-----	------

>D>	AB			0.125MG	N020405 002	Sep 30, 1997	Dec	CAHN
-----	----	--	--	---------	-------------	--------------	-----	------

>D>		@		0.1875MG	N020405 003	Sep 30, 1997	Dec	CAHN
-----	--	---	--	----------	-------------	--------------	-----	------

>D>	AB	+		0.25MG	N020405 004	Sep 30, 1997	Dec	CAHN
-----	----	---	--	--------	-------------	--------------	-----	------

>D>		@		0.375MG	N020405 005	Sep 30, 1997	Dec	CAHN
-----	--	---	--	---------	-------------	--------------	-----	------

>D>		@		0.5MG	N020405 006	Sep 30, 1997	Dec	CAHN
-----	--	---	--	-------	-------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

AB3		VALEANT INTL	120MG	N020062 001	Aug 10, 1992	Jun	CAHN
-----	--	--------------	-------	-------------	--------------	-----	------

AB3			180MG	N020062 002	Dec 27, 1991	Jun	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB3			240MG	N020062 003	Dec 27, 1991	Jun	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB3			300MG	N020062 004	Dec 27, 1991	Oct	CRLD
-----	--	--	-------	-------------	--------------	-----	------

AB3	+		300MG	N020062 004	Dec 27, 1991	Jun	CAHN
-----	---	--	-------	-------------	--------------	-----	------

AB3	+		360MG	N020062 005	Aug 24, 1999	Oct	CTEC
-----	---	--	-------	-------------	--------------	-----	------

BC	+		360MG	N020062 005	Aug 24, 1999	Jun	CAHN
----	---	--	-------	-------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

AB4		NESHER PHARMS	120MG	A076563 002	Sep 12, 2006	Nov	CAHN
-----	--	---------------	-------	-------------	--------------	-----	------

AB4			180MG	A076563 003	Sep 12, 2006	Nov	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			240MG	A076563 004	Sep 12, 2006	Nov	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			300MG	A076563 005	Sep 12, 2006	Nov	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB4			360MG	A076563 006	Sep 12, 2006	Nov	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB3		SUN PHARMA GLOBAL	120MG	A090492 001	Oct 28, 2011	Oct	NEWA
-----	--	-------------------	-------	-------------	--------------	-----	------

AB3			180MG	A090492 002	Oct 28, 2011	Oct	NEWA
-----	--	--	-------	-------------	--------------	-----	------

AB3			240MG	A090492 003	Oct 28, 2011	Oct	NEWA
-----	--	--	-------	-------------	--------------	-----	------

AB3			300MG	A090492 004	Oct 28, 2011	Oct	NEWA
-----	--	--	-------	-------------	--------------	-----	------

AB3			360MG	A090492 005	Oct 28, 2011	Oct	NEWA
-----	--	--	-------	-------------	--------------	-----	------

AB3		VALEANT INTL	120MG	A075116 001	Dec 23, 1999	Apr	CAHN
-----	--	--------------	-------	-------------	--------------	-----	------

AB3			180MG	A075116 002	Dec 23, 1999	Apr	CAHN
-----	--	--	-------	-------------	--------------	-----	------

AB3			240MG	A075116 003	Dec 23, 1999	Apr	CAHN
-----	--	--	-------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL						
DILTIAZEM HYDROCHLORIDE						
AB3	VALEANT INTL	300MG	A075116	004	Dec 23, 1999	Apr CAHN
TIAZAC						
AB4	VALEANT INTL	120MG	N020401	001	Sep 11, 1995	Jun CAHN
AB4		180MG	N020401	002	Sep 11, 1995	Jun CAHN
AB4		240MG	N020401	003	Sep 11, 1995	Jun CAHN
AB4		300MG	N020401	004	Sep 11, 1995	Jun CAHN
AB4		360MG	N020401	005	Sep 11, 1995	Jun CAHN
AB4	+	420MG	N020401	006	Oct 16, 1998	Jun CAHN
TABLET; ORAL						
CARDIZEM						
AB	VALEANT INTL	30MG	N018602	001	Nov 05, 1982	Jun CAHN
AB		60MG	N018602	002	Nov 05, 1982	Jun CAHN
AB		90MG	N018602	003	Dec 08, 1986	Jun CAHN
AB	+	120MG	N018602	004	Dec 08, 1986	Jun CAHN
DILTIAZEM HYDROCHLORIDE						
AB	MYLAN	30MG	A072838	004	Nov 05, 1992	Aug CMS1
AB		60MG	A072838	003	Nov 05, 1992	Aug CMS1
AB		90MG	A072838	002	Nov 05, 1992	Aug CMS1
TABLET, EXTENDED RELEASE; ORAL						
CARDIZEM LA						
AB	VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Jun CAHN
AB		180MG	N021392	002	Feb 06, 2003	Jun CAHN
AB		240MG	N021392	003	Feb 06, 2003	Jun CAHN
AB		300MG	N021392	004	Feb 06, 2003	Jun CAHN
AB		360MG	N021392	005	Feb 06, 2003	Jun CAHN
AB	+	420MG	N021392	006	Feb 06, 2003	Jun CAHN
<u>DIPYRIDAMOLE</u>						
INJECTABLE; INJECTION						
DIPYRIDAMOLE						
	@ HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997	Aug DISC
TABLET; ORAL						
DIPYRIDAMOLE						
AB	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb CAHN
AB		50MG	A040542	002	Apr 21, 2006	Feb CAHN
AB		75MG	A040542	003	Apr 21, 2006	Feb CAHN
<u>DISOPYRAMIDE PHOSPHATE</u>						
CAPSULE, EXTENDED RELEASE; ORAL						
DISOPYRAMIDE PHOSPHATE						
AB	NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987	Nov CAHN
<u>DISULFIRAM</u>						
TABLET; ORAL						
ANTABUSE						
AB	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar CTEC
AB	+	500MG	A088483	001	Dec 08, 1983	Mar CTEC
DISULFIRAM						
AB	SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar NEWA
AB		500MG	A091619	002	Mar 28, 2011	Mar NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	A090407 001	Mar 28, 2011	Mar	NEWA
----	-------	------------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554 001	Apr 21, 2011	Apr	NEWA
AB		EQ 250MG VALPROIC ACID	A090554 002	Apr 21, 2011	Apr	NEWA
AB		EQ 500MG VALPROIC ACID	A090554 003	Apr 21, 2011	Apr	NEWA
AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163 001	Apr 05, 2011	Mar	NEWA
AB		EQ 250MG VALPROIC ACID	A079163 002	Apr 05, 2011	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	A079163 003	Apr 05, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080 001	Feb 25, 2011	Feb	NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

AP	+	HOSPIRA	EQ 12.5MG BASE/ML	A074292 001	Feb 16, 1995	Aug	CRLD
		@ TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206 001	Oct 19, 1993	Aug	DISC

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011	May	NEWA
+		80MG/VIAL	N022534 002	May 03, 2011	May	NEWA

DOCETAXEL

	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jun	NEWA	
		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jun	NEWA	
AP	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Jun	CTEC
	+		20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Mar	NEWA
AP	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Jun	CTEC
	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Mar	NEWA
AP	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Jun	CTEC
	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Mar	NEWA
AP	SANDOZ	20MG/2ML (10MG/ML)	N201525 001	Jun 29, 2011	Jun	NEWA	
AP		160MG/16ML (10MG/ML)	N201525 003	Jun 29, 2011	Jun	NEWA	
AP	SANDOZ INC	80MG/8ML (10MG/ML)	N201525 002	Jun 29, 2011	Jun	NEWA	
	TAXOTERE						
	@ SANOFI AVENTIS US	40MG/ML	N020449 001	May 14, 1996	Mar	DISC	

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011	Aug	NEWA
AB		10MG	A201335 002	Aug 29, 2011	Aug	NEWA
AB	ACTAVIS PHARMA	5MG	A090551 001	May 31, 2011	May	NEWA
AB		10MG	A090551 002	May 31, 2011	May	NEWA
AB	APOTEX	5MG	A078841 001	Jun 02, 2011	May	NEWA
AB		10MG	A078841 002	Jun 02, 2011	May	NEWA
AB	AUROBINDO	5MG	A090056 001	May 31, 2011	May	NEWA
AB		10MG	A090056 002	May 31, 2011	May	NEWA
AB	CIPLA LTD	5MG	A077518 001	May 31, 2011	May	NEWA
AB		10MG	A077518 002	May 31, 2011	May	NEWA
AB	DR REDDYS LABS LTD	5MG	A201001 001	May 31, 2011	May	NEWA
AB		10MG	A201001 002	May 31, 2011	May	NEWA

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	HIKMA PHARMS	5MG	A090247 001	May 31, 2011	May	NEWA
AB		10MG	A090247 002	May 31, 2011	May	NEWA
AB	HUAHAI US INC	5MG	A200292 001	May 31, 2011	May	NEWA
AB		10MG	A200292 002	May 31, 2011	May	NEWA
AB	JUBILANT LIFE	5MG	A090768 001	May 31, 2011	May	NEWA
AB		10MG	A090768 002	May 31, 2011	May	NEWA
AB	MATRIX LABS LTD	5MG	A090521 001	May 31, 2011	May	NEWA
AB		10MG	A090521 002	May 31, 2011	May	NEWA
AB	PLIVA HRVATSKA DOO	5MG	A090425 001	May 31, 2011	May	NEWA
AB		10MG	A090425 002	May 31, 2011	May	NEWA
AB	ROXANE	5MG	A078662 001	May 31, 2011	May	NEWA
AB		10MG	A078662 002	May 31, 2011	May	NEWA
AB	SANDOZ	5MG	A090290 001	May 31, 2011	May	NEWA
AB		10MG	A090290 002	May 31, 2011	May	NEWA
AB	SUN PHARM INDS	5MG	A090493 001	May 31, 2011	May	NEWA
AB		10MG	A090493 002	May 31, 2011	May	NEWA
AB	TEVA	5MG	A077344 001	May 31, 2011	May	NEWA
AB		10MG	A077344 002	May 31, 2011	May	NEWA
AB	TORRENT PHARMS	5MG	A090686 001	May 31, 2011	May	NEWA
AB		10MG	A090686 002	May 31, 2011	May	NEWA
AB	WOCKHARDT	5MG	A091267 001	May 31, 2011	May	NEWA
AB		10MG	A091267 002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

	@ MUTUAL PHARM	5MG	A077975 002	Dec 11, 2009	Sep	DISC
	@	10MG	A077975 001	Dec 11, 2009	Sep	DISC
AB	SANDOZ	5MG	A091198 001	May 10, 2011	Apr	NEWA
AB		10MG	A091198 002	May 10, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A090175 001	May 10, 2011	Apr	NEWA
AB		10MG	A090175 002	May 10, 2011	Apr	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

	@ ACTAVIS ELIZABETH	EQ 1MG BASE	A075574 001	Oct 18, 2000	Aug	DISC
	@	EQ 2MG BASE	A075574 002	Oct 18, 2000	Aug	DISC
	@	EQ 4MG BASE	A075574 003	Oct 18, 2000	Aug	DISC
	@	EQ 8MG BASE	A075574 004	Oct 18, 2000	Aug	DISC
AB	NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Nov	CAHN
AB		EQ 2MG BASE	A075609 002	Oct 18, 2000	Nov	CAHN
AB		EQ 4MG BASE	A075609 003	Oct 18, 2000	Nov	CAHN
AB		EQ 8MG BASE	A075609 004	Oct 18, 2000	Nov	CAHN

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

AB	ROXANE	0.5MCG	A091433 001	Sep 23, 2011	Sep	NEWA
AB	HECTOROL					
AB	GENZYME CORP	0.5MCG	N020862 002	Apr 23, 2004	Sep	CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	10MG/VIAL	A200170 001	Oct 28, 2011	Oct	NEWA
----	--------------------	-----------	-------------	--------------	-----	------

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	50MG/VIAL	A200170 002	Oct 28, 2011	Oct	NEWA
----	--------------------	-----------	-------------	--------------	-----	------

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065 001	Feb 17, 2011	Jan	NEWA
AB	MYLAN	40MG	A090855 001	Jul 01, 2010	Jan	CDFR
AB	+ PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Feb	CTEC
AB	+	EQ 150MG BASE	A065055 003	Jul 15, 2005	Jan	CTEC

TABLET; ORAL

DOXYCYCLINE

>A>	AB	HERITAGE PHARMS INC	EQ 50MG BASE	A091605 001	Dec 20, 2011	Dec	NEWA
>A>	AB		EQ 75MG BASE	A091605 002	Dec 20, 2011	Dec	NEWA
>A>	AB		EQ 100MG BASE	A091605 003	Dec 20, 2011	Dec	NEWA
>A>	AB		EQ 150MG BASE	A091605 004	Dec 20, 2011	Dec	NEWA
		@ MUTUAL PHARM	EQ 50MG BASE	A065471 001	Apr 17, 2009	Sep	DISC
		@	EQ 75MG BASE	A065471 002	Apr 17, 2009	Sep	DISC
		@	EQ 100MG BASE	A065471 003	Apr 17, 2009	Sep	DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	WATSON LABS FLORIDA	EQ 50MG BASE	A062031 002	Oct 13, 1982	May	CAHN
AB		EQ 100MG BASE	A062031 001		May	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

>D>	AB	WEST WARD	EQ 100MG BASE	A065095 001	Jul 02, 2003	Dec	CRLD
>A>	AB	+ WEST-WARD PHARM CORP	EQ 100MG BASE	A065095 001	Jul 02, 2003	Dec	CRLD
>D>		VIBRA-TABS					
>D>	AB	+ PFIZER	EQ 100MG BASE	N050533 001		Dec	DISC
>A>		@	EQ 100MG BASE	N050533 001		Dec	DISC

TABLET, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

>A>	AB	ACTAVIS ELIZABETH	EQ 75MG BASE	A090134 001	Dec 14, 2011	Dec	NEWA
>A>	AB		EQ 100MG BASE	A090134 002	Dec 14, 2011	Dec	NEWA

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB	INSYS THERAP	2.5MG	A078501 001	Aug 19, 2011	Aug	NEWA
AB		5MG	A078501 002	Aug 19, 2011	Aug	NEWA
AB		10MG	A078501 003	Aug 19, 2011	Aug	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	WATSON LABS	3MG;0.02MG	A078833 001	Nov 28, 2011	Nov	NEWA
	LORYNA					
AB	SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011	Mar	NEWA

TABLET; ORAL-28

SYEDA

AB	SANDOZ	3MG;0.03MG	A090114 001	Mar 28, 2011	Mar	NEWA
----	--------	------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

@ ORTHO JANSSEN

1%

N018751 001 Dec 23, 1982 Jul CAHN

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

>D> + GRACEWAY 200MG/ML

N008922 001 Dec CAHN

>A> + MEDICIS 200MG/ML

N008922 001 Dec CAHN

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

>D> @ GRACEWAY 500MG

N008922 002 Dec CAHN

>A> @ MEDICIS 500MG

N008922 002 Dec CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

@ HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998 Aug DISC

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

GLAXOSMITHKLINE

EQ 12.5MG ACID

N022291 004 Oct 20, 2011 Oct NEWA

EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC 200MG;25MG;300MG

N202123 001 Aug 10, 2011 Aug NEWA

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB VALEANT INTL 2.5MG

N018998 005 Jul 26, 1988 Jun CAHN

AB 5MG

N018998 001 Dec 24, 1985 Jun CAHN

AB 10MG

N018998 002 Dec 24, 1985 Jun CAHN

AB + 20MG

N018998 003 Dec 24, 1985 Jun CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB VALEANT INTL 5MG;12.5MG

N019221 003 Jul 12, 1995 Jun CAHN

AB + 10MG;25MG

N019221 001 Oct 31, 1986 Jun CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB SANDOZ INC 300MG/3ML (100MG/ML)

A078660 001 Nov 28, 2011 Nov NEWA

LOVENOX

AB SANOFI AVENTIS US 300MG/3ML (100MG/ML)

N020164 009 Jan 23, 2003 Nov CFTG

300MG/3ML (100MG/ML)

N020164 009 Jan 23, 2003 Feb CDFR

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP AMPHASTAR PHARM 30MG/0.3ML (100MG/ML)

A076684 001 Sep 19, 2011 Sep NEWA

AP 40MG/0.4ML (100MG/ML)

A076684 002 Sep 19, 2011 Sep NEWA

INJECTABLE; SUBCUTANEOUSENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	AMPHASTAR PHARM	60MG/0.6ML (100MG/ML)	A076684 003	Sep 19, 2011	Sep	NEWA
AP		80MG/0.8ML (100MG/ML)	A076684 004	Sep 19, 2011	Sep	NEWA
AP		100MG/ML (100MG/ML)	A076684 005	Sep 19, 2011	Sep	NEWA
AP		120MG/0.8ML (150MG/ML)	A076684 006	Sep 19, 2011	Sep	NEWA
AP		150MG/ML (150MG/ML)	A076684 007	Sep 19, 2011	Sep	NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMICELESTAT

AT	+	ALLERGAN	0.05%	N021565 001	Oct 16, 2003	Feb	CFTG
----	---	----------	-------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

AT		APOTEX	0.05%	A090919 001	Oct 31, 2011	Oct	NEWA
AT		CYPRESS PHARM	0.05%	A090870 001	Mar 14, 2011	Feb	NEWA
AT		PHARMAFORCE	0.05%	A090951 001	Oct 31, 2011	Oct	NEWA
AT		SUN PHARM INDS	0.05%	A091626 001	Oct 31, 2011	Oct	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDEINJECTABLE; INJECTIONCITANEST FORTE DENTAL

AP	+	DENTSPLY PHARM	0.005MG/ML;4%	N021383 001		Aug	CFTG
----	---	----------------	---------------	-------------	--	-----	------

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	0.005MG/ML;4%	A078959 001	Aug 30, 2011	Aug	NEWA
----	--	---------------	---------------	-------------	--------------	-----	------

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTIONEPIRUBICIN HYDROCHLORIDE

AP		MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011	Apr	NEWA
AP			200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011	Apr	NEWA

EPOPROSTENOL SODIUMINJECTABLE; INJECTIONVELETRI

+	ACTELION	EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008	Aug	CTNA
---	----------	--------------------	-------------	--------------	-----	------

EPROSARTAN MESYLATETABLET; ORALEPROSARTAN MESYLATE

AB		MYLAN PHARMS INC	EQ 400MG BASE	A202012 001	Nov 16, 2011	Nov	NEWA
AB			EQ 600MG BASE	A202012 002	Nov 16, 2011	Nov	NEWA
		TEVETEN					
AB		ABBOTT	EQ 400MG BASE	N020738 005	Dec 22, 1997	Nov	CFTG
AB	+		EQ 600MG BASE	N020738 006	May 27, 1999	Nov	CFTG

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORALERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746 001	Dec 22, 1986	Jan	CAHN
----	--	------------------	-------	-------------	--------------	-----	------

GEL; TOPICALE-GLADES

AT		COREPHARMA	2%	A065009 001	Mar 18, 2002	Apr	CAHN
----	--	------------	----	-------------	--------------	-----	------

OINTMENT; OPHTHALMICERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447 001	Sep 26, 1983	Feb	CAHN
AT	+	NYCOMED US	0.5%	A062447 001	Sep 26, 1983	Jan	CAHN

SOLUTION; TOPICAL

ERYDERM

@ ARBOR PHARMS INC

2%

A062290 001

Jan CAHN

ERYTHROMYCIN

>D> AT + ALTANA 2%

A064187 001 Sep 30, 1997 Dec CAHN

@ COREPHARMA 2%

A064127 001 Feb 14, 1997 Apr CAHN

>A> AT + FOUGERA PHARMS 2%

A064187 001 Sep 30, 1997 Dec CAHN

SWAB; TOPICAL

ERYCETTE

@ ORTHO JANSSEN

2%

N050594 001 Feb 15, 1985 Jul CAHN

ERYTHROMYCIN

@ COREPHARMA 2%

A064128 001 Jul 03, 1996 Apr CAHN

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS INC

250MG

A061621 001

Jan CAHN

+ 500MG

A061621 002 Jan CAHN

TABLET, COATED PARTICLES; ORAL

PCE

ARBOR PHARMS INC

333MG

N050611 001 Sep 09, 1986 Jan CAHN

+ 500MG

N050611 002 Aug 22, 1990 Jan CAHN

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

@ ARBOR PHARMS INC

250MG

A060272 001

Jan CAHN

@ 333MG

A060272 002 Jan CAHN

ERY-TAB

+ ARBOR PHARMS INC 250MG

A062298 001 Jan CAHN

+ 333MG

A062298 003 Mar 29, 1982 Jan CAHN

+ 500MG

A062298 002 Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB ARBOR PHARMS INC EQ 200MG BASE/5ML

N050207 001 Jan CAHN

ERYPED

AB ARBOR PHARMS INC EQ 200MG BASE/5ML

N050207 003 Mar 30, 1987 Jan CAHN

+ EQ 400MG BASE/5ML

N050207 002 Jan CAHN

SUSPENSION; ORAL

E.E.S. 200

AB ARBOR PHARMS INC EQ 200MG BASE/5ML

A061639 001 Jan CAHN

E.E.S. 400

AB + ARBOR PHARMS INC EQ 400MG BASE/5ML

A061639 002 Jan CAHN

PEDIAMYCIN

AB ARBOR PHARMS INC EQ 200MG BASE/5ML

A062304 001 Jan CAHN

PEDIAMYCIN 400

AB ARBOR PHARMS INC EQ 400MG BASE/5ML

A062304 002 Jan CAHN

TABLET; ORAL

E.E.S. 400

BX + ARBOR PHARMS INC EQ 400MG BASE

A061905 002 Aug 12, 1982 Jan CAHN

@ EQ 400MG BASE

A061905 001 Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX + ARBOR PHARMS INC EQ 400MG BASE

A061904 001 Jan CAHN

TABLET, CHEWABLE; ORAL

E.E.S.

@ ARBOR PHARMS INC

EQ 200MG BASE

N050297 002 Jan CAHN

ERYPED

@ ARBOR PHARMS INC

EQ 200MG BASE

N050297 003 Jul 05, 1988 Jan CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

>D> ERYTHROMYCIN LACTOBIONATE

>D>	AP	TEVA PARENTERAL	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993	Dec	DISC
>A>		@	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993	Dec	DISC
>D>	AP		EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993	Dec	DISC
>A>		@	EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993	Dec	DISC

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

	@	ARBOR PHARMS INC	EQ 125MG BASE	A060359 002		Jan	CAHN
+			EQ 250MG BASE	A060359 001		Aug	CRLD
			EQ 250MG BASE	A060359 001		Jan	CAHN
	@		EQ 500MG BASE	A060359 003		Aug	DISC
+			EQ 500MG BASE	A060359 003		Jan	CAHN

ESCITALOPRAM OXALATE

>D> CAPSULE; ORAL

>D> ESCITALOPRAM OXALATE

>D>		ALPHAPHARM	EQ 5MG BASE	A077660 001	Jul 31, 2007	Dec	DISC
>D>			EQ 10MG BASE	A077660 002	Jul 31, 2007	Dec	DISC
>D>	+		EQ 20MG BASE	A077660 003	Jul 31, 2007	Dec	DISC
>A>	@	MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007	Dec	DISC
>A>	@		EQ 10MG BASE	A077660 002	Jul 31, 2007	Dec	DISC
>A>	@		EQ 20MG BASE	A077660 003	Jul 31, 2007	Dec	DISC

ESTRADIOL

TABLET; ORAL

ESTRACE

@	BRISTOL MYERS SQUIBB	0.5MG	A081295 001	Jun 30, 1993	Aug	DISC
---	----------------------	-------	-------------	--------------	-----	------

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

>D>	+	GRACEWAY	0.25%	N021371 001	Oct 09, 2003	Dec	CAHN
>A>	+	MEDICIS	0.25%	N021371 001	Oct 09, 2003	Dec	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC
	ESTRADIOL AND NORETHINDRONE ACETATE					
AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Jun 09, 2011	May	NEWA

ESTROPIPATE

CREAM; VAGINAL

OGEN

@	PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001		Apr	DISC
---	----------------------	----------	-------------	--	-----	------

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

	@	LUPIN LTD	1MG	A091124 001	Sep 13, 2011	Oct	DISC
AB			1MG	A091124 001	Sep 13, 2011	Aug	NEWA

TABLET; ORAL

ESZOPICLONE

	@ LUPIN LTD	2MG	A091124 002	Sep 13, 2011	Oct	DISC
AB		2MG	A091124 002	Sep 13, 2011	Aug	NEWA
	@	3MG	A091124 003	Sep 13, 2011	Oct	DISC
AB		3MG	A091124 003	Sep 13, 2011	Aug	NEWA
	@ TEVA	1MG	A091169 001	May 23, 2011	Jun	DISC
AB		1MG	A091169 001	May 23, 2011	May	NEWA
	@	2MG	A091169 002	May 23, 2011	Jun	DISC
AB		2MG	A091169 002	May 23, 2011	May	NEWA
	@	3MG	A091169 003	May 23, 2011	Jun	DISC
AB		3MG	A091169 003	May 23, 2011	May	NEWA
	@ WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011	Jul	NEWA
	@	2MG	A091165 002	Jul 14, 2011	Jul	NEWA
	@	3MG	A091165 003	Jul 14, 2011	Jul	NEWA

LUNESTA

	SUNOVION PHARMS INC	1MG	N021476 001	Dec 15, 2004	Oct	CTEC
AB		1MG	N021476 001	Dec 15, 2004	Aug	CTEC
		1MG	N021476 001	Dec 15, 2004	Jun	CTEC
AB		1MG	N021476 001	Dec 15, 2004	May	CFTG
		2MG	N021476 002	Dec 15, 2004	Oct	CTEC
AB		2MG	N021476 002	Dec 15, 2004	Aug	CTEC
		2MG	N021476 002	Dec 15, 2004	Jun	CTEC
AB		2MG	N021476 002	Dec 15, 2004	May	CFTG
	+	3MG	N021476 003	Dec 15, 2004	Oct	CTEC
AB	+	3MG	N021476 003	Dec 15, 2004	Aug	CTEC
	+	3MG	N021476 003	Dec 15, 2004	Jun	CTEC
AB	+	3MG	N021476 003	Dec 15, 2004	May	CFTG

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	LUPIN LTD	0.02MG,0.01MG;0.1MG,N/A	A091674 001	Oct 26, 2011	Oct	NEWA
AB	VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502 001	Nov 23, 2011	Nov	NEWA
AB	WATSON LABS	0.02MG,0.01MG;0.1MG,N/A	A200407 001	Oct 25, 2011	Oct	NEWA
AB		0.02MG;0.09MG	A079218 001	Jun 06, 2011	May	NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A	A078834 001	May 31, 2011	May	NEWA
	LOSEASONIQUE					
AB	TEVA WOMENS	0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008	Oct	CFTG
		0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008	Aug	CAHN
	LYBREL					
AB	+ WYETH PHARMS INC	0.02MG;0.09MG	N021864 001	May 22, 2007	May	CFTG
	SEASONIQUE					
AB	+ TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006	May	CFTG

TABLET; ORAL-21

ALESSE

@ AKRIMAX PHARMS

0.02MG;0.1MG

N020683 001 Mar 27, 1997 Jul CAHN

@ WYETH PHARMS

0.02MG;0.1MG

N020683 001 Mar 27, 1997 Aug CAHN

TRIPHASIL-21

@ WYETH PHARMS

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

N019192 001 Nov 01, 1984 Aug CAHN

TABLET; ORAL-28

ALESSE

@ AKRIMAX PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997 Jul CAHN

@ WYETH PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997 Aug CAHN

TABLET; ORAL-28

ORSYTHIA

AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099 001	May 11, 2011	Apr	NEWA
-----	----------------	--------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BRIELLYN

AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538 001	Mar 22, 2011	Mar	NEWA
>A>	DASETTA 1/35					
>A>	AB	NOVAST LABS LTD	0.035MG;1MG	A090948 001	Dec 22, 2011	Dec
	DASETTA 7/7/7					
>A>	AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A090946 001	Dec 22, 2011	Dec
>A>	PHILITH					
>A>	AB	NOVAST LABS LTD	0.035MG;0.4MG	A090947 001	Dec 22, 2011	Dec

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+	WARNER CHILCOTT	0.025MG;0.8MG	N022573 001	Dec 22, 2010	Jan	CRLD
AB	WATSON LABS	0.035MG;0.4MG	A078892 001	Sep 26, 2011	Sep	NEWA
+	WATSON LABS INC	0.025MG;0.8MG	N022573 001	Dec 22, 2010	Jun	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LO LOESTRIN FE

+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	May	CRLD
---	--------------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL-28

GILDESS FE 1.5/30

AB	VINTAGE	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Jan	CTNA
----	---------	--------------	-------------	--------------	-----	------

GILDESS FE 1/20

AB	VINTAGE	0.02MG;1MG	A077077 001	May 20, 2005	Jan	CTNA
----	---------	------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494 001	Jun 17, 2011	Jun	NEWA
----	-------------------	---	-------------	--------------	-----	------

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479 001	Mar 09, 2011	Feb	NEWA
----	-------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

OVRAL

@	WYETH PHARMS	0.05MG;0.5MG	N016672 001		Aug	CAHN
---	--------------	--------------	-------------	--	-----	------

TABLET; ORAL-28

LO/OVRAL-28

AB	WYETH PHARMS	0.03MG;0.3MG	N017802 001		Aug	CAHN
----	--------------	--------------	-------------	--	-----	------

OVRAL-28

@	WYETH PHARMS	0.05MG;0.5MG	N016806 001		Aug	CAHN
---	--------------	--------------	-------------	--	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	VERSAPHARM	250MG	A040686 001	May 28, 2008	May	CAHN
----	------------	-------	-------------	--------------	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ MYLAN	200MG	A075071 001	Sep 30, 1998	Feb	CAHN
---------	-------	-------------	--------------	-----	------

@	300MG	A075071 002	Sep 30, 1998	Feb	CAHN
---	-------	-------------	--------------	-----	------

TABLET; ORAL

ETODOLAC

@ ACTAVIS ELIZABETH	400MG	A074819 001	Feb 28, 1997	Aug	DISC
---------------------	-------	-------------	--------------	-----	------

@	500MG	A074819 002	Apr 28, 1998	Sep	NEWA
---	-------	-------------	--------------	-----	------

@ MYLAN	400MG	A075012 001	Sep 30, 1998	Feb	CAHN
---------	-------	-------------	--------------	-----	------

@	500MG	A075012 002	Sep 30, 1998	Feb	CAHN
---	-------	-------------	--------------	-----	------

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+ ORGANON USA INC	68MG/IMPLANT	N021529 002	May 31, 2011	May	NEWA
-------------------	--------------	-------------	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

TIBOTEC	100MG	N022187 001	Jan 18, 2008	Jan	CRLD
---------	-------	-------------	--------------	-----	------

+	200MG	N022187 002	Dec 22, 2010	Jan	NEWA
---	-------	-------------	--------------	-----	------

EXEMESTANE

TABLET; ORAL

AROMASIN

AB + PHARMACIA AND UPJOHN	25MG	N020753 001	Oct 21, 1999	Mar	CFTG
---------------------------	------	-------------	--------------	-----	------

EXEMESTANE

AB ROXANE	25MG	A077431 001	Apr 01, 2011	Mar	NEWA
-----------	------	-------------	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL	10MG;10MG	N021687 001	Jul 23, 2004	Oct	CAHN
----------	-----------	-------------	--------------	-----	------

	10MG;20MG	N021687 002	Jul 23, 2004	Oct	CAHN
--	-----------	-------------	--------------	-----	------

	10MG;40MG	N021687 003	Jul 23, 2004	Oct	CAHN
--	-----------	-------------	--------------	-----	------

+	10MG;80MG	N021687 004	Jul 23, 2004	Oct	CAHN
---	-----------	-------------	--------------	-----	------

EZOGABINE

TABLET; ORAL

POTIGA

VALEANT PHARMS	50MG	N022345 001	Jun 10, 2011	Jun	NEWA
----------------	------	-------------	--------------	-----	------

	200MG	N022345 002	Jun 10, 2011	Jun	NEWA
--	-------	-------------	--------------	-----	------

	300MG	N022345 003	Jun 10, 2011	Jun	NEWA
--	-------	-------------	--------------	-----	------

+	400MG	N022345 004	Jun 10, 2011	Jun	NEWA
---	-------	-------------	--------------	-----	------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB APOTEX	125MG	A091480 001	Jul 22, 2011	Jul	NEWA
-----------	-------	-------------	--------------	-----	------

AB	250MG	A091480 002	Jul 22, 2011	Jul	NEWA
----	-------	-------------	--------------	-----	------

AB	500MG	A091480 003	Jul 22, 2011	Jul	NEWA
----	-------	-------------	--------------	-----	------

AB AUROBINDO PHARMA LTD	125MG	A091114 001	Mar 21, 2011	Mar	NEWA
-------------------------	-------	-------------	--------------	-----	------

AB	250MG	A091114 002	Mar 21, 2011	Mar	NEWA
----	-------	-------------	--------------	-----	------

AB	500MG	A091114 003	Mar 21, 2011	Mar	NEWA
----	-------	-------------	--------------	-----	------

TABLET; ORAL

FAMCICLOVIR

AB	MYLAN	125MG	A201333 001	Mar 24, 2011	Mar	NEWA
AB		250MG	A201333 002	Mar 24, 2011	Mar	NEWA
AB		500MG	A201333 003	Mar 24, 2011	Mar	NEWA
AB	ROXANE	125MG	A090128 001	Mar 21, 2011	Mar	NEWA
AB		250MG	A090128 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128 003	Mar 21, 2011	Mar	NEWA
AB	WATSON LABS	125MG	A078278 001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278 003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

	@ HOSPIRA	10MG/ML	A075870 001	Nov 23, 2001	Aug	DISC
AP	PFIZER	10MG/ML	A078641 001	Jun 25, 2008	May	CAHN
	FAMOTIDINE PRESERVATIVE FREE					
AP	PFIZER	10MG/ML	A078642 001	Jun 25, 2008	May	CAHN
	PEPCID					
	@ MERCK	10MG/ML	N019510 001	Nov 04, 1986	Jan	DISC
	PEPCID PRESERVATIVE FREE					
	@ MERCK	10MG/ML	N019510 004	Nov 04, 1986	Jan	DISC
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
	@ MERCK	0.4MG/ML	N020249 001	Feb 18, 1994	Jan	DISC

TABLET; ORAL

FAMOTIDINE

	@ ACTAVIS ELIZABETH	20MG	A075650 001	Sep 14, 2001	Aug	DISC
	@	40MG	A075650 002	Sep 14, 2001	Aug	DISC
AB	ALEMBIC PHARMS LTD	20MG	A078916 001	May 22, 2009	Jul	CAHN
AB		40MG	A078916 002	May 22, 2009	Jul	CAHN
AB	MYLAN	20MG	A075457 001	Apr 18, 2001	Feb	CAHN
AB		40MG	A075457 002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	26.6MG;800MG	N022519 001	Apr 23, 2011	Apr	NEWA
---	----------------	--------------	-------------	--------------	-----	------

FELBAMATE

SUSPENSION; ORAL

>A>		FELBAMATE						
>A>	AB	AMNEAL PHARMS	600MG/5ML	A202385 001	Dec 16, 2011	Dec	NEWA	
		FELBATOL						
>D>	+	MEDA PHARMS	600MG/5ML	N020189 003	Jul 29, 1993	Dec	CFTG	
>A>	AB	+	600MG/5ML	N020189 003	Jul 29, 1993	Dec	CFTG	

TABLET; ORAL

FELBAMATE

AB	AMNEAL PHARMS	400MG	A201680 001	Sep 13, 2011	Aug	NEWA
AB		600MG	A201680 002	Sep 13, 2011	Aug	NEWA
	FELBATOL					
AB	MEDA PHARMS	400MG	N020189 001	Jul 29, 1993	Aug	CFTG
AB	+	600MG	N020189 002	Jul 29, 1993	Aug	CFTG

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	ENDO PHARMS	2.5MG	A200815 001	Oct 28, 2011	Oct	NEWA
AB		5MG	A200815 002	Oct 28, 2011	Oct	NEWA
AB		10MG	A200815 003	Oct 28, 2011	Oct	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A202170 001	Nov 28, 2011	Nov	NEWA
AB		5MG	A202170 002	Nov 28, 2011	Nov	NEWA
AB		10MG	A202170 003	Nov 28, 2011	Nov	NEWA

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN

@ CIPHER PHARMS INC	100MG	N021612 002	Jan 11, 2006	Sep	DISC
---------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

FENOFIBRATE

>A>	AB	LUPIN LTD	48MG	A090856 001	Dec 23, 2011	Dec	NEWA
>A>	AB		145MG	A090856 002	Dec 23, 2011	Dec	NEWA
		FENOGLIDE					
>A>		SANTARUS	40MG	N022118 001	Aug 10, 2007	Dec	CAHN
>A>	+		120MG	N022118 002	Aug 10, 2007	Dec	CAHN
>D>		SHORE THERAP	40MG	N022118 001	Aug 10, 2007	Dec	CAHN
			40MG	N022118 001	Aug 10, 2007	Feb	CAHN
>D>	+		120MG	N022118 002	Aug 10, 2007	Dec	CAHN
	+		120MG	N022118 002	Aug 10, 2007	Feb	CAHN
		TRICOR					
>D>		ABBOTT	48MG	N021656 001	Nov 05, 2004	Dec	CFTG
>D>	+		145MG	N021656 002	Nov 05, 2004	Dec	CFTG
>A>	AB	ABBOTT LABS PHARM	48MG	N021656 001	Nov 05, 2004	Dec	CFTG
>A>	AB	+	145MG	N021656 002	Nov 05, 2004	Dec	CFTG

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

>D>	AP	TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007	Dec	DISC
>A>	@		EQ 10MG BASE/ML	A077826 001	Mar 07, 2007	Dec	DISC

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	MALLINCKRODT INC	100MCG/HR	A077154 004	Feb 09, 2011	Jan	NEWA
	FENTANYL-25					
AB	MALLINCKRODT INC	25MCG/HR	A077154 001	Feb 09, 2011	Jan	NEWA
	FENTANYL-50					
AB	MALLINCKRODT INC	50MCG/HR	A077154 002	Feb 09, 2011	Jan	NEWA
	FENTANYL-75					
AB	MALLINCKRODT INC	75MCG/HR	A077154 003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES	100MCG	N022569 001	Jun 30, 2011	Jun	NEWA
+	400MCG	N022569 002	Jun 30, 2011	Jun	NEWA

TABLET; SUBLINGUAL

ABSTRAL

PROSTRAKAN INC	EQ 0.1MG BASE	N022510 001	Jan 07, 2011	Jan	NEWA
	EQ 0.2MG BASE	N022510 002	Jan 07, 2011	Jan	NEWA
	EQ 0.3MG BASE	N022510 003	Jan 07, 2011	Jan	NEWA
+	EQ 0.4MG BASE	N022510 004	Jan 07, 2011	Jan	NEWA
	EQ 0.6MG BASE	N022510 005	Jan 07, 2011	Jan	NEWA
	EQ 0.8MG BASE	N022510 006	Jan 07, 2011	Jan	NEWA

FIDAXOMICIN

TABLET; ORAL

DIFICID

+ OPTIMER PHARMS	200MG	N201699 001	May 27, 2011	May	NEWA
------------------	-------	-------------	--------------	-----	------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB SUN PHARMA GLOBAL	5MG	A090507 001	Aug 16, 2011	Aug	NEWA
----------------------	-----	-------------	--------------	-----	------

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

AB + PADDOCK LLC	100MG	A076831 001	Dec 16, 2004	Nov	CRLD
------------------	-------	-------------	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

>D> AB GRACEWAY	50MG	N018830 004	Aug 23, 1988	Dec	CAHN
>D> AB	100MG	N018830 001	Oct 31, 1985	Dec	CAHN
>D> AB +	150MG	N018830 003	Jun 03, 1988	Dec	CAHN
>D> @	200MG	N018830 002	Oct 31, 1985	Dec	CAHN
>A> AB MEDICIS	50MG	N018830 004	Aug 23, 1988	Dec	CAHN
>A> AB	100MG	N018830 001	Oct 31, 1985	Dec	CAHN
>A> AB +	150MG	N018830 003	Jun 03, 1988	Dec	CAHN
>A> @	200MG	N018830 002	Oct 31, 1985	Dec	CAHN

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB AMNEAL PHARM	50MG	A078423 001	Mar 07, 2011	Feb	NEWA
AB	100MG	A078423 002	Mar 07, 2011	Feb	NEWA
AB	150MG	A078423 003	Mar 07, 2011	Feb	NEWA
AB	200MG	A078423 004	Mar 07, 2011	Feb	NEWA
AB MYLAN	50MG	A076042 001	Jul 29, 2004	Feb	CAHN
AB	100MG	A076042 002	Jul 29, 2004	Feb	CAHN
AB	150MG	A076042 003	Jul 29, 2004	Feb	CAHN
AB	200MG	A076042 004	Jul 29, 2004	Feb	CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

AB VALEANT	250MG	N017001 001		Jun	CFTG
AB +	500MG	N017001 002		Jun	CFTG

FLUCYTOSINE

AB SIGMAPHARM LABS LLC	250MG	A201566 001	Jun 28, 2011	Jun	NEWA
AB	500MG	A201566 002	Jun 28, 2011	Jun	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

>A>	AP	ONCO THERAPIES LTD	50MG/2ML (25MG/ML)	A200647 001	Dec 21, 2011	Dec	NEWA	
		TABLET; ORAL						
		OFORTA						
	+	SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	Apr	CMFD	
	@		10MG	N022273 001	Dec 18, 2008	Jan	DISC	

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870 001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086 001	Feb 25, 2011	Feb	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB		WEST-WARD PHARM CORP	0.1MG	A091302 001	Jul 22, 2011	Jul	NEWA
----	--	----------------------	-------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		PFIZER	0.5MG/5ML (0.1MG/ML)	A078595 001	May 13, 2008	May	CAHN
AP			1MG/10ML (0.1MG/ML)	A078595 002	May 13, 2008	May	CAHN

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

>A>	AB	HH AND P	0.025MG/SPRAY	A077704 001	Aug 03, 2006	Dec	CAHN
>D>	AB	QPHARMA	0.025MG/SPRAY	A077704 001	Aug 03, 2006	Dec	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

AT		G AND W LABS	0.01%	A089526 001	Jul 26, 1988	Nov	CMFD
AT			0.025%	A089525 001	Jul 26, 1988	Oct	CMFD

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N012787 004		Jun	CAHN
AT	+		0.025%	N012787 005		Jun	CAHN
AT	+		0.025%	N012787 002		Jun	CAHN

SYNALAR-HP

@ MEDIMETRIKS PHARMS

0.2%

N016161 002		Jun	CAHN
-------------	--	-----	------

OIL; TOPICAL

DERMA-SMOOTH/FS

AT	+	HILL DERMAC	0.01%	N019452 002	Nov 09, 2005	Oct	CFTG
AT	+		0.01%	N019452 001	Feb 03, 1988	Oct	CFTG

FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.01%	A201759 001	Oct 17, 2011	Oct	NEWA
AT			0.01%	A201764 001	Oct 17, 2011	Oct	NEWA

OIL/DROPS; OTIC

DERMOTIC

AT	+	HILL DERMAC	0.01%	N019452 003	Nov 09, 2005	Oct	CFTG
----	---	-------------	-------	-------------	--------------	-----	------

FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.1%	A091306 001	Oct 17, 2011	Oct	NEWA
----	--	-------------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

AT	G AND W LABS	0.025%	A089524 001	Jul 26, 1988	Oct	CMFD
----	--------------	--------	-------------	--------------	-----	------

SYNALAR

AT	+ MEDIMETRIKS PHARMS	0.025%	N013960 001		Jun	CAHN
----	----------------------	--------	-------------	--	-----	------

SOLUTION; TOPICAL

SYNALAR

AT	+ MEDIMETRIKS PHARMS	0.01%	N015296 001		Jun	CAHN
----	----------------------	-------	-------------	--	-----	------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

	@ MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700 001		Aug	CAHN
--	----------------------	-------------------------	-------------	--	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	SANDOZ	2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
----	--------	----------------------	-------------	--------------	-----	------

AP		5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
----	--	---------------------	-------------	--------------	-----	------

	@ VALEANT	500MG/10ML (50MG/ML)	N012209 001		Mar	DISC
--	-----------	----------------------	-------------	--	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
-----	--------------------	--------------	-------------	--------------	-----	------

AB1		EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
-----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN
----	--	--------------	-------------	--------------	-----	------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133 001	Oct 06, 2011	Oct	NEWA
--	---------------------	--------------	-------------	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>D>	AO	TEVA PARENTERAL	25MG/ML	A074795 001	Sep 10, 1996	Dec	DISC
-----	----	-----------------	---------	-------------	--------------	-----	------

>A>		@	25MG/ML	A074795 001	Sep 10, 1996	Dec	DISC
-----	--	---	---------	-------------	--------------	-----	------

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

	WATSON PHARMS	0.025%	N012806 003		Oct	CMFD
--	---------------	--------	-------------	--	-----	------

	@	0.025%	N012806 003		Jul	DISC
--	---	--------	-------------	--	-----	------

	@	0.05%	N012806 002		Jul	DISC
--	---	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

	@ WATSON PHARMS	0.025%	N012806 004		Jun	DISC
--	-----------------	--------	-------------	--	-----	------

	@	0.05%	N012806 001		Jun	DISC
--	---	-------	-------------	--	-----	------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

	@ VALEANT PHARM INTL	15MG	N016721 001		Oct	DISC
--	----------------------	------	-------------	--	-----	------

	@	30MG	N016721 002		Oct	DISC
--	---	------	-------------	--	-----	------

FLURAZEPAM HYDROCHLORIDE

AB	+ MYLAN PHARMS INC	30MG	A070345 001	Nov 27, 1985	Nov	CRLD
----	--------------------	------	-------------	--------------	-----	------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	MYLAN	125MG	A076224 001	May 09, 2003	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Nov	CAHN
----	---------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

CUTIVATE

AB	+ FOUGERA PHARMS	0.05%	N021152 001	Mar 31, 2005	Nov	CAHN
----	------------------	-------	-------------	--------------	-----	------

AB	+ NYCOMED US	0.05%	N021152 001	Mar 31, 2005	Apr	CFTG
----	--------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB	GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011	Apr	NEWA
----	-------------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CUTIVATE

AB	+ FOUGERA PHARMS	0.005%	N019957 001	Dec 14, 1990	Nov	CAHN
----	------------------	--------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

>A>	AB	WOCKHARDT	0.05MG/SPRAY	A078492 001	Jan 09, 2012	Dec	NEWA
-----	----	-----------	--------------	-------------	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN

50MG

A075950 001	Oct 15, 2001	Feb	CAHN
-------------	--------------	-----	------

@

100MG

A075950 002	Oct 15, 2001	Feb	CAHN
-------------	--------------	-----	------

FOLIC ACID

INJECTABLE; INJECTION

FOLVITE

>A>	@ HIKMA (MAPLE)	5MG/ML	N005897 008		Dec	CAHN
-----	-----------------	--------	-------------	--	-----	------

>D>	@ WYETH PHARMS INC	5MG/ML	N005897 008		Dec	CAHN
-----	--------------------	--------	-------------	--	-----	------

TABLET; ORAL

FOLIC ACID

AA	+ AMNEAL PHARM	1MG	A040625 001	Jul 21, 2005	Apr	CAHN
----	----------------	-----	-------------	--------------	-----	------

AA	JUBILANT CADISTA	1MG	A040514 001	Jun 14, 2005	Jan	CAHN
----	------------------	-----	-------------	--------------	-----	------

@	MUTUAL PHARM	1MG	A040582 001	Jul 18, 2005	Sep	DISC
---	--------------	-----	-------------	--------------	-----	------

FOLVITE

>A>	@ HIKMA (MAPLE)	1MG	N005897 004		Dec	CAHN
-----	-----------------	-----	-------------	--	-----	------

>D>	@ WYETH PHARMS INC	1MG	N005897 004		Dec	CAHN
-----	--------------------	-----	-------------	--	-----	------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+ GLAXOSMITHKLINE	2.5MG/0.5ML	N021345 001	Dec 07, 2001	Jun	CFTG
----	-------------------	-------------	-------------	--------------	-----	------

AP	+	5MG/0.4ML	N021345 002	May 28, 2004	Jun	CFTG
----	---	-----------	-------------	--------------	-----	------

AP	+	7.5MG/0.6ML	N021345 003	May 28, 2004	Jun	CFTG
----	---	-------------	-------------	--------------	-----	------

AP	+	10MG/0.8ML	N021345 004	May 28, 2004	Jun	CFTG
----	---	------------	-------------	--------------	-----	------

FONDAPARINUX SODIUM

AP	DR REDDYS LABS LTD	2.5MG/0.5ML	A091316 001	Jul 11, 2011	Jun	NEWA
----	--------------------	-------------	-------------	--------------	-----	------

AP		5MG/0.4ML	A091316 002	Jul 11, 2011	Jun	NEWA
----	--	-----------	-------------	--------------	-----	------

AP		7.5MG/0.6ML	A091316 003	Jul 11, 2011	Jun	NEWA
----	--	-------------	-------------	--------------	-----	------

AP		10MG/0.8ML	A091316 004	Jul 11, 2011	Jun	NEWA
----	--	------------	-------------	--------------	-----	------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

@ NOVARTIS

0.0085MG/INH

N021592 001 Dec 15, 2006 Jun DISC

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB AUROBINDO PHARMA LTD 10MG

A091163 001 Mar 30, 2011 Mar NEWA

AB 20MG

A091163 002 Mar 30, 2011 Mar NEWA

AB 40MG

A091163 003 Mar 30, 2011 Mar NEWA

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB EMCURE PHARMS USA 10MG;12.5MG

A079025 001 Sep 17, 2010 Jul CAHN

AB 20MG;12.5MG

A079025 002 Sep 17, 2010 Jul CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP + APP PHARMS EQ 50MG PHENYTOIN NA/ML

A078052 001 Aug 06, 2007 Apr CRLD

AP PFIZER EQ 50MG PNENYTOIN NA/ML

A078476 001 Mar 18, 2008 May CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB MARKSANS PHARMA 100MG

A090007 001 Jul 21, 2011 Jul NEWA

AB 300MG

A090007 002 Jul 21, 2011 Jul NEWA

AB 400MG

A090007 003 Jul 21, 2011 Jul NEWA

AB MATRIX LABS LTD 100MG

A090158 001 Feb 14, 2011 Jan NEWA

AB 300MG

A090158 002 Feb 14, 2011 Jan NEWA

AB 400MG

A090158 003 Feb 14, 2011 Jan NEWA

AB MYLAN 100MG

A090158 001 Feb 14, 2011 May CAHN

AB 300MG

A090158 002 Feb 14, 2011 May CAHN

AB 400MG

A090158 003 Feb 14, 2011 May CAHN

SOLUTION; ORAL

GABAPENTIN

AA HI TECH PHARMA 250MG/5ML

A078974 001 Feb 18, 2011 Feb NEWA

NEURONTIN

AA + PARKE DAVIS 250MG/5ML

N021129 001 Mar 02, 2000 Feb CFTG

TABLET; ORAL

GABAPENTIN

AB AUROBINDO PHARMA LTD 600MG

A200651 001 Oct 06, 2011 Sep NEWA

AB 800MG

A200651 002 Oct 06, 2011 Sep NEWA

AB HIKMA PHARMS 600MG

A078782 001 Jul 21, 2011 Jul NEWA

AB 800MG

A078782 002 Jul 21, 2011 Jul NEWA

AB ZYDUS PHARMS USA INC 600MG

A078926 001 Feb 11, 2011 Jan NEWA

AB 800MG

A078926 002 Feb 11, 2011 Jan NEWA

GRALISE

BX + ABBOTT PRODS 300MG

N022544 001 Jan 28, 2011 Jan NEWA

BX + 600MG

N022544 002 Jan 28, 2011 Jan NEWA

BX + DEPOMED INC 300MG

N022544 001 Jan 28, 2011 Jul CAHN

BX + 600MG

N022544 002 Jan 28, 2011 Jul CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

>A>	GLAXO GRP LTD	300MG	N022399 002	Dec 13, 2011	Dec	NEWA
	+	600MG	N022399 001	Apr 06, 2011	Apr	NEWA

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011	Mar	NEWA
+		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011	Mar	NEWA
+		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011	Mar	NEWA
+		18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011	Mar	NEWA
+		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900 002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900 003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178 001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178 002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178 003	Feb 02, 2011	Jan	NEWA
	RAZADYNE ER					
AB	+	JANSSEN PHARMS	EQ 8MG BASE	N021615 001	Apr 01, 2005	Jul CAHN
AB			EQ 16MG BASE	N021615 002	Apr 01, 2005	Jul CAHN
AB			EQ 24MG BASE	N021615 003	Apr 01, 2005	Jul CAHN

SOLUTION; ORAL

RAZADYNE

AA	+	JANSSEN PHARMS	4MG/ML	N021224 001	Jun 22, 2001	Jul CAHN
----	---	----------------	--------	-------------	--------------	----------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	@	ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009	Aug DISC
	@		EQ 8MG BASE	A077585 002	Sep 15, 2009	Aug DISC
	@		EQ 12MG BASE	A077585 003	Sep 15, 2009	Aug DISC
AB		APOTEX INC	EQ 4MG BASE	A077781 001	Sep 27, 2011	Sep NEWA
AB			EQ 8MG BASE	A077781 002	Sep 27, 2011	Sep NEWA
AB			EQ 12MG BASE	A077781 003	Sep 27, 2011	Sep NEWA
AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957 001	Mar 29, 2011	Mar NEWA
AB			EQ 8MG BASE	A090957 002	Mar 29, 2011	Mar NEWA
AB			EQ 12MG BASE	A090957 003	Mar 29, 2011	Mar NEWA
AB		ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011	Jan NEWA
AB			EQ 8MG BASE	A078898 002	Feb 17, 2011	Jan NEWA
AB			EQ 12MG BASE	A078898 003	Feb 17, 2011	Jan NEWA
		RAZADYNE				
AB	+	JANSSEN PHARMS	EQ 4MG BASE	N021169 001	Feb 28, 2001	Jul CAHN
AB			EQ 8MG BASE	N021169 002	Feb 28, 2001	Jul CAHN
AB			EQ 12MG BASE	N021169 003	Feb 28, 2001	Jul CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT	APOTEX CORP	0.3%	A079084 001	Aug 19, 2011	Aug	NEWA
----	-------------	------	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

ZYMAR

AT	+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Aug	CFTG
----	---	----------	------	---------	-----	--------------	-----	------

GEFITINIB

TABLET; ORAL

IRESSA

	@	ASTRAZENECA	250MG	N021399	001	May 05, 2003	Sep	DISC
--	---	-------------	-------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Aug	NEWA
+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Aug	NEWA
+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Aug	NEWA
+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD

GEMCITABINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Jul	NEWA
AP		ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Jul	NEWA
AP		APP PHARMS	EQ 2GM BASE/VIAL	A090242	003	May 16, 2011	May	NEWA
AP		DR REDDYS LABS LTD	EQ 200MG BASE/VIAL	A091365	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A091365	002	Jul 25, 2011	Jul	NEWA
AP		FRESENIUS KABI ONCOL	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	May	NEWA
AP		HOSPIRA	EQ 200MG BASE/VIAL	A078339	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078339	002	Jul 25, 2011	Jul	NEWA
AP	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Jul	CTEC
	+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	May	CTNA
AP		ONCO THERAPIES LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Jul	NEWA
AP		SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078433	002	Jul 25, 2011	Jul	NEWA
AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA
AP		WATSON LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul	NEWA
AP			EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul	NEWA
		GEMZAR						
AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065121 001	Jan 30, 2004	Feb	CAHN
----	-------------	--------------	-------------	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	MYLAN	1MG	A077486 001	Feb 10, 2006	Feb	CAHN
AB		2MG	A077486 002	Feb 10, 2006	Feb	CAHN
AB		4MG	A077486 003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	MYLAN	5MG	A074438 001	Jun 20, 1995	Aug	CAHN
AB		10MG	A074438 002	Jun 20, 1995	Aug	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	+	TEVA PHARMS	5MG;500MG	A077270 003	Oct 28, 2005	Aug	CRLD
AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905 001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905 002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905 003	Jan 31, 2011	Jan	NEWA

METAGLIP

@	BRISTOL MYERS SQUIBB	2.5MG;250MG
@		2.5MG;500MG
@		5MG;500MG

N021460 001	Oct 21, 2002	Aug	DISC
N021460 002	Oct 21, 2002	Aug	DISC
N021460 003	Oct 21, 2002	Aug	DISC

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

GLYBURIDE

TABLET; ORAL

GLYBURIDE

@	ACTAVIS TOTOWA	1.5MG	A075947 001	Nov 14, 2002	Jul	DISC
@		3MG	A075947 002	Nov 14, 2002	Jul	DISC
@		6MG	A075947 003	Nov 14, 2002	Jul	DISC
AB	HERITAGE PHARMS INC	1.25MG	A090937 001	Feb 28, 2011	May	CAHN
AB		2.5MG	A090937 002	Feb 28, 2011	May	CAHN
AB		5MG	A090937 003	Feb 28, 2011	May	CAHN
AB	INDICUS PHARMA	1.25MG	A090937 001	Feb 28, 2011	Feb	NEWA
AB		2.5MG	A090937 002	Feb 28, 2011	Feb	NEWA
AB		5MG	A090937 003	Feb 28, 2011	Feb	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	HIKMA FARMACEUTICA	0.2MG/ML	A090963 001	Sep 21, 2011	Sep	NEWA
----	--------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

GLYCOPYRROLATE

AA	BOCA PHARMA	1MG	A090020 001	Oct 19, 2011	Oct	NEWA
AA		2MG	A090020 002	Oct 19, 2011	Oct	NEWA

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@	HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123 001	Sep 30, 1982	Nov	CAHN
@		EQ 0.2MG BASE/VIAL	N018123 002	Sep 30, 1982	Nov	CAHN
@		EQ 0.5MG BASE/VIAL	N018123 003	Sep 30, 1982	Nov	CAHN

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

+	PROSTRAKAN INC	3.1MG/24HR	N022198 001	Sep 12, 2008	Jun	CAHN
---	----------------	------------	-------------	--------------	-----	------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@	ELORAC	125MG	A061996 001		Jan	CAHN
@		250MG	A061996 002		Jan	CAHN

FULVICIN P/G 165

@	ELORAC	165MG	A061996 003	Apr 06, 1982	Jan	CAHN
---	--------	-------	-------------	--------------	-----	------

FULVICIN P/G 330

@	ELORAC	330MG	A061996 004	Apr 06, 1982	Jan	CAHN
---	--------	-------	-------------	--------------	-----	------

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@	ACTAVIS MID ATLANTIC	0.05%	A077109 001	Jun 14, 2005	Aug	DISC
---	----------------------	-------	-------------	--------------	-----	------

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	PFIZER	EQ 5MG BASE/ML	A078347 001	Sep 14, 2009	May	CAHN
AP	SAGENT PHARMS	EQ 5MG BASE/ML	A200742 001	Sep 02, 2011	Aug	NEWA
AP		EQ 5MG BASE/ML	A091637 001	Sep 02, 2011	Aug	NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011	Jul	NEWA
		5,000 UNITS/ML	N201370 002	Jul 21, 2011	Jul	NEWA
		10,000 UNITS/ML	N201370 003	Jul 21, 2011	Jul	NEWA
AP	SANDOZ	1,000 UNITS/ML	A091682 001	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091682 002	Jun 08, 2011	May	NEWA
AP		5,000 UNITS/ML	A091659 001	Jun 08, 2011	May	NEWA
AP		10,000 UNITS/ML	A201002 001	Jun 08, 2011	May	NEWA
	HEPARIN SODIUM PRESERVATIVE FREE					
	PFIZER	1,000 UNITS/ML	N201370 004	Jul 21, 2011	Jul	NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	GE HEALTHCARE	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB		NOVEL LABS INC	1.5MG;5MG	A091528 001	Apr 20, 2011	Apr	NEWA
		TUSSIGON					
AB	+	KING PHARMS	1.5MG;5MG	A088508 001	Jul 30, 1985	Apr	CTEC

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

	+	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jul	CAHN
--	---	-----------	--------------	-------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		HETERO LABS UNIT III	10MG	A040901 001	Sep 12, 2008	Jul	CAHN
AA			25MG	A040901 002	Sep 12, 2008	Jul	CAHN
AA			50MG	A040901 003	Sep 12, 2008	Jul	CAHN
AA			100MG	A040901 004	Sep 12, 2008	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

>A>	+	ARBOR PHARMS INC	37.5MG;20MG	N020727 001	Jun 23, 2005	Dec	CAHN
>D>	+	NITROMED	37.5MG;20MG	N020727 001	Jun 23, 2005	Dec	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG	A200645 001	Nov 30, 2010	Apr	CAHN
AB		JUBILANT CADISTA	12.5MG	A078391 001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

		@ ACTAVIS ELIZABETH	25MG	A085054 002		Aug	DISC
		@	50MG	A085208 001		Aug	DISC
AB	+	IVAX SUB TEVA PHARMS	50MG	A083177 002		Nov	CRLD
AB		JUBILANT CADISTA	25MG	A040809 001	Sep 04, 2007	Jan	CAHN
AB			50MG	A040809 002	Sep 04, 2007	Jan	CAHN
AB		MYLAN PHARMS INC	50MG	A040735 003	Jan 23, 2007	Nov	CRLD

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

	@	SANOFI AVENTIS	12.5MG;75MG	N020758 001	Sep 30, 1997	Jun	CAHN
	+		12.5MG;150MG	N020758 002	Sep 30, 1997	Sep	CRLD
			12.5MG;150MG	N020758 002	Sep 30, 1997	Jun	CAHN
			12.5MG;300MG	N020758 003	Aug 31, 1998	Sep	CRLD
	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Aug	CRLD
			12.5MG;300MG	N020758 003	Aug 31, 1998	Jun	CAHN
	@		25MG;300MG	N020758 004	Mar 15, 2005	Aug	DISC
	+		25MG;300MG	N020758 004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;10MG	A076230 001	Jul 01, 2002	Aug	CAHN
AB		12.5MG;20MG	A076230 002	Jul 01, 2002	Aug	CAHN
AB		25MG;20MG	A076230 003	Jul 01, 2002	Aug	CAHN
AB	PRINSTON PHARM LLC	12.5MG;10MG	A076230 001	Jul 01, 2002	May	CAHN
AB		12.5MG;20MG	A076230 002	Jul 01, 2002	May	CAHN
AB		25MG;20MG	A076230 003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180 002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180 003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356 001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356 002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356 003	Apr 20, 2011	Apr	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	LANNETT HOLDINGS INC	25MG;37.5MG	A201407 001	Dec 09, 2011	Nov	NEWA
----	----------------------	-------------	-------------	--------------	-----	------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

REZIRA

+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442 001	Jun 08, 2011	Jun	NEWA
---	---------------	------------------	-------------	--------------	-----	------

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

AT	CROWN LABS	1%	A080706 006		Sep	CAHN
----	------------	----	-------------	--	-----	------

LOTION; TOPICAL

ALA-CORT

AT	CROWN LABS	1%	A083201 001		Sep	CAHN
----	------------	----	-------------	--	-----	------

ALA-SCALP

	CROWN LABS	2%	A083231 001		Sep	CAHN
--	------------	----	-------------	--	-----	------

SOLUTION; TOPICAL

TEXACORT

>D>	@ JSJ PHARMS	1%	A080425 001		Dec	CAHN
>A>	@ MISSION PHARMA	1%	A080425 001		Dec	CAHN
>A>	+	2.5%	A081271 001	Apr 17, 1992	Dec	CAHN
>D>	+	2.5%	A081271 001	Apr 17, 1992	Dec	CAHN
	+	2.5%	A081271 001	Apr 17, 1992	Aug	CAHN
	+	2.5%	A081271 001	Apr 17, 1992	May	CAHN

TABLET; ORAL

HYDROCORTISONE

AB	COREPHARMA	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN

TABLET; ORAL

	HYDROCORTISONE						
AB	COREPHARMA	20MG	A040646	003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

	@ FERA PHARMS	0.5%	A080828	001		Mar	CAHN
--	---------------	------	---------	-----	--	-----	------

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

>A>	+	FOUGERA PHARMS	0.1%	N020453	001	Feb 28, 1997	Dec	CAHN
>D>	+	NYCOMED US	0.1%	N020453	001	Feb 28, 1997	Dec	CAHN
	+		0.1%	N020453	001	Feb 28, 1997	Nov	CAHN

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

	@ HOSPIRA	EQ 250MG BASE/VIAL	A085930	001		Aug	DISC
	@	EQ 500MG BASE/VIAL	A085931	001		Aug	DISC
	@	EQ 1GM BASE/VIAL	A085932	001		Aug	DISC

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

	@ PAR PHARM	50MG	A088850	001	May 31, 1985	May	DISC
--	-------------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

>D>	+	PURDUE PHARM PRODS	1MG/ML	N019034	003	Apr 30, 2009	Dec	CTEC
>A>	AP	+	1MG/ML	N019034	003	Apr 30, 2009	Dec	CTEC
>D>	+		2MG/ML	N019034	004	Apr 30, 2009	Dec	CTEC
>A>	AP	+	2MG/ML	N019034	004	Apr 30, 2009	Dec	CTEC
>D>	+		4MG/ML	N019034	005	Apr 30, 2009	Dec	CTEC
>A>	AP	+	4MG/ML	N019034	005	Apr 30, 2009	Dec	CTEC

HYDROMORPHONE HYDROCHLORIDE

>A>	AP	HOSPIRA INC	1MG/ML	N200403	001	Dec 01, 2011	Dec	NEWA
>A>	AP		2MG/ML	N200403	002	Dec 01, 2011	Dec	NEWA
>A>	AP		4MG/ML	N200403	003	Dec 01, 2011	Dec	NEWA

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

	AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN
>A>	AB	MALLINCKRODT INC	2MG	A078273	001	Sep 19, 2007	Dec	CAHN
>A>	AB		4MG	A078273	002	Sep 19, 2007	Dec	CAHN
	AB	NESHER PHARMS	2MG	A077311	001	Nov 09, 2005	Nov	CAHN
	AB		4MG	A077311	002	Nov 09, 2005	Nov	CAHN
	AB		8MG	A077311	003	Nov 09, 2005	Nov	CAHN
>D>	AB	TYCO HLTHCARE	2MG	A078273	001	Sep 19, 2007	Dec	CAHN
>D>	AB		4MG	A078273	002	Sep 19, 2007	Dec	CAHN

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

	@ MERCK SANTE SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Sep	DISC
--	-------------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

CYANOKIT

+	MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Sep	CMFD
	@	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIE

@	PHARMICS	1%	N000004	004		Jan	CAHN
---	----------	----	---------	-----	--	-----	------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Feb	NEWA
---	----------	-----------------------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@	ACTAVIS TOTOWA	10MG	A040600	001	Dec 28, 2004	Jul	DISC
	@		25MG	A040602	001	Dec 28, 2004	Jul	DISC
	@		50MG	A040604	001	Dec 28, 2004	Jul	DISC
AB		HETERO LABS UNIT III	10MG	A040805	001	May 29, 2008	Jul	CAHN
AB			25MG	A040805	002	May 29, 2008	Jul	CAHN
AB			50MG	A040805	003	May 29, 2008	Jul	CAHN

IBUPROFEN

TABLET; ORAL

IBUPROHM

@	OHM LABS	400MG	A070469	001	Aug 29, 1985	Aug	DISC
---	----------	-------	---------	-----	--------------	-----	------

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

@	FOREST LABS	400MG;5MG	N021378	001	Nov 26, 2004	Aug	DISC
---	-------------	-----------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

AB	+	ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008	Nov	CRLD
AB	+		400MG;5MG	A078769	001	Jan 04, 2008	Aug	CRLD
AB	+	BARR LABS INC	400MG;5MG	A078316	001	Nov 29, 2007	Nov	CRLD

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Aug	NEWA
---	---------------------	------------------------------------	---------	-----	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP		SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Mar	NEWA
----	--	--------	--------	---------	-----	--------------	-----	------

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP		BEDFORD LABS	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Jun	NEWA
AP			3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Jun	NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

@ ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Jun DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ ACTAVIS TOTOWA

10MG

A040753 001 Feb 28, 2008 Jul DISC

@

25MG

A040752 001 Feb 28, 2008 Jul DISC

@

50MG

A040751 001 Feb 28, 2008 Jul DISC

TOFRANIL

>A> AB MALLINCKRODT INC

10MG

A087844 001 May 22, 1984 Dec CAHN

>A> AB

25MG

A087845 001 May 22, 1984 Dec CAHN

>A> AB +

50MG

A087846 001 May 22, 1984 Dec CAHN

>D> AB TYCO HLTHCARE

10MG

A087844 001 May 22, 1984 Dec CAHN

>D> AB

25MG

A087845 001 May 22, 1984 Dec CAHN

>D> AB +

50MG

A087846 001 May 22, 1984 Dec CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

>A> AB + MALLINCKRODT INC

EQ 75MG HCL

N017090 001 Dec CAHN

>A> AB

EQ 100MG HCL

N017090 004 Dec CAHN

>A> AB

EQ 125MG HCL

N017090 003 Dec CAHN

>A> AB

EQ 150MG HCL

N017090 002 Dec CAHN

>D> AB + TYCO HLTHCARE

EQ 75MG HCL

N017090 001 Dec CAHN

>D> AB

EQ 100MG HCL

N017090 004 Dec CAHN

>D> AB

EQ 125MG HCL

N017090 003 Dec CAHN

>D> AB

EQ 150MG HCL

N017090 002 Dec CAHN

IMIQUIMOD

CREAM; TOPICAL

ALDARA

>D> AB + GRACEWAY

5%

N020723 001 Feb 27, 1997 Dec CAHN

>A> AB + MEDICIS

5%

N020723 001 Feb 27, 1997 Dec CAHN

IMIQUIMOD

AB TARO

5%

A200173 001 Apr 15, 2011 Apr NEWA

AB TEVA PHARMS USA

5%

A200481 001 Apr 18, 2011 Apr NEWA

AB TOLMAR

5%

A091044 001 Feb 28, 2011 Feb NEWA

ZYCLARA

>D> + GRACEWAY

2.5%

N022483 002 Jul 15, 2011 Dec CAHN

+

2.5%

N022483 002 Jul 15, 2011 Jul NEWA

>D> +

3.75%

N022483 001 Mar 25, 2010 Dec CAHN

>A> + MEDICIS

2.5%

N022483 002 Jul 15, 2011 Dec CAHN

>A> +

3.75%

N022483 001 Mar 25, 2010 Dec CAHN

INDACATEROL MALEATE

POWDER; INHALATION
ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jul	NEWA
---	----------	---------------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA
AB	HETERO LABS UNIT III	25MG	A091240	001	Apr 12, 2011	Jul	CAHN
AB		50MG	A091240	002	Apr 12, 2011	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+	SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA
----	---	--------	------	---------	-----	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA
---	-----------------	----------------------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

@	HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-200 IN PLASTIC CONTAINER

@	HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250

@	HOSPIRA	51%	A075005	001	Feb 24, 1998	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		51%	A074898	002	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250 IN PLASTIC CONTAINER

@	HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300

@	HOSPIRA	61%	A075005	002	Feb 24, 1998	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		61%	A074898	003	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300 IN PLASTIC CONTAINER

@	HOSPIRA	61%	A074637	001	Apr 03, 1997	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		61%	A074636	003	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370

@	HOSPIRA	76%	A075005	003	Feb 24, 1998	Aug	DISC
---	---------	-----	---------	-----	--------------	-----	------

@		76%	A074898	004	Dec 30, 1997	Feb	DISC
---	--	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370 IN PLASTIC CONTAINER

@	HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

	@	ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999	Aug	DISC
AN		RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	AP	JIANGSU HENGRUI MED	40MG/2ML (20MG/ML)	A090675 002	Dec 16, 2011	Dec	NEWA
>A>	AP		100MG/5ML (20MG/ML)	A090675 001	Dec 16, 2011	Dec	NEWA
	AP	X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Jul	CAHN
	AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Jul	CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

		LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002	Mar 20, 2005	Apr	CMFD
--	--	----------	--------------------------------------	-------------	--------------	-----	------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB		VALEANT INTL	5MG	N012093 007	Jul 29, 1988	Jun	CAHN
AB			10MG	N012093 002	Jul 29, 1988	Jun	CAHN
AB			20MG	N012093 006	Jul 29, 1988	Jun	CAHN
AB	+		30MG	N012093 005	Jul 29, 1988	Jun	CAHN
	+		40MG	N012093 001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB		NESHER PHARMS	30MG	A075395 001	Mar 16, 2000	Nov	CAHN
AB			60MG	A075395 002	Mar 16, 2000	Nov	CAHN
AB			120MG	A075395 003	Mar 16, 2000	Nov	CAHN
AB		TORRENT PHARMS	30MG	A200270 001	Jun 03, 2011	May	NEWA
AB			60MG	A200495 001	Jun 03, 2011	May	NEWA
AB			120MG	A200495 002	Jun 03, 2011	May	NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB		MIKAH PHARMA	2.5MG	A077169 001	Apr 24, 2006	Feb	CAHN
AB			5MG	A077169 002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

		@ ORTHO MCNEIL JANSSEN	10MG/ML	N020966 001	Mar 30, 1999	May	DISC
--	--	------------------------	---------	-------------	--------------	-----	------

TABLET; ORAL

ONMEL

	+	STIEFEL LABS INC	200MG	N022484 001	Apr 29, 2010	May	CTNA
--	---	------------------	-------	-------------	--------------	-----	------

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

AT	+	STIEFEL LABS INC	2%	N021738 001	Jun 12, 2007	Aug	CFTG
----	---	------------------	----	-------------	--------------	-----	------

KETOCONAZOLE

AT		PERRIGO ISRAEL	2%	A091550 001	Aug 25, 2011	Aug	NEWA
----	--	----------------	----	-------------	--------------	-----	------

GEL; TOPICAL

XOLEGEL

	+	AQUA PHARMS	2%	N021946 001	Jul 28, 2006	May	CAHN
--	---	-------------	----	-------------	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	PFIZER	15MG/ML	A078299 001	Jul 16, 2007	May	CAHN
AP		30MG/ML	A078299 002	Jul 16, 2007	May	CAHN

SPRAY, METERED; NASAL

SPRIX

+	LUITPOLD	15.75MG/SPRAY	N022382 001	May 14, 2010	May	CAHN
---	----------	---------------	-------------	--------------	-----	------

LAMIVUDINE

TABLET; ORAL

EPIVIR

AB	VIIV HLTHCARE	150MG	N020564 001	Nov 17, 1995	Nov	CFTG
AB	+	300MG	N020564 003	Jun 24, 2002	Nov	CFTG

LAMIVUDINE

AB	APOTEX	150MG	A091606 001	Dec 02, 2011	Nov	NEWA
AB		300MG	A091606 002	Dec 02, 2011	Nov	NEWA
AB	AUROBINDO PHARMA LTD	150MG	A202032 001	Nov 17, 2011	Nov	NEWA
AB		300MG	A202032 002	Nov 17, 2011	Nov	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

AB	+	VIIV HLTHCARE	150MG;300MG	N020857 001	Sep 26, 1997	May	CFTG
----	---	---------------	-------------	-------------	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

AB	TEVA PHARMS	150MG;300MG	A079081 001	May 25, 2011	May	NEWA
----	-------------	-------------	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011	Mar	NEWA
AB		100MG	A078669 002	Apr 08, 2011	Mar	NEWA
AB		150MG	A078669 003	Apr 08, 2011	Mar	NEWA
AB		200MG	A078669 004	Apr 08, 2011	Mar	NEWA
AB	ALEMBIC LTD	25MG	A090607 001	Jan 13, 2011	Jan	NEWA
AB		100MG	A090607 002	Jan 13, 2011	Jan	NEWA
AB		150MG	A090607 003	Jan 13, 2011	Jan	NEWA
AB		200MG	A090607 004	Jan 13, 2011	Jan	NEWA
AB	ALEMBIC PHARMS LTD	25MG	A090607 001	Jan 13, 2011	Apr	CAHN
AB		100MG	A090607 002	Jan 13, 2011	Apr	CAHN
AB		150MG	A090607 003	Jan 13, 2011	Apr	CAHN
AB		200MG	A090607 004	Jan 13, 2011	Apr	CAHN
AB	HIKMA PHARMS	25MG	A078134 001	Apr 19, 2011	Apr	NEWA
AB		100MG	A078134 002	Apr 19, 2011	Apr	NEWA
AB		150MG	A078134 003	Apr 19, 2011	Apr	NEWA
AB		200MG	A078134 004	Apr 19, 2011	Apr	NEWA
AB	UNICHEM LABS LTD	25MG	A090170 001	Oct 06, 2011	Sep	NEWA
AB		100MG	A090170 002	Oct 06, 2011	Sep	NEWA
AB		150MG	A090170 003	Oct 06, 2011	Sep	NEWA
AB		200MG	A090170 004	Oct 06, 2011	Sep	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	JUBILANT LIFE	5MG	A200220 001	Feb 28, 2011	Feb	NEWA
AB		25MG	A200220 002	Feb 28, 2011	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

SMITHKLINE BEECHAM 250MG

N022115 006 Jun 21, 2011 Sep NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+ IPSEN PHARMS EQ 60MG BASE
 + EQ 90MG BASE
 + EQ 120MG BASE

N022074 001 Aug 30, 2007 Nov CAHN

N022074 002 Aug 30, 2007 Nov CAHN

N022074 003 Aug 30, 2007 Nov CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT ALCON RES 0.005%
 AT APOTEX 0.005%
 AT BAUSCH AND LOMB 0.005%
 AT LUITPOLD 0.005%
 AT MYLAN 0.005%
 AT PADDOCK LABS 0.005%
 AT PHARMAFORCE 0.005%

A091449 001 Mar 22, 2011 Mar NEWA

A077697 001 Mar 22, 2011 Mar NEWA

A201006 001 Mar 22, 2011 Mar NEWA

A200925 001 Mar 22, 2011 May CAHN

A201786 001 Mar 22, 2011 Mar NEWA

A090887 001 Jul 19, 2011 Jul NEWA

A200925 001 Mar 22, 2011 Mar NEWA

XALATAN

AT + PHARMACIA AND UPJOHN 0.005%

N020597 001 Jun 05, 1996 Mar CFTG

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB ALEMBIC PHARMS LTD 10MG
 AB 20MG

A091369 001 Nov 21, 2011 Nov NEWA

A091369 002 Nov 21, 2011 Nov NEWA

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

>A> CELGENE 2.5MG

N021880 005 Dec 21, 2011 Dec NEWA

LETROZOLE

TABLET; ORAL

LETROZOLE

AB ACCORD HLTHCARE 2.5MG
 AB ACTAVIS TOTOWA 2.5MG
 AB AMIDE PHARM 2.5MG
 AB DR REDDYS LABS LTD 2.5MG
 AB ENDO PHARMS 2.5MG
 AB FRESENIUS KABI ONCOL 2.5MG
 AB IMPAX LABS 2.5MG
 AB INDICUS PHARMA 2.5MG
 AB KUDCO IRELAND 2.5MG
 AB NATCO PHARMA LTD 2.5MG
 AB ROXANE 2.5MG
 AB SUN PHARM INDS LTD 2.5MG
 @ SYNTHON PHARMS 2.5MG
 AB 2.5MG
 AB TEVA PHARMS 2.5MG

A090934 001 Jun 03, 2011 May NEWA

A090292 001 Jul 13, 2011 Aug CAHN

A090292 001 Jul 13, 2011 Jul NEWA

A091191 001 Jun 03, 2011 May NEWA

A090789 001 Jun 03, 2011 May NEWA

A090491 001 Jun 03, 2011 May NEWA

A091638 001 Jun 03, 2011 May NEWA

A201804 001 Jun 03, 2011 May NEWA

A091098 001 Jun 03, 2011 May NEWA

A200161 001 Jun 03, 2011 May NEWA

A090838 001 Jun 03, 2011 May NEWA

A091466 001 Jun 03, 2011 May NEWA

A090196 001 Jun 03, 2011 Jun DISC

A090196 001 Jun 03, 2011 May NEWA

A090289 001 Jun 03, 2011 May NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

@ GENZYME	1MG/0.2ML	A075721 001	Nov 29, 2001	Apr	DISC
LUPRON DEPOT					
+ ABBOTT ENDOCRINE	22.5MG/VIAL	N020517 001	Dec 22, 1995	Jun	CAHN
+ 30MG/VIAL		N020517 002	May 30, 1997	Jun	CAHN
+ 45MG/VIAL		N020517 003	Jun 17, 2011	Jun	NEWA
LUPRON DEPOT-PED					
+ ABBOTT ENDOCRINE	11.25MG/VIAL	N020263 007	Aug 15, 2011	Aug	NEWA
+ 30MG/VIAL		N020263 008	Aug 15, 2011	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN WATSON LABS INC	EQ 0.0103% BASE	A077756 003	Apr 09, 2008	Aug	CAHN
AN	EQ 0.021% BASE	A077756 001	Apr 09, 2008	Aug	CAHN
AN	EQ 0.042% BASE	A077756 002	Apr 09, 2008	Aug	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP HIKMA FARMACEUTICA	500MG/5ML(100MG/ML)	A090981 001	Oct 13, 2011	Oct	NEWA
AP INNOPHARMA LLC	500MG/5ML (100MG/ML)	A091485 001	Aug 05, 2011	Jul	NEWA
LEVETIRACETAM IN SODIUM CHLORIDE					
+ HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543 001	Nov 09, 2011	Nov	NEWA
+ 1000MG/100ML (10MG/ML)		N202543 002	Nov 09, 2011	Nov	NEWA
+ 1500MG/100ML (15MG/ML)		N202543 003	Nov 09, 2011	Nov	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA APOTEX	100MG/ML	A090187 001	Aug 05, 2011	Jul	NEWA
AA LUPIN LTD	100MG/ML	A090893 001	Oct 17, 2011	Oct	NEWA

TABLET; ORAL

LEVETIRACETAM

AB ACCORD HLTHCARE	250MG	A090843 001	Feb 14, 2011	Jan	NEWA
AB	500MG	A090843 002	Feb 14, 2011	Jan	NEWA
AB	750MG	A090843 003	Feb 14, 2011	Jan	NEWA
AB	1GM	A090843 004	Feb 14, 2011	Jan	NEWA
AB AJANTA PHARMA	250MG	A201293 001	Jun 14, 2011	May	NEWA
AB	500MG	A201293 002	Jun 14, 2011	May	NEWA
AB	750MG	A201293 003	Jun 14, 2011	May	NEWA
AB	1GM	A201293 004	Jun 14, 2011	May	NEWA
AB BRECKENRIDGE PHARM	250MG	A090511 001	Aug 18, 2011	Aug	NEWA
AB	500MG	A090511 002	Aug 18, 2011	Aug	NEWA
AB	750MG	A090511 003	Aug 18, 2011	Aug	NEWA
AB	1GM	A090511 004	Aug 18, 2011	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

AB UCB INC	500MG	N022285 001	Sep 12, 2008	Aug	CFTG
AB +	750MG	N022285 002	Feb 12, 2009	Aug	CFTG

LEVETIRACETAM

AB ACTAVIS ELIZABETH	500MG	A091557 001	Sep 12, 2011	Aug	NEWA
AB	750MG	A091557 002	Sep 12, 2011	Aug	NEWA
AB ANCHEN PHARMS	500MG	A091360 001	Oct 04, 2011	Sep	NEWA
AB	750MG	A091360 002	Oct 04, 2011	Sep	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	APOTEX INC	500MG	A091261 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091261 002	Sep 12, 2011	Aug	NEWA
AB	LUPIN LTD	500MG	A091399 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091399 002	Sep 12, 2011	Aug	NEWA
AB	MUTUAL PHARM CO INC	500MG	A091285 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091285 002	Sep 12, 2011	Aug	NEWA
>A>	MYLAN PHARMS INC	500MG	A200475 001	Dec 19, 2011	Dec	NEWA
>A>		750MG	A200475 002	Dec 19, 2011	Dec	NEWA
AB	PAR PHARM	500MG	A091291 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091291 002	Sep 12, 2011	Aug	NEWA
AB	TEVA PHARMS	500MG	A091430 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091430 002	Sep 12, 2011	Aug	NEWA
AB	WATSON LABS FLORIDA	500MG	A091093 001	Sep 12, 2011	Aug	NEWA
AB		750MG	A091093 002	Sep 12, 2011	Aug	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	SYNTHON PHARMS	2.5MG/5ML	A091263 001	Nov 07, 2011	Oct	NEWA
----	----------------	-----------	-------------	--------------	-----	------

XYZAL

AA	+ UCB INC	2.5MG/5ML	N022157 001	Jan 28, 2008	Oct	CFTG
----	-----------	-----------	-------------	--------------	-----	------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	A090392 001	Feb 24, 2011	Feb	NEWA
AB	GLENMARK GENERICS	5MG	A090385 001	Feb 24, 2011	Feb	NEWA
AB	TEVA PHARMS	5MG	A090199 001	Aug 22, 2011	Aug	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

AP	+ ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996	Jun	CFTG
AP	+	EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996	Jun	CFTG
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+ ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635 002	Dec 20, 1996	Jun	CFTG
AP	+	EQ 500MG/100ML (EQ 5MG/ML)	N020635 003	Dec 20, 1996	Jun	CFTG
AP	+	EQ 750MG/150ML (EQ 5MG/ML)	N020635 005	Dec 20, 1996	Jun	CFTG

LEVOFLOXACIN

AP	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011	Jun	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011	Jun	NEWA
AP	SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011	Jun	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011	Jun	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343 001	Jul 07, 2011	Jun	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A090343 002	Jul 07, 2011	Jun	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A090343 003	Jul 07, 2011	Jun	NEWA
AP	HIKMA FARMACEUTICA	EQ 250MG/50ML (EQ 5MG/ML)	A091375 001	Sep 16, 2011	Sep	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091375 002	Sep 16, 2011	Sep	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091375 003	Sep 16, 2011	Sep	NEWA

SOLUTION; ORAL

LEVAQUIN

AA	+ ORTHO MCNEIL JANSSEN	250MG/10ML	N021721 001	Oct 21, 2004	Jun	CFTG
----	------------------------	------------	-------------	--------------	-----	------

LEVOFLOXACIN

AA	HI TECH PHARMA	250MG/10ML	A091678 001	Jun 20, 2011	Jun	NEWA
----	----------------	------------	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC						
LEVOFLOXACIN						
AT	HI TECH PHARMA	0.5%	A076826 001	Feb 10, 2011	Jan	NEWA
TABLET; ORAL						
LEVAQUIN						
AB	ORTHO MCNEIL JANSSEN	250MG	N020634 001	Dec 20, 1996	Jun	CFTG
AB		500MG	N020634 002	Dec 20, 1996	Jun	CFTG
AB	+	750MG	N020634 003	Sep 08, 2000	Jun	CFTG
LEVOFLOXACIN						
AB	APOTEX INC	250MG	A090787 001	Sep 29, 2011	Sep	NEWA
AB		500MG	A090787 002	Sep 29, 2011	Sep	NEWA
AB		750MG	A090787 003	Sep 29, 2011	Sep	NEWA
AB	AUROBINDO PHARMA LTD	250MG	A201043 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A201043 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A201043 003	Jun 20, 2011	Jun	NEWA
AB	DR REDDYS LABS INC	250MG	A076710 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076710 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076710 003	Jun 20, 2011	Jun	NEWA
AB	GLENMARK GENERICS	250MG	A200250 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A200250 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A200250 003	Jun 20, 2011	Jun	NEWA
AB	LUPIN	250MG	A078424 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A078424 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A078424 003	Jun 20, 2011	Jun	NEWA
AB	MYLAN	250MG	A076276 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076276 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077097 001	Jun 20, 2011	Jun	NEWA
AB	SANDOZ	250MG	A077438 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A077438 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077438 003	Jun 20, 2011	Jun	NEWA
AB	TEVA	250MG	A076361 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076361 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076361 003	Jun 20, 2011	Jun	NEWA
AB	TORRENT PHARMS	250MG	A090722 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090722 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090722 003	Jun 20, 2011	Jun	NEWA
AB	WOCKHARDT	250MG	A090367 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090367 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090367 003	Jun 20, 2011	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 20, 2011	Apr	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 20, 2011	Apr	NEWA

SOLUTION; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 29, 2011	Oct	CMS1
+		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 20, 2011	May	CDFR
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 29, 2011	Oct	CMS1
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 20, 2011	May	CDFR

LEVONORGESTREL

TABLET; ORAL

PLAN B

AB	+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
		@	0.75MG	N021045 001	Jul 28, 1999	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991 Mar DISC

LEVORPHANOL TARTRATE

ROXANE

2MG

A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+ APP PHARMS

100MCG/VIAL

N202231 001 Jun 24, 2011 Jun NEWA

+

200MCG/VIAL

N202231 002 Jun 24, 2011 Jun NEWA

+

500MCG/VIAL

N202231 003 Jun 24, 2011 Jun NEWA

TABLET; ORAL

LEVO-T

AB1, ALARA PHARM

0.025MG

N021342 001 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.05MG

N021342 002 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.075MG

N021342 003 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.088MG

N021342 004 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.1MG

N021342 005 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.112MG

N021342 006 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.125MG

N021342 007 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.137MG

N021342 012 Dec 08, 2003 Feb CTEC

AB2,

AB3

AB1,

0.15MG

N021342 008 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.175MG

N021342 009 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1,

0.2MG

N021342 010 Mar 01, 2002 Feb CTEC

AB2,

AB3

AB1, +

0.3MG

N021342 011 Mar 01, 2002 Feb CTEC

AB2,

AB3

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT NOVOCOL INC

5%

A040911 001 May 23, 2011 May NEWA

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL						
LIDOCAINE HYDROCHLORIDE						
AT	HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
XYLOCAINE						
AT	+ OAK PHARMS	2%	N008816 001		Aug	CAHN
SOLUTION; ORAL						
LIDOCAINE HYDROCHLORIDE VISCOUS						
	@ ACTAVIS MID ATLANTIC	2%	A086578 001		Aug	DISC
SOLUTION; TOPICAL						
PEDIATRIC LTA KIT						
	@ HOSPIRA	2%	A085995 001		Aug	DISC
SYSTEM; INTRADERMAL						
ZINGO						
	@ POWDER PHARMS	0.5MG	N022114 001	Aug 16, 2007	Jun	CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL						
EMLA						
AB	+ OAK PHARMS	2.5%;2.5%	N019941 001	Dec 30, 1992	Aug	CAHN

LINAGLIPTIN

TABLET; ORAL						
TRADJENTA						
	+ BOEHRINGER INGELHEIM	5MG	N201280 001	May 02, 2011	May	NEWA

LINDANE

LOTION; TOPICAL						
LINDANE						
AT	OLTA PHARMS	1%	A087313 001		Oct	CMFD
AT	+ WOCKHARDT	1%	A088190 001	Aug 16, 1984	Oct	CTEC

LISINOPRIL

TABLET; ORAL						
LISINOPRIL						
AB	PRINSTON INC	2.5MG	A076180 001	Jul 01, 2002	Aug	CAHN
AB		5MG	A076180 002	Jul 01, 2002	Aug	CAHN
AB		10MG	A076180 003	Jul 01, 2002	Aug	CAHN
AB		20MG	A076164 001	Jul 01, 2002	Aug	CAHN
AB		30MG	A076164 002	Jul 01, 2002	Aug	CAHN
AB		40MG	A076164 003	Jul 01, 2002	Aug	CAHN
AB	PRINSTON PHARM LLC	2.5MG	A076180 001	Jul 01, 2002	May	CAHN
AB		5MG	A076180 002	Jul 01, 2002	May	CAHN
AB		10MG	A076180 003	Jul 01, 2002	May	CAHN
AB		20MG	A076164 001	Jul 01, 2002	May	CAHN
AB		30MG	A076164 002	Jul 01, 2002	May	CAHN
AB		40MG	A076164 003	Jul 01, 2002	May	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL						
LITHIUM CARBONATE						
AB	GLENMARK GENERICS	450MG	A091616 001	Feb 14, 2011	Jan	NEWA

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AP	TAYLOR	2MG/ML	A075025 001	Jul 23, 1998	Sep	CMFD
TABLET; ORAL						
ATIVAN						
AB	VALEANT INTL	0.5MG	N017794 001		Jul	CAHN
AB		1MG	N017794 002		Jul	CAHN
AB	+	2MG	N017794 003		Jul	CAHN
LORAZEPAM						
	@ MUTUAL PHARM	0.5MG	A072553 001	Mar 29, 1991	Sep	DISC
	@	1MG	A072554 001	Mar 29, 1991	Sep	DISC
	@	2MG	A072555 001	Mar 29, 1991	Sep	DISC

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN
AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA
AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN
AB	HUAHAI US INC	25MG	A091497 001	Jun 06, 2011	May	NEWA
AB		50MG	A091497 002	Jun 06, 2011	May	NEWA
AB		100MG	A091497 003	Jun 06, 2011	May	NEWA
AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA
AB	PRINSTON INC	25MG	A091497 001	Jun 06, 2011	Aug	CAHN
AB		50MG	A091497 002	Jun 06, 2011	Aug	CAHN
AB		100MG	A091497 003	Jun 06, 2011	Aug	CAHN

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011	Apr	NEWA
---	-----------------	------	-------------	--------------	-----	------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	LANNETT HOLDINGS INC	EQ 5MG BASE	A090695 001	Sep 26, 2011	Sep	NEWA
AB		EQ 10MG BASE	A090695 002	Sep 26, 2011	Sep	NEWA
AB		EQ 25MG BASE	A090695 003	Sep 26, 2011	Sep	NEWA
AB		EQ 50MG BASE	A090695 004	Sep 26, 2011	Sep	NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

@	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N018406 002	Jul 08, 1982	Aug	DISC
---	---------	---	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA

TABLET; ORAL							
MECLIZINE HYDROCHLORIDE							
AA	JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659	002	Jun 04, 2010	Jan	CAHN
<u>MEFENAMIC ACID</u>							
CAPSULE; ORAL							
MEFENAMIC ACID							
AB	LUPIN LTD	250MG	A091322	001	Jul 22, 2011	Jul	NEWA
<u>MELOXICAM</u>							
TABLET; ORAL							
MELOXICAM							
AB	MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934	002	Jul 20, 2006	Feb	CAHN
AB	PURACAP PHARM	7.5MG	A077938	001	Jul 19, 2006	Jun	CAHN
AB		15MG	A077938	002	Jul 19, 2006	Jun	CAHN
<u>MEMANTINE HYDROCHLORIDE</u>							
TABLET; ORAL							
MEMANTINE							
	@ SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	May	CAHN
	@	10MG	A090058	002	May 05, 2010	May	CAHN
MEMANTINE HYDROCHLORIDE							
	@ TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	Oct	NEWA
	@	10MG	A090052	002	Oct 25, 2011	Oct	NEWA
<u>MEPERIDINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	BAXTER HLTHCARE CORP	10MG/ML	A081002	001	Jul 30, 1993	May	CAHN
<u>MEPROBAMATE</u>							
TABLET; ORAL							
MEPROBAMATE							
AA	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	May	CAHN
AA		400MG	A090122	002	Feb 18, 2009	May	CAHN
AA	TARO	200MG	A200998	001	May 23, 2011	May	NEWA
AA		400MG	A200998	002	May 23, 2011	May	NEWA
<u>MEQUINOL; TRETINOIN</u>							
SOLUTION; TOPICAL							
SOLAGE							
+	AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999	May	CAHN
<u>MEROPENEM</u>							
INJECTABLE; INJECTION							
MEROPENEM							
AP	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Oct	NEWA
AP		1GM/VIAL	A091404	002	Oct 26, 2011	Oct	NEWA
AP	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Mar	NEWA
AP		1GM/VIAL	A091201	002	Mar 29, 2011	Mar	NEWA
MERREM							
AP	+ ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
AP	+	1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+	MEDA PHARMS	4GM/60ML	N019618 001	Dec 24, 1987	Jun	CAHN
----	---	-------------	----------	-------------	--------------	-----	------

SFROWASA

AB		MEDA PHARMS	4GM/60ML	N019618 002	Jun 20, 2008	Jun	CAHN
----	--	-------------	----------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

ASACOL

+		WARNER CHILCOTT LLC	400MG	N019651 001	Jan 31, 1992	Jun	CAHN
---	--	---------------------	-------	-------------	--------------	-----	------

ASACOL HD

+		WARNER CHILCOTT LLC	800MG	N021830 001	May 29, 2008	Jun	CAHN
---	--	---------------------	-------	-------------	--------------	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

>D>	AN		NEPHRON	0.4%	A071855 001	Jul 14, 1988	Dec	DISC
-----	----	--	---------	------	-------------	--------------	-----	------

>A>		@		0.4%	A071855 001	Jul 14, 1988	Dec	DISC
-----	--	---	--	------	-------------	--------------	-----	------

>D>	AN			0.6%	A071726 001	Jul 14, 1988	Dec	DISC
-----	----	--	--	------	-------------	--------------	-----	------

>A>		@		0.6%	A071726 001	Jul 14, 1988	Dec	DISC
-----	--	---	--	------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		APOTEX	500MG	A090666 001	Dec 07, 2011	Nov	NEWA
----	--	--------	-------	-------------	--------------	-----	------

AB			850MG	A090666 002	Dec 07, 2011	Nov	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			1GM	A090666 003	Dec 07, 2011	Nov	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB		MYLAN	500MG	A075973 001	Jan 25, 2002	Feb	CAHN
----	--	-------	-------	-------------	--------------	-----	------

AB			850MG	A075973 002	Jan 25, 2002	Feb	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB			1GM	A075973 003	Jan 25, 2002	Feb	CAHN
----	--	--	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

AB2		ANDRX LABS LLC	500MG	N021574 001	Apr 27, 2004	Jun	CTEC
-----	--	----------------	-------	-------------	--------------	-----	------

AB	+		1GM	N021574 002	Apr 27, 2004	Jun	CTEC
----	---	--	-----	-------------	--------------	-----	------

GLUCOPHAGE XR

AB1		BRISTOL MYERS SQUIBB	500MG	N021202 001	Oct 13, 2000	Jun	CTEC
-----	--	----------------------	-------	-------------	--------------	-----	------

GLUMETZA

BX		SANTARUS	500MG	N021748 001	Jun 03, 2005	Nov	CAHN
----	--	----------	-------	-------------	--------------	-----	------

BX	+		1GM	N021748 002	Jun 03, 2005	Nov	CAHN
----	---	--	-----	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

@		ACTAVIS ELIZABETH	500MG	A076450 001	Oct 01, 2004	Aug	DISC
---	--	-------------------	-------	-------------	--------------	-----	------

AB1			500MG	A076450 001	Oct 01, 2004	Jun	CTEC
-----	--	--	-------	-------------	--------------	-----	------

@			750MG	A076878 001	Apr 13, 2005	Aug	DISC
---	--	--	-------	-------------	--------------	-----	------

AB1		ALVOGEN	500MG	A078321 001	Apr 17, 2008	Aug	CAHN
-----	--	---------	-------	-------------	--------------	-----	------

AB			750MG	A078321 002	Apr 17, 2008	Aug	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB1		AMNEAL PHARMS NY	500MG	A078596 001	Jan 03, 2008	Jun	CTEC
-----	--	------------------	-------	-------------	--------------	-----	------

AB1		APOTEX	500MG	A076706 001	Dec 14, 2004	Jun	CTEC
-----	--	--------	-------	-------------	--------------	-----	------

AB			750MG	A076706 002	Dec 29, 2005	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB1		IMPAX LABS	500MG	A076249 001	Jul 30, 2004	Jun	CTEC
-----	--	------------	-------	-------------	--------------	-----	------

AB2		LUPIN LTD	500MG	A090692 001	Jun 29, 2011	Aug	CAHN
-----	--	-----------	-------	-------------	--------------	-----	------

AB2			500MG	A090692 001	Jun 29, 2011	Jun	NEWA
-----	--	--	-------	-------------	--------------	-----	------

AB			1GM	A090692 002	Jun 29, 2011	Aug	CAHN
----	--	--	-----	-------------	--------------	-----	------

AB			1GM	A090692 002	Jun 29, 2011	Jun	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB1		MYLAN	500MG	A076650 001	Sep 13, 2005	Jun	CTEC
-----	--	-------	-------	-------------	--------------	-----	------

AB1		NEUROSCI INC	500MG	A078321 001	Apr 17, 2008	Jun	CTEC
-----	--	--------------	-------	-------------	--------------	-----	------

AB1		NOSTRUM	500MG	A076756 001	Jul 26, 2006	Jun	CTEC
-----	--	---------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Jun	CTEC
AB1	SANDOZ	500MG	A076873 001	Dec 14, 2004	Jun	CTEC
AB1	SUN PHARM INDS (IN)	500MG	A077336 001	Feb 09, 2006	Jun	CTEC
AB1	TEVA	500MG	A076269 001	Jun 18, 2004	Jun	CTEC
AB1	TORRENT PHARM	500MG	A090014 001	Dec 30, 2009	Jun	CTEC
AB1	WATSON LABS FLORIDA	500MG	A076172 001	Jun 16, 2004	Jun	CTEC
AB1	WATSON LABS INC	500MG	A076818 001	Dec 14, 2004	Jun	CTEC
AB1	ZYDUS PHARMS USA	500MG	A077060 001	Apr 20, 2005	Jun	CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Feb	CFTG
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG;EQ 15MG BASE	A090406 001	Feb 25, 2011	Feb	NEWA
AB		850MG;EQ 15MG BASE	A090406 002	Feb 25, 2011	Feb	NEWA

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+	MYLAN INSTITUTIONAL	10MG/ML	N021624 001		Oct	CAHN
---	---------------------	---------	-------------	--	-----	------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	EMCURE PHARMS USA	5MG	A040734 001	Dec 14, 2007	Jul	CAHN
AB		10MG	A040734 002	Dec 14, 2007	Jul	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	AUSTARPHARMA LLC	500MG	A200958 001	Oct 21, 2011	Oct	NEWA
AA		750MG	A200958 002	Oct 21, 2011	Oct	NEWA
AA	LANNETT HOLDINGS INC	500MG	A084756 002	Mar 31, 2003	Jun	CAHN
AA		750MG	A084756 001		Jun	CAHN
	@ PURACAP PHARM	500MG	A084231 002		Jun	CAHN
	@	750MG	A084471 001		Jun	CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BRECKENRIDGE PHARM	2.5MG	A040642 001	Dec 06, 2011	Nov	NEWA
AA		5MG	A040642 002	Dec 06, 2011	Nov	NEWA

PAMINE

>A>	AA	+	FOUGERA PHARMS	2.5MG		Dec	CAHN
>D>	AA	+	NYCOMED US	2.5MG		Dec	CAHN

PAMINE FORTE

>A>	AA	+	FOUGERA PHARMS	5MG	Mar 25, 2003	Dec	CAHN
>D>	AA	+	NYCOMED US	5MG	Mar 25, 2003	Dec	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

AB	+	NOVARTIS	0.2MG	N006035 003		Apr	CTEC
----	---	----------	-------	-------------	--	-----	------

METHYLERGONOVINE MALEATE

AB		NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011	Apr	NEWA
----	--	----------------	-------	-------------	--------------	-----	------

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

PROGENICS

8MG/0.4ML

N021964 002	Sep 27, 2010	Oct	NEWA
-------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS	20MG	A078458 001	Dec 01, 2011	Nov	NEWA
----	--	---------	------	-------------	--------------	-----	------

AB			30MG	A078458 002	Dec 01, 2011	Nov	NEWA
----	--	--	------	-------------	--------------	-----	------

AB			40MG	A078458 003	Dec 01, 2011	Nov	NEWA
----	--	--	------	-------------	--------------	-----	------

RITALIN LA

AB		NOVARTIS	20MG	N021284 001	Jun 05, 2002	Nov	CFTG
----	--	----------	------	-------------	--------------	-----	------

AB			30MG	N021284 002	Jun 05, 2002	Nov	CFTG
----	--	--	------	-------------	--------------	-----	------

AB	+		40MG	N021284 003	Jun 05, 2002	Nov	CFTG
----	---	--	------	-------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS ELIZABETH

5MG

A040321 001	Feb 05, 2002	Aug	DISC
-------------	--------------	-----	------

@

10MG

A040321 002	Feb 05, 2002	Aug	DISC
-------------	--------------	-----	------

@

20MG

A040321 003	Feb 05, 2002	Aug	DISC
-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS ELIZABETH

20MG

A075450 001	Dec 21, 2001	Aug	DISC
-------------	--------------	-----	------

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189 001	Oct 31, 1997	Jan	CAHN
----	--	------------------	-----	-------------	--------------	-----	------

AB			8MG	A040189 002	Oct 31, 1997	Jan	CAHN
----	--	--	-----	-------------	--------------	-----	------

AB			16MG	A040189 003	Jul 20, 2007	Jan	CAHN
----	--	--	------	-------------	--------------	-----	------

AB			32MG	A040189 004	Jul 20, 2007	Jan	CAHN
----	--	--	------	-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP		HEMOFARM	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Apr	CAHN
----	--	----------	-------------------	-------------	--------------	-----	------

AP			EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Apr	CAHN
----	--	--	--------------------	-------------	--------------	-----	------

@ HOSPIRA

EQ 500MG BASE/VIAL

A089173 001	Aug 18, 1987	Feb	DISC
-------------	--------------	-----	------

@

EQ 1GM BASE/VIAL

A089174 001	Aug 18, 1987	Feb	DISC
-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		MUSTAFA NEVSAT	EQ 40MG BASE/VIAL	A040888 001	Jul 18, 2011	Jul	NEWA
----	--	----------------	-------------------	-------------	--------------	-----	------

AP			EQ 125MG BASE/VIAL	A040888 002	Jul 18, 2011	Jul	NEWA
----	--	--	--------------------	-------------	--------------	-----	------

AP			EQ 500MG BASE/VIAL	A040888 003	Jul 18, 2011	Jul	NEWA
----	--	--	--------------------	-------------	--------------	-----	------

AP			EQ 1GM BASE/VIAL	A040888 004	Jul 18, 2011	Jul	NEWA
----	--	--	------------------	-------------	--------------	-----	------

AP			EQ 2GM BASE/VIAL	A040888 005	Jul 18, 2011	Jul	NEWA
----	--	--	------------------	-------------	--------------	-----	------

SOLU-MEDROL

AP	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856 007	Feb 27, 1985	Jul	CTEC
----	---	----------------------	------------------	-------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@ HOSPIRA EQ 5MG BASE/ML

A073117 001 Jan 17, 1991 Aug DISC

TABLET; ORAL

REGLAN

AB ANI PHARMS EQ 5MG BASE

N017854 002 May 05, 1987 Aug CAHN

AB + EQ 10MG BASE

N017854 001 Aug CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

@ MEDA PHARMS EQ 5MG BASE

N021793 001 Jun 10, 2005 Aug CAHN

@ EQ 10MG BASE

N021793 002 Jun 10, 2005 Aug CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>A> AB MYLAN PHARMS INC EQ 25MG TARTRATE

A202033 001 Dec 15, 2011 Dec NEWA

>A> AB EQ 50MG TARTRATE

A202033 002 Dec 15, 2011 Dec NEWA

>A> AB EQ 100MG TARTRATE

A202033 003 Dec 15, 2011 Dec NEWA

>A> AB EQ 200MG TARTRATE

A202033 004 Dec 15, 2011 Dec NEWA

AB NESHER PHARMS EQ 25MG TARTRATE

A077779 001 Mar 20, 2008 Nov CAHN

AB EQ 50MG TARTRATE

A077176 001 May 14, 2008 Nov CAHN

AB EQ 100MG TARTRATE

A076640 002 May 18, 2007 Nov CAHN

AB EQ 200MG TARTRATE

A076640 001 May 18, 2007 Nov CAHN

METRONIDAZOLE

GEL; TOPICAL

METROGEL

AB + GALDERMA LABS LP 1%

N021789 001 Jun 30, 2005 Jul CTEC

METRONIDAZOLE

AB G AND W LABS INC 0.75%

A078178 001 Jan 19, 2011 Jan NEWA

AB TOLMAR 1%

A090903 001 Jul 22, 2011 Jul NEWA

GEL; VAGINAL

METROGEL-VAGINAL

>D> AB + GRACEWAY 0.75%

N020208 001 Aug 17, 1992 Dec CAHN

>A> AB + MEDICIS 0.75%

N020208 001 Aug 17, 1992 Dec CAHN

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP + PFIZER 500MG/100ML

N018353 002 Jun CAHN

TABLET; ORAL

METRONIDAZOLE

AB ALEMBIC PHARMS LTD 250MG

A079067 001 Mar 13, 2009 May CAHN

AB 500MG

A079067 002 Mar 13, 2009 May CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

@ PFIZER EQ 500MG BASE/VIAL

N018353 001 Jun DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+ ASTELLAS 100MG/VIAL

N021506 003 Jun 27, 2006 Jan CRLD

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

>A>	@ INSIGHT PHARMS	2%	N017494 001		Dec	CAHN
>D>	@ ORTHO JANSSEN	2%	N017494 001		Dec	CAHN
	@	2%	N017494 001		Jul	CAHN

LOTION; TOPICAL

MONISTAT-DERM

>A>	@ INSIGHT PHARMS	2%	N017739 001		Dec	CAHN
>D>	@ JOHNSON AND JOHNSON	2%	N017739 001		Dec	CAHN

SUPPOSITORY; VAGINAL

MONISTAT 3

>A>	AB +	INSIGHT PHARMS	200MG	N018888 001	Aug 15, 1984	Dec	CAHN
>D>	AB +	PERSONAL PRODS	200MG	N018888 001	Aug 15, 1984	Dec	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ HOSPIRA	EQ 1MG BASE/ML	A075409 002	Jun 20, 2000	Aug	DISC
--	-----------	----------------	-------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316 001	May 04, 2011	Apr	NEWA
AP		EQ 5MG BASE/ML	A090316 002	May 04, 2011	Apr	NEWA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	+ CYPRESS BIOSCIENCE	50MG	N022256 003	Jan 14, 2009	Aug	CRLD
		100MG	N022256 004	Jan 14, 2009	Aug	CRLD

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@ HOSPIRA	EQ 1MG BASE/ML	A075884 001	May 28, 2002	Feb	DISC
--	-----------	----------------	-------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	PAR PHARM	EQ 50MG BASE	A065131 001	Apr 16, 2003	Oct	CAHN
AB		EQ 75MG BASE	A065131 002	Apr 16, 2003	Oct	CAHN
AB	+	EQ 100MG BASE	A065131 003	Apr 16, 2003	Oct	CAHN

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 45MG BASE	A091424 001	Nov 30, 2011	Nov	NEWA
	@	EQ 55MG BASE	A091424 002	Nov 30, 2011	Nov	NEWA
AB		EQ 90MG BASE	A091424 003	Nov 30, 2011	Nov	NEWA
AB		EQ 135MG BASE	A091424 004	Nov 30, 2011	Nov	NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076308 001	Jun 20, 2003	Aug	DISC
	@	30MG	A076308 002	Jun 20, 2003	Aug	DISC
	@	45MG	A076308 003	Jun 20, 2003	Aug	DISC
	@ ACTAVIS TOTOWA	15MG	A076241 001	Jun 25, 2003	Jul	DISC
	@	30MG	A076241 002	Jun 25, 2003	Jul	DISC

TABLET; ORAL

MIRTAZAPINE

@ ACTAVIS TOTOWA 45MG

A076241 003 Jun 25, 2003 Jul DISC

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB ACTAVIS ELIZABETH 15MG

A077959 001 Feb 14, 2011 Jan NEWA

AB 30MG

A077959 002 Feb 14, 2011 Jan NEWA

AB 45MG

A077959 003 Feb 14, 2011 Jan NEWA

@ ACTAVIS TOTOWA 15MG

A076689 001 Aug 31, 2005 Jul DISC

@ 30MG

A076689 002 Aug 31, 2005 Jul DISC

@ 45MG

A076689 003 Aug 31, 2005 Jul DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP + HOSPIRA EQ 20MG BASE/10ML (EQ 2MG
BASE/ML)

A076871 001 Apr 11, 2006 Aug CRLD

AP + EQ 25MG BASE/12.5ML (EQ 2MG
BASE/ML)

A076871 002 Apr 11, 2006 Aug CRLD

AP + EQ 30MG BASE/15ML (EQ 2MG
BASE/ML)

A076871 003 Apr 11, 2006 Aug CRLD

AP MYLAN INSTITUTIONAL EQ 20MG BASE/10ML (EQ 2MG
BASE/ML)

A078980 001 Apr 13, 2009 Nov CAHN

AP EQ 30MG BASE/15ML (EQ 2MG
BASE/ML)

A078980 002 Apr 13, 2009 Nov CAHN

NOVANTRONE

@ EMD SERONO EQ 20MG BASE/10ML (EQ 2MG
BASE/ML)

N019297 001 Dec 23, 1987 Aug DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB ACTAVIS ELIZABETH 20MG

N020616 001 Jul 03, 1996 Oct CFTG

AB 30MG

N020616 004 Mar 09, 2001 Oct CFTG

AB 50MG

N020616 002 Jul 03, 1996 Oct CFTG

AB 60MG

N020616 005 Mar 09, 2001 Oct CFTG

AB 80MG

N020616 006 Oct 27, 2006 Oct CFTG

AB + 100MG

N020616 003 Jul 03, 1996 Oct CFTG

MORPHINE SULFATE

AB WATSON LABS 20MG

A200812 001 Nov 10, 2011 Oct NEWA

AB 30MG

A200812 002 Nov 10, 2011 Oct NEWA

AB 50MG

A200812 003 Nov 10, 2011 Oct NEWA

AB 60MG

A200812 004 Nov 10, 2011 Oct NEWA

AB 80MG

A200812 005 Nov 10, 2011 Oct NEWA

AB 100MG

A200812 006 Nov 10, 2011 Oct NEWA

INJECTABLE; INJECTION

MORPHINE SULFATE

+ HOSPIRA INC 2MG/ML

N202515 001 Nov 14, 2011 Nov NEWA

+ 4MG/ML

N202515 002 Nov 14, 2011 Nov NEWA

+ 8MG/ML

N202515 003 Nov 14, 2011 Nov NEWA

+ 10MG/ML

N202515 004 Nov 14, 2011 Nov NEWA

+ 15MG/ML

N202515 005 Nov 14, 2011 Nov NEWA

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

+ EKR THERAP 10MG/ML (10MG/ML)

N021671 001 May 18, 2004 May CRLD

@ 15MG/1.5ML (10MG/ML)

N021671 002 May 18, 2004 May DISC

SOLUTION; ORAL

MORPHINE SULFATE

		LANNETT HOLDINGS INC	20MG/ML	N201517	001	Jun 23, 2011	Jun	NEWA
AA		MALLINCKRODT INC	100MG/5ML	A202348	001	Jul 15, 2011	Jul	NEWA
>D>		ROXANE	10MG/5ML	N022195	001	Mar 17, 2008	Dec	CTEC
>A>	AA		10MG/5ML	N022195	001	Mar 17, 2008	Dec	CTEC
>D>			20MG/5ML	N022195	002	Mar 17, 2008	Dec	CTEC
>A>	AA		20MG/5ML	N022195	002	Mar 17, 2008	Dec	CTEC
	AA	+	100MG/5ML	N022195	003	Jan 25, 2010	Aug	CTEC
>A>	AA	VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012	Dec	NEWA
>A>	AA		20MG/5ML	A201947	002	Jan 05, 2012	Dec	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Oct	NEWA
AB			30MG	A200824	002	Oct 18, 2011	Oct	NEWA
AB			60MG	A200824	003	Oct 18, 2011	Oct	NEWA
AB			100MG	A200824	004	Oct 18, 2011	Oct	NEWA
AB			200MG	A200824	005	Oct 18, 2011	Oct	NEWA
AB		NESHER PHARMS	15MG	A076733	001	May 19, 2004	Nov	CAHN
AB			30MG	A076720	002	Dec 23, 2005	Nov	CAHN
AB			60MG	A076720	001	May 19, 2004	Nov	CAHN
AB			100MG	A077855	001	Sep 27, 2007	Nov	CAHN
AB			200MG	A077855	002	Sep 27, 2007	Nov	CAHN
		@ WATSON LABS	100MG	A075656	001	Jan 30, 2001	Aug	DISC

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB		GLENMARK PHARMS	2%	A090480	001	Jun 08, 2011	May	NEWA
----	--	-----------------	----	---------	-----	--------------	-----	------

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

		+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR
--	--	---	-----------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB		DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct	NEWA
----	--	--------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB		ALKEM LABS LTD	500MG	A091249	001	Nov 04, 2011	Oct	NEWA
		@ DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010	Oct	DISC

NABUMETONE

TABLET; ORAL

NABUMETONE

		@ ACTAVIS ELIZABETH	500MG	A079093	001	Feb 27, 2009	Aug	DISC
		@	750MG	A079093	002	Feb 27, 2009	Aug	DISC
>A>	AB	APOTEX INC	500MG	A090427	001	Dec 30, 2011	Dec	NEWA
>A>	AB		750MG	A090427	002	Dec 30, 2011	Dec	NEWA
	AB	LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
	AB		750MG	A090445	002	Jan 12, 2011	Jan	NEWA
	AB	WATSON LABS	500MG	A091083	001	Jun 13, 2011	May	NEWA
	AB		750MG	A091083	002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	ACIC FINE CHEMS	EQ 1GM BASE	A090560 001	Oct 03, 2011	Sep	NEWA
AP		EQ 2GM BASE	A090560 002	Oct 03, 2011	Sep	NEWA
AP	IBI	EQ 1GM BASE/VIAL	A090002 001	Jun 30, 2011	Jun	NEWA
AP		EQ 2GM BASE/VIAL	A090002 002	Jun 30, 2011	Jun	NEWA
AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005 001	Apr 20, 2011	Apr	NEWA
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A062527 004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	50MG	A091205 001	Aug 17, 2011	Aug	NEWA
AB	ELITE LABS	50MG	A075274 001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	AUROBINDO PHARMA USA	250MG	A200429 001	Nov 08, 2011	Oct	NEWA
AB		375MG	A200429 002	Nov 08, 2011	Oct	NEWA
AB		500MG	A200429 003	Nov 08, 2011	Oct	NEWA
AB	INVAGEN PHARMS	250MG	A091305 001	Aug 24, 2011	Aug	NEWA
AB		375MG	A091305 002	Aug 24, 2011	Aug	NEWA
AB		500MG	A091305 003	Aug 24, 2011	Aug	NEWA
AB	MARKSANS PHARMA	250MG	A091416 001	Feb 14, 2011	Jan	NEWA
AB		375MG	A091416 002	Feb 14, 2011	Jan	NEWA
AB		500MG	A091416 003	Feb 14, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

	@ ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998	Aug	DISC
	@	500MG	A074936 002	Feb 24, 1998	Aug	DISC
AB	INVAGEN PHARMS	375MG	A091432 001	Sep 19, 2011	Sep	NEWA
AB		500MG	A091432 002	Sep 19, 2011	Sep	NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A200629 001	Oct 31, 2011	Oct	NEWA
AB		EQ 500MG BASE	A200629 002	Oct 31, 2011	Oct	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011	Apr	NEWA
AB		EQ 2.5MG BASE	A091373 002	Apr 22, 2011	Apr	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	HERITAGE PHARMS INC	EQ 1MG BASE	A200502 001	Feb 28, 2011	Oct	CAHN
AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Oct	CAHN
AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+	BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
---	----------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

@	EKR THERAP	45MG	N020005 002	Feb 21, 1992	May	DISC
---	------------	------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	VALEANT INTL	30MG	A075269 001	Dec 04, 2000	Apr	CAHN
AB2		30MG	A075289 002	Feb 06, 2001	Apr	CAHN
AB2		60MG	A075289 001	Sep 27, 2000	Apr	CAHN
AB1		60MG	A075269 002	Dec 04, 2000	Apr	CAHN
AB1		90MG	A076070 001	Aug 16, 2002	Apr	CAHN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

	NOVARTIS	EQ 150MG BASE	N022068 002	Jun 17, 2010	Aug	NEWA
--	----------	---------------	-------------	--------------	-----	------

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

>D>	AB	+	BANNER PHARMACAPS	30MG	A076740 001	Jan 17, 2008	Dec	CRLD
>A>	AB			30MG	A076740 001	Jan 17, 2008	Dec	CRLD
	AB	+		30MG	A076740 001	Jan 17, 2008	Sep	CRLD
	AB		BARR LABS INC	30MG	A077811 001	May 02, 2007	Sep	CRLD
>D>	AB		SUN PHARM INDS INC	30MG	A077067 001	Apr 17, 2007	Dec	CRLD
>A>	AB	+		30MG	A077067 001	Apr 17, 2007	Dec	CRLD

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA	
AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA	
AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA	
AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA	
	SULAR						
AB	+	SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356 007	Jan 02, 2008	Jan	CFTG
AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG	
AB	+	34MG	N020356 005	Jan 02, 2008	Jan	CFTG	

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175 001		Apr	CFTG
AB		NITROFURANTOIN					
AB		AMNEAL PHARMS	25MG/5ML	A201679 001	May 11, 2011	Apr	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL
RECTIV

	+	PROSTRAKAN INC	0.4%	N021359 001	Jun 21, 2011	Jun	NEWA
--	---	----------------	------	-------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

AB		GLENMARK GENERICS	150MG	A090618 001	Jul 15, 2011	Jul	NEWA
AB			300MG	A090618 002	Jul 15, 2011	Jul	NEWA
AB		MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934 002	Jul 09, 2002	Feb	CAHN

NORETHINDRONE

TABLET; ORAL-28
NORETHINDRONE

AB1		LUPIN LTD	0.35MG	A091325 001	Sep 19, 2011	Sep	NEWA
-----	--	-----------	--------	-------------	--------------	-----	------

NORGESTREL

TABLET; ORAL
OVRETTE

	@	WYETH PHARMS	0.075MG	N017031 001		Aug	CAHN
--	---	--------------	---------	-------------	--	-----	------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
PAMELOR

AB		MALLINCKRODT LLC	EQ 10MG BASE	N018013 001		Aug	CAHN
AB			EQ 25MG BASE	N018013 002		Aug	CAHN
AB			EQ 50MG BASE	N018013 004		Aug	CAHN
AB	+		EQ 75MG BASE	N018013 003		Aug	CAHN

SOLUTION; ORAL

PAMELOR

	@	MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012 001		Sep	DISC
AA			EQ 10MG BASE/5ML	N018012 001		Jul	CAHN

NYSTATIN

CREAM; TOPICAL

MYCOSTATIN

	@	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060575 001		Aug	DISC
--	---	----------------------	------------------	-------------	--	-----	------

NYSTATIN

AT		TARO	100,000 UNITS/GM	A064022 001	Jan 29, 1993	Aug	CRLD
----	--	------	------------------	-------------	--------------	-----	------

POWDER; TOPICAL

MYCOSTATIN

	@	BRISTOL MYERS SQUIBB	100,000 UNITS/GM	A060578 001		Aug	DISC
--	---	----------------------	------------------	-------------	--	-----	------

NYSTATIN

AT	+	COASTAL PHARMS	100,000 UNITS/GM	A065203 001	Jul 15, 2004	Oct	CRLD
AT			100,000 UNITS/GM	A065203 001	Jul 15, 2004	Aug	CRLD
AT		NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006	Nov	CAHN

SUSPENSION; ORAL

NYSTATIN

AA	HI TECH PHARMA	100,000 UNITS/ML	A064042 001	Feb 28, 1994	Aug	CAHN
AA	VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Aug	DISC
------------------------	-----------------------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

@ ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Aug	DISC
------------------------	-----------------------	-------------	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011	Apr	NEWA
AP		EQ 1MG BASE/ML	A090986 002	May 11, 2011	Apr	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
AP		EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
AP	MYLAN INSTITUTIONAL	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Aug	CAHN
AP		EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Aug	CAHN
AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Aug	CAHN
AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011	Apr	NEWA
AP		EQ 0.1MG BASE/ML	A090985 002	May 11, 2011	Apr	NEWA
AP		EQ 0.5MG BASE/ML	A090985 003	May 11, 2011	Apr	NEWA

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT	FERA PHARMS	0.3%	A076830 001	Aug 31, 2004	Oct	CAHN
----	-------------	------	-------------	--------------	-----	------

SOLUTION/DROPS; OTIC

OFLOXACIN

AT	FERA PHARMS	0.3%	A090395 001	Aug 11, 2009	Oct	CAHN
----	-------------	------	-------------	--------------	-----	------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	INNOPHARMA LLC	10MG/VIAL	A201588 001	Oct 24, 2011	Oct	NEWA
----	----------------	-----------	-------------	--------------	-----	------

ZYPREXA

AP	+ LILLY	10MG/VIAL	N021253 001	Mar 29, 2004	Oct	CFTG
----	---------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OLANZAPINE

AB	DR REDDYS LABS LTD	20MG	A076133 002	Oct 24, 2011	Oct	NEWA
AB	TEVA PHARMS	2.5MG	A076000 001	Oct 24, 2011	Oct	NEWA
AB		5MG	A076000 002	Oct 24, 2011	Oct	NEWA
AB		7.5MG	A076000 003	Oct 24, 2011	Oct	NEWA
AB		10MG	A076000 004	Oct 24, 2011	Oct	NEWA
AB		15MG	A076000 005	Oct 24, 2011	Oct	NEWA

ZYPREXA

AB	LILLY	2.5MG	N020592 001	Sep 30, 1996	Oct	CFTG
AB	+	5MG	N020592 002	Sep 30, 1996	Oct	CFTG
AB		7.5MG	N020592 003	Sep 30, 1996	Oct	CFTG
AB		10MG	N020592 004	Sep 30, 1996	Oct	CFTG

TABLET; ORAL

ZYPREXA

AB	LILLY	15MG	N020592 005	Sep 09, 1997	Oct	CFTG
AB		20MG	N020592 006	Sep 09, 1997	Oct	CFTG

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	APOTEX INC	5MG	A091265 001	Oct 24, 2011	Oct	NEWA
AB		10MG	A091265 002	Oct 24, 2011	Oct	NEWA
AB		15MG	A091265 003	Oct 24, 2011	Oct	NEWA
AB		20MG	A091265 004	Oct 24, 2011	Oct	NEWA
AB	DR REDDYS LABS LTD	5MG	A076534 001	Oct 24, 2011	Oct	NEWA
AB		10MG	A076534 002	Oct 24, 2011	Oct	NEWA
AB		15MG	A076534 003	Oct 24, 2011	Oct	NEWA
AB		20MG	A076534 004	Oct 24, 2011	Oct	NEWA
AB	PAR PHARM	5MG	A078109 001	Oct 24, 2011	Oct	NEWA
AB		10MG	A078109 002	Oct 24, 2011	Oct	NEWA
AB		15MG	A078109 003	Oct 24, 2011	Oct	NEWA
AB		20MG	A078109 004	Oct 24, 2011	Oct	NEWA
AB	TORRENT PHARMS LLC	5MG	A091415 001	Oct 25, 2011	Oct	NEWA
AB		10MG	A091415 002	Oct 25, 2011	Oct	NEWA
AB		15MG	A091415 003	Oct 25, 2011	Oct	NEWA
AB		20MG	A091415 004	Oct 25, 2011	Oct	NEWA

ZYPREXA ZYDIS

AB	+ LILLY	5MG	N021086 001	Apr 06, 2000	Oct	CFTG
AB		10MG	N021086 002	Apr 06, 2000	Oct	CFTG
AB		15MG	N021086 003	Apr 06, 2000	Oct	CFTG
AB		20MG	N021086 004	Apr 06, 2000	Oct	CFTG

ONDANSETRON

FILM; ORAL

ZUPLENZ

>A>	MONOSOL RX LLC	4MG	N022524 001	Jul 02, 2010	Dec	CAHN
>A>	+	8MG	N022524 002	Jul 02, 2010	Dec	CAHN
>D>	PAR PHARM	4MG	N022524 001	Jul 02, 2010	Dec	CAHN
>D>	+	8MG	N022524 002	Jul 02, 2010	Dec	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	NESHER PHARMS	4MG	A077717 001	Jun 25, 2007	Nov	CAHN
AB		8MG	A077717 002	Jun 25, 2007	Nov	CAHN
AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	PFIZER	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+ HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Apr	CRLD
AP	TEVA PHARMS	EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006	Aug	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	PFIZER	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076759 001	Nov 22, 2006	Sep	CMFD

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
----	---------------	-----------------	-------------	--------------	-----	------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA
----	--------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
AB		EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

>D>	AP	+	GRACEWAY	30MG/ML	N013055 001		Dec	CAHN
>A>	AP	+	MEDICIS	30MG/ML	N013055 001		Dec	CAHN

ORPHENADRINE CITRATE

AP	SAGENT PHARMS	30MG/ML	A090585 001	Aug 30, 2011	Aug	NEWA
----	---------------	---------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

>D>		@	GRACEWAY	100MG	N012157 001		Dec	CAHN
>A>		@	MEDICIS	100MG	N012157 001		Dec	CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE

@

EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jun	NEWA
EQ 12MG BASE/ML	N021246 001	Dec 14, 2000	Jul	DISC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	HOSPIRA INC	50MG/VIAL	A078815 001	Sep 30, 2009	Nov	CRLD	
AP		100MG/VIAL	A078815 002	Sep 30, 2009	Nov	CRLD	
AP	SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA	
AP		50MG/VIAL	A090849 001	Apr 28, 2011	Apr	NEWA	
AP		100MG/VIAL	A090849 002	Apr 28, 2011	Apr	NEWA	
AP		100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA	
AP	+	SUN PHARMA GLOBAL	50MG/VIAL	A078818 001	Aug 07, 2009	Nov	CRLD
AP	+		100MG/VIAL	A078818 002	Aug 07, 2009	Nov	CRLD

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ ACTAVIS ELIZABETH

AB	MYLAN	600MG	A075843 001	Oct 03, 2001	Aug	DISC
		600MG	A075847 001	Feb 28, 2001	Feb	CAHN

OXICONAZOLE NITRATE

LOTION; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N020209 001	Sep 30, 1992	Nov	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXYBUTYNIN

>A>	GEL, METERED; TRANSDERMAL						
>A>	ANTUROL						
>A>	+	ANTARES PHARMA INC	3%	N202513 001	Dec 07, 2011	Dec	NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE

KING PHARMS R AND D

5MG

N202080 001 Jun 17, 2011 Jun NEWA

7.5MG

N202080 002 Jun 17, 2011 Jun NEWA

OXYCODONE HYDROCHLORIDE

>A>	AB	ALVOGEN INC	5MG	A202116 001	Dec 30, 2011	Dec	NEWA
>A>	AB		15MG	A202116 002	Dec 30, 2011	Dec	NEWA
>A>	AB		30MG	A202116 003	Dec 30, 2011	Dec	NEWA
	AB	COASTAL PHARMS	5MG	A091313 001	Feb 18, 2011	Feb	NEWA
	AB		15MG	A091313 002	Feb 18, 2011	Feb	NEWA
	AB		30MG	A091313 003	Feb 18, 2011	Feb	NEWA
>A>	AB	MALLINCKRODT INC	5MG	A078206 001	Mar 19, 2007	Dec	CAHN
	AB	NESHER PHARMS	5MG	A077290 001	Dec 08, 2005	Nov	CAHN
	AB		10MG	A077290 002	Dec 08, 2005	Nov	CAHN
	AB		15MG	A077290 003	Dec 08, 2005	Nov	CAHN
	AB		20MG	A077290 004	Dec 08, 2005	Nov	CAHN
	AB		30MG	A077290 005	Dec 08, 2005	Nov	CAHN
	AB	RHODES PHARMS	5MG	A091490 001	Mar 09, 2011	Feb	NEWA
	AB		10MG	A091490 002	Mar 09, 2011	Feb	NEWA
	AB		15MG	A091490 003	Mar 09, 2011	Feb	NEWA
	AB		20MG	A091490 004	Mar 09, 2011	Feb	NEWA
	AB		30MG	A091490 005	Mar 09, 2011	Feb	NEWA
>D>	AB	TYCO HLTHCARE	5MG	A078206 001	Mar 19, 2007	Dec	CAHN

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+ MEDA PHARMS

50MG

N016848 001

May CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB TEVA

5MG

A091443 002 Feb 15, 2011 Jan NEWA

AB

10MG

A091443 001 Feb 15, 2011 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

>A>		ENDO PHARMS	5MG	N201655 001	Dec 09, 2011	Dec	NEWA
>A>			7.5MG	N201655 002	Dec 09, 2011	Dec	NEWA
		@	7.5MG	N021610 005	Feb 29, 2008	Feb	DISC
>A>			10MG	N201655 003	Dec 09, 2011	Dec	NEWA
>A>			15MG	N201655 004	Dec 09, 2011	Dec	NEWA
		@	15MG	N021610 006	Feb 29, 2008	Feb	DISC
>A>			20MG	N201655 005	Dec 09, 2011	Dec	NEWA
>A>			30MG	N201655 006	Dec 09, 2011	Dec	NEWA
>A>			40MG	N201655 007	Dec 09, 2011	Dec	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP ONCO THERAPIES LTD

6MG/ML

A091540 001 Sep 29, 2011 Sep NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS	1.5MG	N021999 006	Aug 26, 2008	Jul	CAHN
	3MG	N021999 001	Dec 19, 2006	Jul	CAHN
+	6MG	N021999 002	Dec 19, 2006	Jul	CAHN
	9MG	N021999 003	Dec 19, 2006	Jul	CAHN
@	12MG	N021999 004	Dec 19, 2006	Jul	CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009	Jun	CAHN
	78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009	Jun	CAHN
+	117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009	Aug	CRLD
	117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009	Jun	CAHN
	156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009	Jun	CAHN
	234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Aug	CRLD
+	234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Jun	CAHN

PALONOSETRON HYDROCHLORIDE

>D> CAPSULE; ORAL

>D> ALOXI

>D>	+	HELSINN HLTHCARE	EQ 0.5MG BASE	N022233 001	Aug 22, 2008	Dec	DISC
-----	---	------------------	---------------	-------------	--------------	-----	------

>A>	+	@	EQ 0.5MG BASE	N022233 001	Aug 22, 2008	Dec	DISC
-----	---	---	---------------	-------------	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS

90MG/VIAL

N020036 004 May 06, 1993 Oct DISC

PAMIDRONATE DISODIUM

>D>	AP	AESGEN	30MG/VIAL	A075594 001	May 06, 2002	Dec	DISC
-----	----	--------	-----------	-------------	--------------	-----	------

>A>		@	30MG/VIAL	A075594 001	May 06, 2002	Dec	DISC
-----	--	---	-----------	-------------	--------------	-----	------

>D>	AP		90MG/VIAL	A075594 002	May 06, 2002	Dec	DISC
-----	----	--	-----------	-------------	--------------	-----	------

>A>		@	90MG/VIAL	A075594 002	May 06, 2002	Dec	DISC
-----	--	---	-----------	-------------	--------------	-----	------

AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373 001	Dec 23, 2008	May	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

AP		90MG/10ML (9MG/ML)	A078373 002	Dec 23, 2008	May	CAHN
----	--	--------------------	-------------	--------------	-----	------

AP	PFIZER	30MG/10ML (3MG/ML)	A078520 001	Oct 31, 2008	Aug	CAHN
----	--------	--------------------	-------------	--------------	-----	------

AP		90MG/10ML (9MG/ML)	A078520 002	Oct 31, 2008	Aug	CAHN
----	--	--------------------	-------------	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

JANSSEN PHARMS

17,500USP/ UNITS;4,200USP/
UNITS;10,000USP/ UNITS
43,750USP/ UNITS;10,500USP/
UNITS;25,000USP/ UNITS
70,000USP/ UNITS;16,800USP/
UNITS;40,000USP/ UNITS
61,000USP/ UNITS;21,000USP/
UNITS;37,000USP/ UNITS

N022523 001 Apr 12, 2010 Jun CAHN

N022523 002 Apr 12, 2010 Jun CAHN

N022523 004 Apr 12, 2010 Jun CAHN

N022523 003 Apr 12, 2010 Jun CAHN

ZENPEP

APTALIS PHARMA US

27,000USP UNITS;5,000USP
UNITS;17,000USP UNITS
55,000USP UNITS;10,000USP
UNITS;34,000USP UNITS
82,000USP UNITS;15,000USP
UNITS;51,000USP UNITS

N022210 001 Aug 27, 2009 Oct CAHN

N022210 002 Aug 27, 2009 Oct CAHN

N022210 003 Aug 27, 2009 Oct CAHN

CAPSULE, DELAYED RELEASE; ORAL

ZENPEP

+	APTALIS PHARMA US	109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009	Oct	CAHN
---	-------------------	---	-------------	--------------	-----	------

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797 002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619 002	Jan 19, 2011	Jan	NEWA
AB	JUBILANT ORGANOSYS	EQ 20MG BASE	A090901 001	Aug 30, 2011	Aug	NEWA
AB		EQ 40MG BASE	A090901 002	Aug 30, 2011	Aug	NEWA
AB	KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PARICALCITOL

INJECTABLE; INJECTION

PARICALCITOL

AP	SANDOZ CANADA INC	0.002MG/ML	A091108 001	Jul 27, 2011	Jul	NEWA
AP		0.005MG/ML	A091108 002	Jul 27, 2011	Jul	NEWA
	ZEMPLAR					
AP	+ ABBOTT	0.002MG/ML	N020819 002	Feb 01, 2000	Jul	CFTG
AP	+	0.005MG/ML	N020819 001	Apr 17, 1998	Jul	CFTG

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

@	KING PFIZER	EQ 250MG BASE	A062310 001		Aug	CAHN
@	MONARCH PHARMS	EQ 250MG BASE	A062310 001		May	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Aug	DISC
@		EQ 20MG BASE	A076968 002	Jun 21, 2010	Aug	DISC
@		EQ 30MG BASE	A076968 003	Jun 21, 2010	Aug	DISC
@		EQ 40MG BASE	A076968 004	Jun 21, 2010	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	MYLAN	EQ 37.5MG BASE	A091427 001	Apr 14, 2011	Apr	NEWA
	PAXIL CR					
AB	+ GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936 003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	VALEANT INTL	400MG	A075028 001	Jul 20, 1998	Apr	CAHN
----	--------------	-------	-------------	--------------	-----	------

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	EMCURE PHARMS USA	35MG	A040762 001	Jan 28, 2008	Jul	CAHN
AA	MIKAH PHARMA	35MG	A040762 001	Jan 28, 2008	Aug	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

	@ ACTAVIS TOTOWA	15MG	A040460 001	Jan 14, 2003	Jul	DISC
	@	30MG	A040227 001	Jun 18, 1997	Jul	DISC
	@	30MG	A040448 001	Jan 22, 2003	Jul	DISC
	@	37.5MG	A040228 001	Jun 19, 1997	Jul	DISC
AA	LANNETT HOLDINGS INC	37.5MG	A201961 001	Jul 20, 2011	Jul	NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

	@ ACTAVIS TOTOWA	37.5MG	A040190 001	May 30, 1997	Jul	DISC
AA	ELITE LABS	37.5MG	A200272 001	Jan 31, 2011	May	CAHN
AA	EPIC PHARMA LLC	37.5MG	A200272 001	Jan 31, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

	CITIUS PHARMS	15MG	N202088 001	Jun 13, 2011	Jun	NEWA
+		30MG	N202088 002	Jun 13, 2011	Jun	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jul	NEWA
		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jul	NEWA

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

ORAVERSE

+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159 001	May 09, 2008	Aug	CAHN
---	-------------------	-------------	-------------	--------------	-----	------

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	X-GEN PHARMS	50MG/ML	A040573 001	Sep 13, 2006	May	CAHN
----	--------------	---------	-------------	--------------	-----	------

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

	@ BIOVAIL TECHNOLOGIES	1MG/0.5ML	N012223 002		Aug	CAHN
	@	10MG/ML	N012223 001		Aug	CAHN

TABLET; ORAL

MEPHYTON

+	BIOVAIL TECHNOLOGIES	5MG	N010104 003		Aug	CAHN
---	----------------------	-----	-------------	--	-----	------

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

	ALCON RES	1%	N200890 001	Jun 22, 2010	May	CTNA
		2%	N200890 002	Jun 22, 2010	May	CTNA
+		4%	N200890 003	Jun 22, 2010	May	CTNA

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+	VALEANT INTL	1%	N021302	001	Dec 13, 2001	Jul	CAHN
---	--------------	----	---------	-----	--------------	-----	------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	AUROBINDO PHARMA LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065498	001	May 23, 2011	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065498	002	May 23, 2011	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065498	003	May 23, 2011	May	NEWA
AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN
AP	INSTITUTO BIOCHEMICO	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	May	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	May	NEWA

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

>D>	+	GRACEWAY	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Dec	CAHN
>D>	@		EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Dec	CAHN
>A>	@	MEDICIS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Dec	CAHN
>A>	+		EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Dec	CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ MYLAN

10MG

A074043 001 Sep 22, 1992 Feb CAHN

@

20MG

A074043 002 Sep 22, 1992 Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA CO

EQ 1MG BASE

N022363 001 Aug 03, 2009 Jul CAHN

EQ 2MG BASE

N022363 002 Aug 03, 2009 Jul CAHN

+

EQ 4MG BASE

N022363 003 Aug 03, 2009 Jul CAHN

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

AT	PRECISION DERMAT	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN
----	------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

AA		KREMERS URBAN PHARMS	17GM/SCOOPFUL	A076652 001	Jul 02, 2004	Sep	CAHN
----	--	----------------------	---------------	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@ MEDA PHARMS

120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET

N018983 005 Oct 26, 1984 Jun CAHN

@

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET

N018983 004 Oct 26, 1984 Jul DISC

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET

N018983 004 Oct 26, 1984 Jun CAHN

AA	+		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 010	Jan 31, 1989	Jun	CAHN
----	---	--	---	-------------	--------------	-----	------

AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 007	Jun 12, 1987	Jun	CAHN
----	---	--	--	-------------	--------------	-----	------

@

360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET

N018983 006 Oct 26, 1984 Jun CAHN

COLYTE WITH FLAVOR PACKS

AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 012	Oct 08, 1998	Jun	CAHN
----	---	-------------	--	-------------	--------------	-----	------

COLYTE-FLAVORED

AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 008	Nov 14, 1991	Jun	CAHN
----	---	-------------	---	-------------	--------------	-----	------

AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 009	Nov 14, 1991	Jun	CAHN
----	---	--	--	-------------	--------------	-----	------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLMYCIN B SULFATE

AP		SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011	Jun	NEWA
----	--	----------------	----------------------------	-------------	--------------	-----	------

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

PINNACLE BIOLGS

75MG/VIAL

N020451 001 Dec 27, 1995 Aug CMFD

@

75MG/VIAL

N020451 001 Dec 27, 1995 Jun DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

AB		NESHER PHARMS	8MEQ	N018238 001		Aug	CAHN
----	--	---------------	------	-------------	--	-----	------

MICRO-K 10

AB		NESHER PHARMS	10MEQ	N018238 002	May 14, 1984	Aug	CAHN
----	--	---------------	-------	-------------	--------------	-----	------

POTASSIUM CHLORIDE

@ NESHER PHARMS

10MEQ

A070980 001 Feb 17, 1987 Nov CAHN

AB		PADDOCK LABS	8MEQ	A200185 001	May 18, 2011	May	NEWA
----	--	--------------	------	-------------	--------------	-----	------

AB			10MEQ	A200185 002	May 18, 2011	May	NEWA
----	--	--	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

BC	+	UPSHER-SMITH LABS	10MEQ	N019123 002	Apr 17, 1986	Oct	CRLD
----	---	-------------------	-------	-------------	--------------	-----	------

POTASSIUM CHLORIDE

AB		NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Nov	CAHN
----	--	---------------	-------	-------------	--------------	-----	------

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

@ UNIV TX SW MEDCTR 10MEQ/PACKET

N019647 002 Oct 13, 1988 Oct CAHN

@ 20MEQ/PACKET

N019647 001 Oct 13, 1988 Oct CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

BOEHRINGER INGELHEIM 2.25MG

N022421 006 Jun 17, 2011 Jun NEWA

3.75MG

N022421 007 Jun 17, 2011 Jun NEWA

PRAZICUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER PHARMA AG 600MG

N018714 001 Dec 29, 1982 Sep CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA + NESHER PHARMS 5MG/5ML

A040423 001 Oct 22, 2001 Nov CAHN

AA + 15MG/5ML

A040364 001 Apr 10, 2002 Nov CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA NESHER PHARMS EQ 5MG BASE/5ML

A076982 001 May 24, 2005 Nov CAHN

AA EQ 15MG BASE/5ML

A076988 001 May 24, 2005 Nov CAHN

@ VINTAGE PHARMS EQ 5MG BASE/5ML

A078416 001 Oct 31, 2007 May DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB JUBILANT CADISTA 1MG

A040611 001 Jun 06, 2005 Jan CAHN

AB 5MG

A040362 002 Aug 29, 2001 Jan CAHN

AB 10MG

A040362 001 Aug 29, 2001 Jan CAHN

AB 20MG

A040362 003 Jun 29, 2005 Jan CAHN

PREGABALIN

CAPSULE; ORAL

LYRICA

CPPI CV 25MG

N021446 001 Dec 30, 2004 Sep CAHN

50MG

N021446 002 Dec 30, 2004 Sep CAHN

75MG

N021446 003 Dec 30, 2004 Sep CAHN

100MG

N021446 004 Dec 30, 2004 Sep CAHN

150MG

N021446 005 Dec 30, 2004 Sep CAHN

225MG

N021446 007 Dec 30, 2004 Sep CAHN

+ 300MG

N021446 008 Dec 30, 2004 Sep CAHN

SOLUTION; ORAL

LYRICA

+ CPPI CV 20MG/ML

N022488 001 Jan 04, 2010 Sep CAHN

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

@ NURO PHARMA	250MG/5ML	N010401 001		Oct	CAHN
---------------	-----------	-------------	--	-----	------

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998	Jan	CAHN

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

	ABBOTT LABS	100MG	N019781 001	May 14, 1998	Nov	CAHN
+		200MG	N019781 002	Oct 15, 1999	Nov	CAHN
@		300MG	N019781 003	Oct 15, 1999	Nov	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	X-GEN PHARMS	25MG/ML	A040737 001	Apr 24, 2008	May	CAHN
AP		50MG/ML	A040737 002	Apr 24, 2008	May	CAHN

SUPPOSITORY; RECTAL

PHENERGAN

@	SHIONOGI INC	12.5MG	N010926 002		Aug	CAHN
@		25MG	N010926 001		Aug	CAHN
@		50MG	N011689 001		Aug	CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	EMCURE PHARMS USA	12.5MG	A040673 001	Mar 05, 2008	Jul	CAHN
AB		25MG	A040673 002	Mar 05, 2008	Jul	CAHN
AB		50MG	A040673 003	Mar 05, 2008	Jul	CAHN
AB	MYLAN	12.5MG	A091054 001	Aug 30, 2011	Aug	NEWA
AB		25MG	A091054 002	Aug 30, 2011	Aug	NEWA
AB		50MG	A091054 003	Aug 30, 2011	Aug	NEWA

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Nov	CAHN
AB		225MG	A076193 002	Feb 07, 2002	Nov	CAHN
AB		300MG	A076193 003	Feb 07, 2002	Nov	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927 002		Jan	CMFD
---	--------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@	XANODYNE PHARM	65MG	N010997 003		Jan	DISC
---	----------------	------	-------------	--	-----	------

DOLENE

@	HERITAGE PHARMS INC	65MG	A080530 001		Aug	DISC
---	---------------------	------	-------------	--	-----	------

CAPSULE; ORALPROPOXYPHENE HYDROCHLORIDE

@ MYLAN	65MG	A040569 001	Dec 16, 2004	Aug	DISC
@ TEVA	65MG	A088615 001	Oct 22, 1984	Mar	DISC
@ VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009	Mar	DISC
@ WEST WARD	65MG	A083501 001		Jan	DISC

PROPOXYPHENE NAPSYLATETABLET; ORALDARVON-N

@ XANODYNE PHARM	100MG	N016862 002		Jan	DISC
------------------	-------	-------------	--	-----	------

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORALPROPRANOLOL HYDROCHLORIDE

AB	GLAXOSMITHKLINE	60MG	A078703 001	Jul 15, 2011	Jul	NEWA
AB		80MG	A078703 002	Jul 15, 2011	Jul	NEWA
AB		120MG	A078703 003	Jul 15, 2011	Jul	NEWA
AB		160MG	A078703 004	Jul 15, 2011	Jul	NEWA
AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA
AB		120MG	A090321 003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA

TABLET; ORALPROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
----	-------	------	-------------	--------------	-----	------

PYRIMETHAMINETABLET; ORALDARAPRIM

+	COREPHARMA	25MG	N008578 001		Jun	CAHN
---	------------	------	-------------	--	-----	------

QUINAPRIL HYDROCHLORIDETABLET; ORALQUINAPRIL HYDROCHLORIDE

	@ ACTAVIS TOTOWA	EQ 5MG BASE	A076459 001	Dec 22, 2004	Jul	DISC
	@	EQ 10MG BASE	A076459 002	Dec 22, 2004	Jul	DISC
	@	EQ 20MG BASE	A076459 003	Dec 22, 2004	Jul	DISC
	@	EQ 40MG BASE	A076459 004	Dec 22, 2004	Jul	DISC
AB	MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN

RALTEGRAVIR POTASSIUM>A> TABLET, CHEWABLE; ORAL>A> ISENTRESS

>A>	MERCK SHARP DOHME	EQ 25MG BASE	N203045 001	Dec 21, 2011	Dec	NEWA
>A>	+	EQ 100MG BASE	N203045 002	Dec 21, 2011	Dec	NEWA

RAMIPRILCAPSULE; ORALRAMIPRIL

@ ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008	Aug	DISC
@	2.5MG	A077513 002	Jun 18, 2008	Aug	DISC
@	5MG	A077513 003	Jun 18, 2008	Aug	DISC

CAPSULE; ORAL

RAMIPRIL

	@ ACTAVIS ELIZABETH	10MG	A077513 004	Jun 18, 2008	Aug	DISC
AB	AUROBINDO PHARMA LTD	1.25MG	A091604 001	Jun 08, 2011	May	NEWA
AB		2.5MG	A091604 002	Jun 08, 2011	May	NEWA
AB		5MG	A091604 003	Jun 08, 2011	May	NEWA
AB		10MG	A091604 004	Jun 08, 2011	May	NEWA

TABLET; ORAL

RAMIPRIL

AB	MATRIX LABS LTD	1.25MG	A090650 001	Jun 30, 2011	Jun	NEWA
AB		2.5MG	A090650 002	Jun 30, 2011	Jun	NEWA
AB		5MG	A090650 003	Jun 30, 2011	Jun	NEWA
AB		10MG	A090650 004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@ MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000	Feb	CAHN
@	EQ 300MG BASE	A075564 002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124 001	Feb 21, 2007	Sep	CAHN
AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011	Mar	NEWA
AA	SUN PHARM INDS INC	EQ 15MG BASE/ML	A091091 001	Sep 20, 2011	Sep	NEWA
AA	TARO	EQ 15MG BASE/ML	A077476 001	Jun 13, 2011	May	NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630 001	Jul 12, 1996	Oct	CAHN
	EQ 2MG BASE/VIAL	N020630 002	Jul 12, 1996	Oct	CAHN
+	EQ 5MG BASE/VIAL	N020630 003	Jul 12, 1996	Oct	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

>D>	@ ACTAVIS TOTOWA	300MG	N050429 001		Dec	CAHN
	@	300MG	N050429 001		Jul	DISC
>A>	@ PROSAM LABS	300MG	N050429 001		Dec	CAHN

INJECTABLE; INJECTION

RIFAMPIN

AP	PFIZER	600MG/VIAL	A065421 001	May 22, 2008	May	CAHN
AP	VERSAPHARM INC	600MG/VIAL	A065502 001	Sep 21, 2010	Nov	CAHN

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	550MG	N022554 001	Mar 24, 2010	Feb	CRLD
---	--------------	-------	-------------	--------------	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	TIBOTEC	EQ 25MG BASE	N202022 001	May 20, 2011	May	NEWA
---	---------	--------------	-------------	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@	ACTAVIS TOTOWA	100MG	A076375 001	Jan 14, 2003	Jul	DISC
---	----------------	-------	-------------	--------------	-----	------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346 004	Apr 12, 2007	Jun	CAHN
+		25MG/VIAL	N021346 001	Oct 29, 2003	Jun	CAHN
		37.5MG/VIAL	N021346 002	Oct 29, 2003	Jun	CAHN
		50MG/VIAL	N021346 003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588 001	Jun 10, 1996	Jun	CAHN
----	---	----------------	--------	-------------	--------------	-----	------

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384 001	May 25, 2011	May	NEWA
----	--	---------------	--------	-------------	--------------	-----	------

AA		TARO	1MG/ML	A090347 001	Feb 07, 2011	Jan	NEWA
----	--	------	--------	-------------	--------------	-----	------

TABLET; ORAL

RISPERDAL

AB		JANSSEN PHARMS	0.25MG	N020272 008	May 10, 1999	Jun	CAHN
AB			0.5MG	N020272 007	Jan 27, 1999	Jun	CAHN
AB	+		1MG	N020272 001	Dec 29, 1993	Jun	CAHN
AB			2MG	N020272 002	Dec 29, 1993	Jun	CAHN
AB			3MG	N020272 003	Dec 29, 1993	Jun	CAHN
AB			4MG	N020272 004	Dec 29, 1993	Jun	CAHN

	@		5MG	N020272 005	Dec 29, 1993	Jun	CAHN
--	---	--	-----	-------------	--------------	-----	------

RISPERIDONE

	@	ACTAVIS TOTOWA	0.25MG	A078071 001	Jun 17, 2009	Jul	DISC
--	---	----------------	--------	-------------	--------------	-----	------

	@		0.5MG	A078071 002	Jun 17, 2009	Jul	DISC
--	---	--	-------	-------------	--------------	-----	------

	@		1MG	A078071 003	Jun 17, 2009	Jul	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		2MG	A078071 004	Jun 17, 2009	Jul	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		3MG	A078071 005	Jun 17, 2009	Jul	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		4MG	A078071 006	Jun 17, 2009	Jul	DISC
--	---	--	-----	-------------	--------------	-----	------

AB		AJANTA PHARMA LTD	0.25MG	A201003 001	Aug 24, 2011	Aug	NEWA
----	--	-------------------	--------	-------------	--------------	-----	------

AB			0.5MG	A201003 002	Aug 24, 2011	Aug	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			1MG	A201003 003	Aug 24, 2011	Aug	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			2MG	A201003 004	Aug 24, 2011	Aug	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			3MG	A201003 005	Aug 24, 2011	Aug	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			4MG	A201003 006	Aug 24, 2011	Aug	NEWA
----	--	--	-----	-------------	--------------	-----	------

	@	CADISTA PHARMS	0.25MG	A078828 001	Mar 23, 2009	Sep	DISC
--	---	----------------	--------	-------------	--------------	-----	------

	@		0.5MG	A078828 002	Mar 23, 2009	Sep	DISC
--	---	--	-------	-------------	--------------	-----	------

	@		1MG	A078828 003	Mar 23, 2009	Sep	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		2MG	A078828 004	Mar 23, 2009	Sep	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		3MG	A078828 005	Mar 23, 2009	Sep	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		4MG	A078828 006	Mar 23, 2009	Sep	DISC
--	---	--	-----	-------------	--------------	-----	------

AB		CIPLA	0.25MG	A077543 001	May 18, 2011	May	NEWA
----	--	-------	--------	-------------	--------------	-----	------

AB			0.5MG	A077543 002	May 18, 2011	May	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			1MG	A077543 003	May 18, 2011	May	NEWA
----	--	--	-----	-------------	--------------	-----	------

AB			2MG	A077543 004	May 18, 2011	May	NEWA
----	--	--	-----	-------------	--------------	-----	------

TABLET; ORAL

RISPERIDONE

AB	CIPLA	3MG	A077543 005	May 18, 2011	May	NEWA
AB		4MG	A077543 006	May 18, 2011	May	NEWA
AB	PRINSTON INC	0.25MG	A077493 001	Nov 29, 2011	Nov	NEWA
AB		0.5MG	A077493 002	Nov 29, 2011	Nov	NEWA
AB		1MG	A077493 003	Nov 29, 2011	Nov	NEWA
AB		2MG	A077493 004	Nov 29, 2011	Nov	NEWA
AB		3MG	A077493 005	Nov 29, 2011	Nov	NEWA
AB		4MG	A077493 006	Nov 29, 2011	Nov	NEWA
	@ RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010	Feb	DISC
	@	0.5MG	A077784 002	Jun 08, 2010	Feb	DISC
	@	1MG	A077784 003	Jun 08, 2010	Feb	DISC
	@	2MG	A077784 004	Jun 08, 2010	Feb	DISC
	@	3MG	A077784 005	Jun 08, 2010	Feb	DISC
	@	4MG	A077784 006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	JANSSEN PHARMS	0.5MG	N021444 001	Apr 02, 2003	Jul	CAHN
AB	+	1MG	N021444 002	Apr 02, 2003	Jul	CAHN
AB		2MG	N021444 003	Apr 02, 2003	Jul	CAHN
AB		3MG	N021444 004	Dec 23, 2004	Jul	CAHN
AB		4MG	N021444 005	Dec 23, 2004	Jul	CAHN

RISPERIDONE

AB	JUBILANT ORGANOSYS	0.5MG	A090839 001	Nov 04, 2011	Oct	NEWA
AB		1MG	A090839 002	Nov 04, 2011	Oct	NEWA
AB		2MG	A090839 003	Nov 04, 2011	Oct	NEWA
AB		3MG	A090839 004	Nov 04, 2011	Oct	NEWA
AB		4MG	A090839 005	Nov 04, 2011	Oct	NEWA
AB	MYLAN	0.5MG	A091537 001	Mar 30, 2011	Mar	NEWA
AB		1MG	A091537 002	Mar 30, 2011	Mar	NEWA
AB		2MG	A091537 003	Mar 30, 2011	Mar	NEWA
AB		3MG	A091537 004	Mar 30, 2011	Mar	NEWA
AB		4MG	A091537 005	Mar 30, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	0.5MG	A076996 001	Apr 19, 2011	Apr	NEWA
AB		1MG	A076996 002	Apr 19, 2011	Apr	NEWA
AB		2MG	A076996 003	Apr 19, 2011	Apr	NEWA
AB		3MG	A076996 004	Apr 19, 2011	Apr	NEWA
AB		4MG	A076996 005	Apr 19, 2011	Apr	NEWA

RIVAROXABAN

TABLET; ORAL

XARELTO

>A>	+	JANSSEN PHARMS	10MG	N022406 001	Jul 01, 2011	Dec	CAHN
			15MG	N202439 001	Nov 04, 2011	Nov	NEWA
	+		20MG	N202439 002	Nov 04, 2011	Nov	NEWA
>D>	+	JOHNSON AND JOHNSON	10MG	N022406 001	Jul 01, 2011	Dec	CAHN
	+		10MG	N022406 001	Jul 01, 2011	Jul	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458 001	Jul 28, 2010	Jan	CAHN
AP		100MG/10ML (10MG/ML)	A091458 002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522 001	Feb 28, 2011	Feb	NEWA
---	---------------------	--------	-------------	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	PRINSTON INC	EQ 0.25MG BASE	A078110 001	May 05, 2008	Aug	CAHN
AB		EQ 0.5MG BASE	A078110 002	May 05, 2008	Aug	CAHN
AB		EQ 1MG BASE	A078110 003	May 05, 2008	Aug	CAHN
AB		EQ 2MG BASE	A078110 004	May 05, 2008	Aug	CAHN
AB		EQ 3MG BASE	A078110 005	May 05, 2008	Aug	CAHN
AB		EQ 4MG BASE	A078110 006	May 05, 2008	Aug	CAHN
AB	PRINSTON PHARM LLC	EQ 0.25MG BASE	A078110 001	May 05, 2008	May	CAHN
AB		EQ 0.5MG BASE	A078110 002	May 05, 2008	May	CAHN
AB		EQ 1MG BASE	A078110 003	May 05, 2008	May	CAHN
AB		EQ 2MG BASE	A078110 004	May 05, 2008	May	CAHN
AB		EQ 3MG BASE	A078110 005	May 05, 2008	May	CAHN
AB		EQ 4MG BASE	A078110 006	May 05, 2008	May	CAHN

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011	Mar	NEWA
---	-----------	---------	-------------	--------------	-----	------

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

	INCYTE CORP	EQ 5MG BASE	N202192 001	Nov 16, 2011	Nov	NEWA
		EQ 10MG BASE	N202192 002	Nov 16, 2011	Nov	NEWA
		EQ 15MG BASE	N202192 003	Nov 16, 2011	Nov	NEWA
		EQ 20MG BASE	N202192 004	Nov 16, 2011	Nov	NEWA
+		EQ 25MG BASE	N202192 005	Nov 16, 2011	Nov	NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101 001	Oct 03, 1983	Jan	CAHN
+		100MG	A086101 002	Oct 03, 1983	Jan	CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

@	ACTAVIS MID ATLANTIC	2.5%	A084394 001		Aug	DISC
---	----------------------	------	-------------	--	-----	------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	ORTHO JANSSEN	2%	N021385 001	Dec 10, 2003	Jul	CAHN
---	---------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@	ROXANE	EQ 20MG BASE/ML	A076934 001	Jun 30, 2006	Mar	DISC
---	--------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@ ACTAVIS TOTOWA	EQ 25MG BASE	A078175 001	Jul 21, 2010	Jul	DISC
	@	EQ 50MG BASE	A078175 002	Jul 21, 2010	Jul	DISC
	@	EQ 100MG BASE	A078175 003	Jul 21, 2010	Jul	DISC
	@ IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006	Apr	DISC
	@	EQ 50MG BASE	A075719 001	Jun 30, 2006	Apr	DISC
	@	EQ 100MG BASE	A075719 002	Jun 30, 2006	Apr	DISC
AB	MYLAN	EQ 25MG BASE	A076540 001	Mar 20, 2007	Feb	CAHN
AB		EQ 50MG BASE	A076540 002	Mar 20, 2007	Feb	CAHN
AB		EQ 100MG BASE	A076540 003	Mar 20, 2007	Feb	CAHN
	@ PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007	Jul	DISC
	@	EQ 50MG BASE	A077299 002	Feb 06, 2007	Jul	DISC
	@	EQ 100MG BASE	A077299 003	Feb 06, 2007	Jul	DISC
	@ ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007	Mar	DISC
	@	EQ 50MG BASE	A076881 002	Feb 06, 2007	Mar	DISC
	@	EQ 100MG BASE	A076881 003	Feb 06, 2007	Mar	DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

	@ ACTAVIS TOTOWA	5MG	A078735 001	Aug 30, 2010	Jul	DISC
	@	10MG	A078735 002	Aug 30, 2010	Jul	DISC
	@	20MG	A078735 003	Aug 30, 2010	Jul	DISC
	@	40MG	A078735 004	Aug 30, 2010	Jul	DISC
	@	80MG	A078735 005	Aug 30, 2010	Jul	DISC
AB	BLU CARIBE	5MG	A078034 001	Dec 20, 2006	Nov	CAHN
AB		10MG	A078034 002	Dec 20, 2006	Nov	CAHN
AB		20MG	A078034 003	Dec 20, 2006	Nov	CAHN
AB		40MG	A078034 004	Dec 20, 2006	Nov	CAHN
AB		80MG	A078034 005	Dec 20, 2006	Nov	CAHN
AB	DR REDDYS LABS INC	5MG	A077752 005	Jan 23, 2008	Nov	NEWA
AB	MICRO LABS LTD	5MG	A090383 001	Sep 16, 2011	Sep	NEWA
AB		10MG	A090383 002	Sep 16, 2011	Sep	NEWA
AB		20MG	A090383 003	Sep 16, 2011	Sep	NEWA
AB		40MG	A090383 004	Sep 16, 2011	Sep	NEWA
AB		80MG	A090383 005	Sep 16, 2011	Sep	NEWA
>D>	AB SANDOZ	5MG	A077766 001	Dec 20, 2006	Dec	DISC
>D>	AB	10MG	A077766 002	Dec 20, 2006	Dec	DISC
>D>	AB	20MG	A077766 003	Dec 20, 2006	Dec	DISC
>D>	AB	40MG	A077766 004	Dec 20, 2006	Dec	DISC
>D>	AB	80MG	A077766 005	Dec 20, 2006	Dec	DISC
>A>	@ SANDOZ INC	5MG	A077766 001	Dec 20, 2006	Dec	DISC
>A>	@	10MG	A077766 002	Dec 20, 2006	Dec	DISC
>A>	@	20MG	A077766 003	Dec 20, 2006	Dec	DISC
>A>	@	40MG	A077766 004	Dec 20, 2006	Dec	DISC
>A>	@	80MG	A077766 005	Dec 20, 2006	Dec	DISC

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

	MERCK SHARP DOHME	10MG;EQ 100MG BASE	N202343 001	Oct 07, 2011	Oct	NEWA
		20MG;EQ 100MG BASE	N202343 002	Oct 07, 2011	Oct	NEWA
+		40MG;EQ 100MG BASE	N202343 003	Oct 07, 2011	Oct	NEWA

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+	MEDIGENE AG	15%	N021902 001	Oct 31, 2006	May	CAHN
---	-------------	-----	-------------	--------------	-----	------

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@	MALLINCKRODT LLC	460MG/GM; 420MG/GM	N018509 001	Aug 07, 1985	Aug	CAHN
---	------------------	--------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	HOSPIRA	450MG/100ML	N018380 001		Aug	DISC
---	---------	-------------	-------------	--	-----	------

@		450MG/100ML	N017670 001		Aug	DISC
---	--	-------------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar	CFTG
----	---	-------------------	------------	-------------	--------------	-----	------

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	Mar	NEWA
----	--	-------------	------------	-------------	--------------	-----	------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

@	NIH NCI DCTD	10-200mCi/ML	N022494 001	Jan 26, 2011	Apr	DISC
---	--------------	--------------	-------------	--------------	-----	------

+		10-200mCi/ML	N022494 001	Jan 26, 2011	Jan	NEWA
---	--	--------------	-------------	--------------	-----	------

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Feb	CTNA
---	-------------	--	-------------	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Jan	NEWA
---	-------------	--	-------------	--------------	-----	------

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

>D>	AP	+	HOSPIRA	25MG/ML	A071961 001	Aug 01, 1988	Dec	CTEC
-----	----	---	---------	---------	-------------	--------------	-----	------

>A>		+		25MG/ML	A071961 001	Aug 01, 1988	Dec	CTEC
-----	--	---	--	---------	-------------	--------------	-----	------

SODIUM NITROPRUSSIDE

>D>	AP		TEVA PARENTERAL	25MG/ML	A073465 001	Mar 30, 1992	Dec	DISC
-----	----	--	-----------------	---------	-------------	--------------	-----	------

>A>		@		25MG/ML	A073465 001	Mar 30, 1992	Dec	DISC
-----	--	---	--	---------	-------------	--------------	-----	------

SODIUM PHENYLBUTYRATE

TABLET; ORAL

BUPHENYL

AB	+	MEDICIS	500MG	N020572 001	May 13, 1996	Nov	CFTG
----	---	---------	-------	-------------	--------------	-----	------

SODIUM PHENYLBUTYRATE

AB		AMPOLGEN	500MG	A090910 001	Nov 18, 2011	Nov	NEWA
----	--	----------	-------	-------------	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

>D>	+	SALIX PHARMS	0.398GM;1.102GM	N021892 001	Mar 16, 2006	Dec	CFTG
-----	---	--------------	-----------------	-------------	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

>A>		MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE					
-----	--	---	--	--	--	--	--

>A>	AB	NOVEL LABS INC	0.398GM;1.102GM	A079247 001	Dec 30, 2011	Dec	NEWA
-----	----	----------------	-----------------	-------------	--------------	-----	------

OSMOPREP

>A>	AB	+	SALIX PHARMS	0.398GM;1.102GM	N021892 001	Mar 16, 2006	Dec	CFTG
-----	----	---	--------------	-----------------	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>A>	AA	CEDAR PHARMS	453.6GM/BOT	A090313 001	Dec 21, 2011	Dec	NEWA
-----	----	--------------	-------------	-------------	--------------	-----	------

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590 001	May 13, 2011	May	NEWA
----	--	--------------	-----------	-------------	--------------	-----	------

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@ PFIZER

EQ 2GM BASE/VIAL

N050347 001

Jun DISC

@

EQ 4GM BASE/VIAL

N050347 002

Jun CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	Jan	NEWA
---	----------------	------	-------------	--------------	-----	------

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

@ PFIZER

EQ 1GM BASE/2.5ML

A060111 001

Jul DISC

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+	APTALIS PHARMA US	1GM/10ML	N019183 001	Dec 16, 1993	Oct	CAHN
---	-------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

CARAFATE

AB	+	APTALIS PHARMA US	1GM	N018333 001		Oct	CAHN
----	---	-------------------	-----	-------------	--	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

+	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Aug	CAHN
---	----------------	-------------------------------------	-------------	--------------	-----	------

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996	Jun	CFTG
----	---	-----------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AB		SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011	Jun	NEWA
----	--	--------------------	-------------------------------------	-------------	--------------	-----	------

INJECTABLE; SUBCUTANEOUSSUMATRIPTAN SUCCINATE

@ TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318 001	Feb 06, 2009	Aug	DISC
-------------------	------------------------------------	-------------	--------------	-----	------

@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318 002	Feb 06, 2009	Aug	DISC
---	-------------------------------------	-------------	--------------	-----	------

TABLET; ORALSUMATRIPTAN SUCCINATE

@ ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar	DISC
----------	--------------	-------------	--------------	-----	------

@	EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar	DISC
---	---------------	-------------	--------------	-----	------

TACRINE HYDROCHLORIDECAPSULE; ORALCOGNEX

@ SHIONOGI INC	EQ 10MG BASE	N020070 001	Sep 09, 1993	Jun	DISC
----------------	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	N020070 002	Sep 09, 1993	Jun	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 30MG BASE	N020070 003	Sep 09, 1993	Jun	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 40MG BASE	N020070 004	Sep 09, 1993	Jun	DISC
---	--------------	-------------	--------------	-----	------

TACROLIMUSCAPSULE; ORALTACROLIMUS

AB	ACCORD HLTHCARE	0.5MG	A091195 001	Aug 31, 2011	Aug	NEWA
----	-----------------	-------	-------------	--------------	-----	------

AB		1MG	A091195 002	Aug 31, 2011	Aug	NEWA
----	--	-----	-------------	--------------	-----	------

AB		5MG	A091195 003	Aug 31, 2011	Aug	NEWA
----	--	-----	-------------	--------------	-----	------

TAMOXIFEN CITRATETABLET; ORALTAMOXIFEN CITRATE

AB	APOTEX	EQ 10MG BASE	A090878 001	Sep 23, 2011	Sep	NEWA
----	--------	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A090878 002	Sep 23, 2011	Sep	NEWA
----	--	--------------	-------------	--------------	-----	------

TAPENTADOL HYDROCHLORIDETABLET; ORALNUCYNTAJANSSSEN PHARMS

		EQ 50MG BASE	N022304 001	Nov 20, 2008	Nov	CAHN
--	--	--------------	-------------	--------------	-----	------

		EQ 75MG BASE	N022304 002	Nov 20, 2008	Nov	CAHN
--	--	--------------	-------------	--------------	-----	------

+		EQ 100MG BASE	N022304 003	Nov 20, 2008	Nov	CAHN
---	--	---------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORALNUCYNTA ERJANSSSEN PHARMS

		EQ 50MG BASE	N200533 001	Aug 25, 2011	Nov	CAHN
--	--	--------------	-------------	--------------	-----	------

		EQ 100MG BASE	N200533 002	Aug 25, 2011	Nov	CAHN
--	--	---------------	-------------	--------------	-----	------

		EQ 150MG BASE	N200533 003	Aug 25, 2011	Nov	CAHN
--	--	---------------	-------------	--------------	-----	------

		EQ 200MG BASE	N200533 004	Aug 25, 2011	Nov	CAHN
--	--	---------------	-------------	--------------	-----	------

+		EQ 250MG BASE	N200533 005	Aug 25, 2011	Nov	CAHN
---	--	---------------	-------------	--------------	-----	------

ORTHO MCNEIL JANSSSEN

		EQ 50MG BASE	N200533 001	Aug 25, 2011	Aug	NEWA
--	--	--------------	-------------	--------------	-----	------

		EQ 100MG BASE	N200533 002	Aug 25, 2011	Aug	NEWA
--	--	---------------	-------------	--------------	-----	------

		EQ 150MG BASE	N200533 003	Aug 25, 2011	Aug	NEWA
--	--	---------------	-------------	--------------	-----	------

		EQ 200MG BASE	N200533 004	Aug 25, 2011	Aug	NEWA
--	--	---------------	-------------	--------------	-----	------

+		EQ 250MG BASE	N200533 005	Aug 25, 2011	Aug	NEWA
---	--	---------------	-------------	--------------	-----	------

TELAPREVIRTABLET; ORALINCIVEK

+	VERTEX PHARMS	375MG	N201917 001	May 23, 2011	May	NEWA
---	---------------	-------	-------------	--------------	-----	------

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

@ NOVARTIS

100MG/5ML

N022154 001 Apr 28, 2009 Jun DISC

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

>A> AB MALLINCKRODT INC

7.5MG

N018163 003 Oct 25, 1991 Dec CAHN

>A> AB

15MG

N018163 001 Dec CAHN

>A> AB

22.5MG

N018163 004 Nov 02, 2004 Dec CAHN

>A> AB +

30MG

N018163 002 Dec CAHN

>D> AB TYCO HLTHCARE

7.5MG

N018163 003 Oct 25, 1991 Dec CAHN

>D> AB

15MG

N018163 001 Dec CAHN

>D> AB

22.5MG

N018163 004 Nov 02, 2004 Dec CAHN

>D> AB +

30MG

N018163 002 Dec CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB JUBILANT CADISTA

EQ 1MG BASE

A075317 001 Dec 20, 2004 Jan CAHN

AB

EQ 2MG BASE

A075317 002 Dec 20, 2004 Jan CAHN

AB

EQ 5MG BASE

A075317 003 Dec 20, 2004 Jan CAHN

AB

EQ 10MG BASE

A075317 004 Dec 20, 2004 Jan CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB MYLAN

EQ 250MG BASE

A077136 001 Jul 02, 2007 Feb CAHN

@ ROXANE

EQ 250MG BASE

A077223 001 Jul 02, 2007 Feb DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB + IMPAX LABS

5MG

A075877 002 Jun 26, 2001 Jan CRLD

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+ WATSON LABS

2MG/24HR

N020489 003 Oct 20, 2011 Oct NEWA

@

2.5MG/24HR

N020489 001 Sep 29, 1995 Oct DISC

+

4MG/24HR

N020489 004 Oct 20, 2011 Oct NEWA

@

5MG/24HR

N020489 002 May 02, 1997 Oct DISC

GEL; TRANSDERMAL

ANDROGEL

ABBOTT LABS

1% (2.5GM/PACKET)

N021015 001 Feb 28, 2000 Aug CAHN

BX +

1% (5GM/PACKET)

N021015 002 Feb 28, 2000 Aug CAHN

GEL, METERED; TRANSDERMAL

ANDROGEL

+ ABBOTT LABS

1% (1.25GM/ACTIVATION)

N021015 003 Sep 26, 2003 Aug CAHN

+

1.62% (20.25MG/1.25GM ACTIVATION)

N022309 001 Apr 29, 2011 Aug CAHN

+ ABBOTT PRODS

1.62% (20.25MG/1.25GM ACTIVATION)

N022309 001 Apr 29, 2011 Apr NEWA

FORTESTA

+ ENDO PHARMS

10MG/0.5GM ACTIVATION

N021463 001 Dec 29, 2010 Mar CPOT

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+	ACTIENT PHARMS	30MG	N021543 001	Jun 19, 2003	Jun	CAHN
---	----------------	------	-------------	--------------	-----	------

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT INTL	12.5MG	N021894 001	Aug 15, 2008	Jun	CAHN
--	--------------	--------	-------------	--------------	-----	------

+		25MG	N021894 002	Aug 15, 2008	Jun	CAHN
---	--	------	-------------	--------------	-----	------

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

@	SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994	Jun	CAHN
---	---------------	--------------	-------------	--------------	-----	------

SUSPENSION; ORAL

SUMYCIN

@	PAR PHARM	125MG/5ML	A060400 001		Jul	DISC
---	-----------	-----------	-------------	--	-----	------

TABLET; ORAL

SUMYCIN

@	PAR PHARM	250MG	A061147 001		Jul	DISC
---	-----------	-------	-------------	--	-----	------

@		500MG	A061147 004		Jul	DISC
---	--	-------	-------------	--	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

BC	ACTIENT PHARMS	100MG	A087942 001	Aug 22, 1983	Jun	CAHN
----	----------------	-------	-------------	--------------	-----	------

BC		200MG	A087943 001	Aug 22, 1983	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

BC		300MG	A087944 001	Aug 22, 1983	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

		400MG	A081034 001	Feb 28, 1992	Jun	CAHN
--	--	-------	-------------	--------------	-----	------

BC	UCB INC	100MG	A087942 001	Aug 22, 1983	Nov	CAHN
----	---------	-------	-------------	--------------	-----	------

BC		200MG	A087943 001	Aug 22, 1983	Nov	CAHN
----	--	-------	-------------	--------------	-----	------

BC		300MG	A087944 001	Aug 22, 1983	Nov	CAHN
----	--	-------	-------------	--------------	-----	------

		400MG	A081034 001	Feb 28, 1992	Nov	CAHN
--	--	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	80MG/100ML	N019211 002	Dec 14, 1984	Aug	DISC
---	---------	------------	-------------	--------------	-----	------

@		200MG/100ML	N019211 004	Dec 14, 1984	Aug	DISC
---	--	-------------	-------------	--------------	-----	------

@		400MG/100ML	N019211 005	Dec 14, 1984	Aug	DISC
---	--	-------------	-------------	--------------	-----	------

SOLUTION; ORAL

THEOPHYLLINE

+	SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Mar	NEWA
---	--------	-----------	-------------	--------------	-----	------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

@	HOSPIRA	100MG/ML	A040079 001	May 03, 1996	May	DISC
---	---------	----------	-------------	--------------	-----	------

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

>D>	AP	APP PHARMS	15MG/VIAL	A075698 001	Sep 20, 2001	Dec	DISC
-----	----	------------	-----------	-------------	--------------	-----	------

>A>		@	15MG/VIAL	A075698 001	Sep 20, 2001	Dec	DISC
-----	--	---	-----------	-------------	--------------	-----	------

>D>	AP	BEDFORD	15MG/VIAL	A075547 001	Apr 02, 2001	Dec	CTEC
-----	----	---------	-----------	-------------	--------------	-----	------

>A>			15MG/VIAL	A075547 001	Apr 02, 2001	Dec	CTEC
-----	--	--	-----------	-------------	--------------	-----	------

>D>	AP	+	TEVA PARENTERAL	15MG/VIAL	A075730 001	Apr 20, 2001	Dec	DISC
-----	----	---	-----------------	-----------	-------------	--------------	-----	------

>A>		@	15MG/VIAL	A075730 001	Apr 20, 2001	Dec	DISC
-----	--	---	-----------	-------------	--------------	-----	------

INJECTABLE; INJECTION

THIOTEPA

>D>	+	TEVA PARENTERAL	30MG/VIAL	A075730 002	Apr 20, 2001	Dec	DISC
>A>	@		30MG/VIAL	A075730 002	Apr 20, 2001	Dec	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

AB		CEPHALON	2MG	N020646 005	Apr 16, 1999	Oct	CFTG
AB	+		4MG	N020646 001	Sep 30, 1997	Oct	CFTG

TIAGABINE HYDROCHLORIDE

AB		SUN PHARM INDS	2MG	A077555 001	Nov 04, 2011	Oct	NEWA
AB			4MG	A077555 002	Nov 04, 2011	Oct	NEWA

TICAGRELOR

TABLET; ORAL

BRILINTA

+	ASTRAZENECA LP	90MG	N022433 001	Jul 20, 2011	Jul	NEWA
---	----------------	------	-------------	--------------	-----	------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	250MG	A075253 001	Aug 20, 1999	Aug	DISC
AB		MYLAN	250MG	A075161 001	Sep 13, 1999	Feb	CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT		APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000	Jun	CAHN
AT			EQ 0.5% BASE	A075412 001	Sep 08, 2000	Sep	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 2MG BASE	A076283 001	Jul 12, 2002	Aug	DISC
@		EQ 4MG BASE	A076283 002	Jul 12, 2002	Aug	DISC
@	ACTAVIS TOTOWA	EQ 2MG BASE	A076281 001	Oct 20, 2003	Jul	DISC
@		EQ 4MG BASE	A076281 002	Oct 20, 2003	Jul	DISC

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT		FERA PHARMS	0.3%	A065026 001	Sep 11, 2001	Mar	CAHN
----	--	-------------	------	-------------	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	@	HOSPIRA	EQ 10MG BASE/ML	A063080 001	Apr 30, 1991	Aug	DISC
AP	+		EQ 10MG BASE/ML	A063112 001	Apr 30, 1991	Aug	CRLD

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARM INTL	100MG	N020697 001	Jan 29, 1998	Jun	CRLD
@		200MG	N020697 002	Jan 29, 1998	Jun	DISC

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ ACTAVIS ELIZABETH	EQ 400MG BASE	A073308 001	Jan 24, 1992	Aug	DISC
---------------------	---------------	-------------	--------------	-----	------

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191 001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284 001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

>D>	AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Dec	CRLD
>A>	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Dec	CRLD
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Feb	NEWA
>D>		SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Dec	DISC
			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Feb	NEWA
>D>			EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Dec	DISC
			EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Feb	NEWA
>D>	AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Dec	DISC
	AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Feb	NEWA
>A>		@ SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Dec	DISC
>A>		@	EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Dec	DISC
>A>		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Dec	DISC

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613 001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613 002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613 003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+	CIPHER PHARMS INC	100MG	N022370 001	May 07, 2010	Aug	CTNA
		150MG	N022370 004	Aug 01, 2011	Aug	NEWA
		200MG	N022370 002	May 07, 2010	Aug	CTNA
		300MG	N022370 003	May 07, 2010	Aug	CTNA

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	50MG	A075960 001	Jun 19, 2002	Aug	DISC
AB	ALVOGEN	50MG	A202075 001	Nov 28, 2011	Nov	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A090404 001	Jan 31, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

>D>	BC	+	PURDUE PHARMA	100MG	N021745 001	Dec 30, 2008	Dec	CTEC
>A>	AB2	+		100MG	N021745 001	Dec 30, 2008	Dec	CTEC
>D>	BC			200MG	N021745 002	Dec 30, 2008	Dec	CTEC
>A>	AB2			200MG	N021745 002	Dec 30, 2008	Dec	CTEC
>D>	BC			300MG	N021745 003	Dec 30, 2008	Dec	CTEC
>A>	AB2			300MG	N021745 003	Dec 30, 2008	Dec	CTEC

TRAMADOL HYDROCHLORIDE

>D>	AB	LUPIN LTD	100MG	A200503 001	Aug 29, 2011	Dec	CTEC
-----	----	-----------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB1	LUPIN LTD	100MG	A200503 001	Aug 29, 2011	Dec	CTEC
	AB		100MG	A200503 001	Aug 29, 2011	Aug	NEWA
>D>	AB		200MG	A200503 002	Aug 29, 2011	Dec	CTEC
>A>	AB1		200MG	A200503 002	Aug 29, 2011	Dec	CTEC
	AB		200MG	A200503 002	Aug 29, 2011	Aug	NEWA
>D>	AB		300MG	A200503 003	Aug 29, 2011	Dec	CTEC
>A>	AB1		300MG	A200503 003	Aug 29, 2011	Dec	CTEC
	AB		300MG	A200503 003	Aug 29, 2011	Aug	NEWA
>D>	AB	PAR PHARM	100MG	A078783 001	Nov 13, 2009	Dec	CTEC
>A>	AB1		100MG	A078783 001	Nov 13, 2009	Dec	CTEC
>D>	AB		200MG	A078783 002	Nov 13, 2009	Dec	CTEC
>A>	AB1		200MG	A078783 002	Nov 13, 2009	Dec	CTEC
>D>	AB		300MG	A078783 003	Sep 20, 2011	Dec	CTEC
>A>	AB1		300MG	A078783 003	Sep 20, 2011	Dec	CTEC
	AB		300MG	A078783 003	Sep 20, 2011	Sep	NEWA
>D>	AB	SUN PHARMA GLOBAL	100MG	A201384 001	Dec 07, 2011	Dec	CTEC
>A>	AB2		100MG	A091607 001	Dec 30, 2011	Dec	NEWA
>A>	AB1		100MG	A201384 001	Dec 07, 2011	Dec	CTEC
	AB		100MG	A201384 001	Dec 07, 2011	Nov	NEWA
>D>	AB		200MG	A201384 002	Dec 07, 2011	Dec	CTEC
>A>	AB1		200MG	A201384 002	Dec 07, 2011	Dec	CTEC
>A>	AB2		200MG	A091607 002	Dec 30, 2011	Dec	NEWA
	AB		200MG	A201384 002	Dec 07, 2011	Nov	NEWA
>D>	AB		300MG	A201384 003	Dec 07, 2011	Dec	CTEC
>A>	AB1		300MG	A201384 003	Dec 07, 2011	Dec	CTEC
>A>	AB2		300MG	A091607 003	Dec 30, 2011	Dec	NEWA
	AB		300MG	A201384 003	Dec 07, 2011	Nov	NEWA

ULTRAM ER

>D>	AB	+ VALEANT INTL	100MG	N021692 001	Sep 08, 2005	Dec	CTEC
>A>	AB1	+	100MG	N021692 001	Sep 08, 2005	Dec	CTEC
	AB	+	100MG	N021692 001	Sep 08, 2005	Jun	CAHN
>D>	AB		200MG	N021692 002	Sep 08, 2005	Dec	CTEC
>A>	AB1		200MG	N021692 002	Sep 08, 2005	Dec	CTEC
	AB		200MG	N021692 002	Sep 08, 2005	Jun	CAHN
>D>	AB		300MG	N021692 003	Sep 08, 2005	Dec	CTEC
>A>	AB1		300MG	N021692 003	Sep 08, 2005	Dec	CTEC
	AB		300MG	N021692 003	Sep 08, 2005	Aug	CTEC
	BC		300MG	N021692 003	Sep 08, 2005	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

	+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Aug	CAHN
--	---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

AP	+	PHARMACIA AND UPJOHN	100MG/ML	N019281 001	Dec 30, 1986	Aug	CFTG
----	---	----------------------	----------	-------------	--------------	-----	------

TRANEXAMIC ACID

AP		BIONICHE PHARMA	100MG/ML	A091657 001	Nov 03, 2011	Oct	NEWA
AP		MYLAN INSTITUTIONAL	100MG/ML	A091657 001	Nov 03, 2011	Nov	CAHN
AP		PHARMAFORCE	100MG/ML	A201885 001	Aug 10, 2011	Aug	NEWA
AP		VERSAPHARM INC	100MG/ML	A202373 001	Nov 17, 2011	Nov	NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

@ ALCON	0.004%	N021257 001	Mar 16, 2001	May	DISC
---------	--------	-------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+	ANGELINI LABOPHARM	150MG	N022411 001	Feb 02, 2010	Jun	CAHN
		300MG	N022411 002	Feb 02, 2010	May	CAHN
+	ANGELINI LLC	150MG	N022411 001	Feb 02, 2010	Aug	CAHN
		300MG	N022411 002	Feb 02, 2010	Aug	CAHN

TRETINOIN

CREAM; TOPICAL

RENOVA

	+	ORTHO JANSSEN	0.02%	N021108 001	Aug 31, 2000	Jul	CAHN
AB2	+		0.05%	N019963 001	Dec 29, 1995	Jul	CAHN

RETIN-A

AB	+	ORTHO JANSSEN	0.025%	N019049 001	Sep 16, 1988	Jul	CAHN
AB1	+		0.05%	N017522 001		Jul	CAHN
AB	+		0.1%	N017340 001		Jul	CAHN

GEL; TOPICAL

RETIN-A

AB	+	ORTHO JANSSEN	0.01%	N017955 001		Jul	CAHN
AB	+		0.025%	N017579 002		Jul	CAHN

RETIN-A MICRO

>D>	+	ORTHO DERMATOLOGICS	0.04%	N020475 002	May 10, 2002	Dec	CAHN
>D>	+		0.1%	N020475 001	Feb 07, 1997	Dec	CAHN
>A>	+	VALEANT INTL	0.04%	N020475 002	May 10, 2002	Dec	CAHN
>A>	+		0.1%	N020475 001	Feb 07, 1997	Dec	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	ORTHO JANSSEN	0.05%	N016921 001		Jul	CAHN
----	---	---------------	-------	-------------	--	-----	------

SWAB; TOPICAL

RETIN-A

@ ORTHO JANSSEN	0.05%	N016921 002		Jul	CAHN
-----------------	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

@ ACTAVIS MID ATLANTIC	0.1%	A087798 001	Jun 04, 1982	Aug	DISC
------------------------	------	-------------	--------------	-----	------

TRIDERM

AT		CROWN LABS	0.1%	A088042 001	Mar 19, 1984	Sep	CAHN
----	--	------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

@ ACTAVIS MID ATLANTIC	0.1%	A087799 001	Jun 07, 1982	Aug	DISC
------------------------	------	-------------	--------------	-----	------

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT	+	TARO	0.1%	A070730 001	Oct 01, 1986	Aug	CTNA
----	---	------	------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

AB		TEVA BRANDED PHARM	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Aug	CAHN
----	--	--------------------	---------------	-------------	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011	May	CAHN
AP	PHARMAFORCE	100MG/ML	A091330 001	Mar 08, 2011	Feb	NEWA
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE						
AP	LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011	May	CAHN
AP	PHARMAFORCE	100MG/ML	A091329 001	Mar 08, 2011	Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011	May	NEWA
----	----------------	-------	-------------	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361 002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361 003	Aug 02, 2006	Feb	CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	WATSON LABS	EQ 3.75MG BASE/VIAL	N020715 001	Jun 15, 2000	Sep	CTNA
+		EQ 11.25MG BASE/VIAL	N021288 001	Jun 29, 2001	Sep	CTNA

TROSPIUM CHLORIDE

TABLET; ORAL

TROSPIUM CHLORIDE

AB	APOTEX	20MG	A091513 001	Dec 06, 2011	Nov	NEWA
----	--------	------	-------------	--------------	-----	------

URSODIOL

TABLET; ORAL

URSO 250

AB	APTALIS PHARMA US	250MG	N020675 001	Dec 10, 1997	Oct	CAHN
----	-------------------	-------	-------------	--------------	-----	------

URSO FORTE

AB	+	APTALIS PHARMA US	500MG	N020675 002	Jul 21, 2004	Oct	CAHN
----	---	-------------------	-------	-------------	--------------	-----	------

URSODIOL

AB	GLENMARK GENERICS	250MG	A090801 001	Jul 12, 2011	Jul	NEWA
----	-------------------	-------	-------------	--------------	-----	------

AB		500MG	A090801 002	Jul 12, 2011	Jul	NEWA
----	--	-------	-------------	--------------	-----	------

>A>	AB	WATSON LABS INC	250MG	A200826 001	Dec 23, 2011	Dec	NEWA
-----	----	-----------------	-------	-------------	--------------	-----	------

>A>	AB		500MG	A200826 002	Dec 23, 2011	Dec	NEWA
-----	----	--	-------	-------------	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370 001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 500MG BASE/VIAL	A065397 001	Dec 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065397 002	Dec 30, 2008	May	CAHN

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 5GM BASE/VIAL	A065432 001	Dec 30, 2008	May	CAHN
AP		EQ 10GM BASE/VIAL	A091469 001	Jul 01, 2011	Jun	NEWA
AP	STRIDES ARCOLAB LTD	EQ 10GM BASE/VIAL	A091554 001	Sep 19, 2011	Sep	NEWA

VANDETANIB

TABLET; ORAL

VANDETANIB

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Apr	NEWA
+		300MG	N022405 002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	PFIZER	10MG/VIAL	A090243 001	May 11, 2010	May	CAHN
AP		20MG/VIAL	A090243 002	May 11, 2010	May	CAHN

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

	@ SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575 002	Feb 26, 2010	Oct	DISC
--	-----------------------	----------------	-------------	--------------	-----	------

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+	HOFFMANN LA ROCHE	240MG	N202429 001	Aug 17, 2011	Aug	NEWA
---	-------------------	-------	-------------	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A200834 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A200834 003	Apr 14, 2011	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078421 002	May 06, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078421 003	May 06, 2011	Apr	NEWA
AB	MYLAN	EQ 37.5MG BASE	A078789 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A078789 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A078789 003	Jun 01, 2011	May	NEWA
AB	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123 001	Jul 11, 2011	Jun	NEWA
AB		EQ 75MG BASE	A091123 002	Jul 11, 2011	Jun	NEWA
AB		EQ 150MG BASE	A091123 003	Jul 11, 2011	Jun	NEWA
AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A090899 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A090899 003	Jun 01, 2011	May	NEWA
AB	VALEANT INTL	EQ 37.5MG BASE	A090071 001	Apr 15, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090071 002	Apr 15, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090071 003	Apr 15, 2011	Apr	NEWA
AB	WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078865 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078865 003	Apr 14, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090174 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090174 003	Apr 14, 2011	Apr	NEWA

TABLET; ORAL

EFFEXOR

@	WYETH PHARMS INC	EQ 25MG BASE	N020151 002	Dec 28, 1993	Aug	DISC
@		EQ 37.5MG BASE	N020151 006	Dec 28, 1993	Aug	DISC
@		EQ 50MG BASE	N020151 003	Dec 28, 1993	Aug	DISC
@		EQ 75MG BASE	N020151 004	Dec 28, 1993	Aug	DISC
@		EQ 100MG BASE	N020151 005	Dec 28, 1993	Aug	DISC

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932 001	Dec 14, 2010	Jul	CAHN
AB		EQ 37.5MG BASE	A078932 002	Dec 14, 2010	Jul	CAHN
AB		EQ 50MG BASE	A078932 003	Dec 14, 2010	Jul	CAHN
AB		EQ 75MG BASE	A078932 004	Dec 14, 2010	Jul	CAHN
AB		EQ 100MG BASE	A078932 005	Dec 14, 2010	Jul	CAHN
	@ PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517 001	Jun 13, 2008	Aug	DISC
	@	EQ 37.5MG BASE	A078517 002	Jun 13, 2008	Aug	DISC
	@	EQ 50MG BASE	A078517 003	Jun 13, 2008	Aug	DISC
	@	EQ 75MG BASE	A078517 004	Jun 13, 2008	Aug	DISC
	@	EQ 100MG BASE	A078517 005	Jun 13, 2008	Aug	DISC
AB	+ TEVA	EQ 50MG BASE	A076690 003	Aug 03, 2006	Aug	CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB	ALKERMES GAINESVILLE	120MG	N019614 001	May 29, 1990	Sep	CAHN
AB		180MG	N019614 003	Jan 09, 1992	Sep	CAHN
AB		240MG	N019614 002	May 29, 1990	Sep	CAHN
	+	360MG	N019614 004	May 10, 1996	Sep	CAHN

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

@	HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987	Aug	DISC
---	---------	----------	-------------	--------------	-----	------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

@	ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986	Aug	DISC
@		120MG	A070468 001	Sep 24, 1986	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

AB	+ PFIZER	120MG	N019152 003	Mar 06, 1991	Nov	CAHN
AB	+	180MG	N019152 002	Dec 15, 1989	Nov	CAHN
AB	+	240MG	N019152 001	Dec 16, 1986	Nov	CAHN

VERAPAMIL HYDROCHLORIDE

	AB	GLENMARK GENERICS	120MG	A090700 001	Aug 03, 2011	Jul	NEWA
	AB		180MG	A090700 002	Aug 03, 2011	Jul	NEWA
>A>	AB	SUN PHARM INDS INC	120MG	A090529 001	Dec 30, 2011	Dec	NEWA
>A>	AB		180MG	A090529 002	Dec 30, 2011	Dec	NEWA
>A>	AB		240MG	A090529 003	Dec 30, 2011	Dec	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	May	CAHN
		20MG	N022567 002	Jan 21, 2011	May	CAHN
	+	40MG	N022567 003	Jan 21, 2011	May	CAHN
	TROVIS PHARMS	10MG	N022567 001	Jan 21, 2011	Jan	NEWA
		20MG	N022567 002	Jan 21, 2011	Jan	NEWA
	+	40MG	N022567 003	Jan 21, 2011	Jan	NEWA

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE

@ APP PHARMS

1MG/ML

A076401 001 Oct 28, 2003 Jan DISC

VINCRIStINE SULFATE PFS

AP + HOSPIRA

1MG/ML

A071484 001 Apr 19, 1988 Sep CRLD

VORICONAZOLE

TABLET; ORAL

VORICONAZOLE

>A> AB SANDOZ INC

50MG

A200265 001 Dec 12, 2011 Dec NEWA

>A> AB

200MG

A200265 002 Dec 12, 2011 Dec NEWA

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB INVAGEN PHARMS

1MG

A090935 001 May 25, 2011 May NEWA

AB

2MG

A090935 002 May 25, 2011 May NEWA

AB

2.5MG

A090935 003 May 25, 2011 May NEWA

AB

3MG

A090935 004 May 25, 2011 May NEWA

AB

4MG

A090935 005 May 25, 2011 May NEWA

AB

5MG

A090935 006 May 25, 2011 May NEWA

AB

6MG

A090935 007 May 25, 2011 May NEWA

AB

7.5MG

A090935 008 May 25, 2011 May NEWA

AB

10MG

A090935 009 May 25, 2011 May NEWA

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+ AZUR PHARMA II

100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004 Nov CAIN

+

500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004 Nov CAIN

+

500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004 Nov CAIN

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP LUITPOLD

10MG/ML

A091457 001 May 06, 2010 Feb CAHN

TABLET; ORAL

ZIDOVUDINE

AB HEC PHARM INC

300MG

A202058 001 Oct 07, 2011 Sep NEWA

@ MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011 Feb NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+ NOVARTIS

EQ 4MG BASE/100ML

N021223 003 Jun 17, 2011 Jun NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB MYLAN

5MG

A078016 001 Apr 23, 2007 Feb CAHN

AB

10MG

A078016 002 Apr 23, 2007 Feb CAHN

TABLET; SUBLINGUAL

INTERMEZZO

>A> PURDUE PHARMA

1.75MG

N022328 001 Nov 23, 2011 Dec CAHN

TABLET; SUBLINGUAL

INTERMEZZO

>A>	+	PURDUE PHARMA	3.5MG	N022328 002	Nov 23, 2011	Dec	CAHN
>D>		TRANSCEPT PHARMS	1.75MG	N022328 001	Nov 23, 2011	Dec	CAHN
			1.75MG	N022328 001	Nov 23, 2011	Nov	NEWA
>D>	+		3.5MG	N022328 002	Nov 23, 2011	Dec	CAHN
	+		3.5MG	N022328 002	Nov 23, 2011	Nov	NEWA

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB		ANCHEN PHARMS	6.25MG	A078148 002	Apr 14, 2011	Apr	NEWA
AB		SANDOZ	6.25MG	A090107 001	Jul 01, 2011	Jun	NEWA
AB			12.5MG	A090107 002	Jul 01, 2011	Jun	NEWA
AB		SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011	Apr	NEWA
AB			12.5MG	A078483 002	Jun 06, 2011	Jul	NEWA
		ZOLPIDEM TATRATE					
AB		ACTAVIS S ATLANTIC	12.5MG	A078179 001	Jun 06, 2011	Sep	NEWA

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

>D>	RANBAXY	650MG	A090205 001	Nov 18, 2009	Dec	DISC
>A>	@	650MG	A090205 001	Nov 18, 2009	Dec	DISC
>A>	RANBAXY LABS LTD	650MG	A078569 001	Dec 14, 2011	Dec	NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	ACTAVIS MID ATLANTIC	5MG/5ML	A090378 002	May 09, 2008	Aug	DISC
	SILARX	5MG/5ML	A091130 001	Apr 22, 2011	Apr	NEWA
	SUN PHARM INDS INC	5MG/5ML	A091327 001	Oct 17, 2011	Oct	NEWA
	TARO	5MG/5ML	A201546 001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	ACTAVIS MID ATLANTIC	5MG/5ML	A090378 001	May 09, 2008	Aug	DISC
	SILARX	5MG/5ML	A091130 002	Apr 22, 2011	Apr	NEWA
	SUN PHARM INDS INC	5MG/5ML	A091327 002	Oct 17, 2011	Oct	NEWA
	TARO	5MG/5ML	A201546 002	May 20, 2011	May	NEWA

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	SUN PHARMA GLOBAL	5MG	A090142 001	Aug 30, 2011	Aug	NEWA
		10MG	A090142 002	Aug 30, 2011	Aug	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	SUN PHARMA GLOBAL	5MG	A090142 003	Aug 30, 2011	Aug	NEWA
		10MG	A090142 004	Aug 30, 2011	Aug	NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBICLENS

+	MOLNLYCKE HLTH	4%	N017768 001		Nov	CAHN
---	----------------	----	-------------	--	-----	------

HIBISTAT

+	MOLNLYCKE HLTH	0.5%	N018300 001		Nov	CAHN
---	----------------	------	-------------	--	-----	------

SPONGE; TOPICAL

PHARMASEAL SCRUB CARE

+	CAREFUSION	4%	N019793 001	Dec 02, 1988	Aug	CAHN
---	------------	----	-------------	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CARDINAL HLTH	2%;70% (0.67ML)	N021555 001	Oct 07, 2002	Apr	CAHN
---	---------------	-----------------	-------------	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	CARDINAL HLTH	2%;70% (1.75ML)	N021555 002	May 10, 2005	Apr	CAHN
---	---------------	-----------------	-------------	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	CARDINAL HLTH	2%;70% (5.25ML)	N021555 003	Jun 10, 2009	Apr	NEWA
---	---------------	-----------------	-------------	--------------	-----	------

CHLORASCRUB MAXI SWABSTICK

+	3M INFECTION	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Nov	CAHN
---	--------------	-------------------	-------------	--------------	-----	------

CHLORASCRUB SWAB

+	3M INFECTION	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Nov	CAHN
---	--------------	-----------------	-------------	--------------	-----	------

CHLORASCRUB SWABSTICK

+	3M INFECTION	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Nov	CAHN
---	--------------	-------------------	-------------	--------------	-----	------

>A> CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

>A> TABLET; ORAL

>A> ADVIL ALLERGY AND CONGESTION RELIEF

>A> + PFIZER CONS HLTHCARE 4MG;200MG;10MG N022113 001 Dec 21, 2011 Dec NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

APOTEX

100MG

A074948 001 Jun 19, 1998 Sep CMFD

200MG

A074948 002 Jul 26, 2002 Sep CMFD

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

@ ACTAVIS MID ATLANTIC 5.2MG/SPRAY

A074800 001 Jul 26, 2001 Aug DISC

>A> HH AND P 5.2MG/SPRAY

A077976 001 Sep 07, 2007 Dec CAHN

>D> QPHARMA 5.2MG/SPRAY

A077976 001 Sep 07, 2007 Dec CAHN

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+ PFIZER CONS HLTHCARE 38MG;200MG

N021394 001 Dec 21, 2005 Nov CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MYLAN

10MG

A075674 001 Dec 21, 2001 Feb CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG/5ML

N201373 001 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG/5ML

N201373 002 Jan 24, 2011 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG

N021909 002 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG

N021909 003 Jan 24, 2011 Jan NEWA

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US

60MG

N020872 007 Jan 24, 2011 Jan NEWA

+ 180MG

N020872 010 Jan 24, 2011 Jan NEWA

ALLEGRA HIVES

SANOFI AVENTIS US

60MG

N020872 008 Jan 24, 2011 Jan NEWA

+ 180MG

N020872 009 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US

30MG

N020872 005 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US

30MG

N020872 006 Jan 24, 2011 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD

30MG

A076502 004 Apr 12, 2011 Mar NEWA

MYLAN

30MG

A077081 004 Jul 21, 2011 Jul NEWA

TEVA

30MG

A076447 004 Apr 13, 2011 Mar NEWA

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502 005	Apr 12, 2011	Mar	NEWA
MYLAN	30MG	A077081 005	Jul 21, 2011	Jul	NEWA
TEVA	30MG	A076447 005	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	60MG	A076502 006	Apr 12, 2011	Mar	NEWA
	180MG	A076502 008	Apr 12, 2011	Mar	NEWA
MYLAN	60MG	A077081 006	Jul 21, 2011	Jul	NEWA
	180MG	A077081 008	Jul 21, 2011	Jul	NEWA
TEVA	60MG	A076447 006	Apr 13, 2011	Mar	NEWA
	180MG	A076447 008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502 007	Apr 12, 2011	Mar	NEWA
	180MG	A076502 009	Apr 12, 2011	Mar	NEWA
MYLAN	60MG	A077081 007	Jul 21, 2011	Jul	NEWA
	180MG	A077081 009	Jul 21, 2011	Jul	NEWA
TEVA	60MG	A076447 007	Apr 13, 2011	Mar	NEWA
	180MG	A076447 009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	60MG;120MG	N020786 002	Jan 24, 2011	Jan	NEWA
---	-------------------	------------	-------------	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	180MG;240MG	N021704 002	Jan 24, 2011	Jan	NEWA
---	-------------------	-------------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	180MG;240MG	A079043 002	Jun 22, 2011	Jun	NEWA
--------------------	-------------	-------------	--------------	-----	------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

PERRIGO R AND D	600MG	A078912 001	Nov 23, 2011	Nov	NEWA
-----------------	-------	-------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

>A>	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300 001	Dec 23, 2011	Dec	NEWA
-----	---------------	---------------------------------------	-------------	--------------	-----	------

SUSPENSION; ORAL

IBUPROFEN

AMNEAL PHARMS	100MG/5ML	A200457 001	Aug 18, 2011	Aug	NEWA
---------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

ADVENT PHARMS	200MG	A076460 001	Nov 26, 2003	Jul	CAHN
AVEMA PHARMA	200MG	A076460 001	Nov 26, 2003	Aug	CAHN
	200MG	A076460 001	Nov 26, 2003	May	CAHN
MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
	200MG	A091239 001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
	200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

	+	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
--	---	------------------	--------------	-------------	--------------	-----	------

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

>A>	+	ALCON PHARMA	EQ 0.025% BASE	N021066 002	Oct 19, 2006	Dec	CAHN
-----	---	--------------	----------------	-------------	--------------	-----	------

>D>	+	NOVARTIS	EQ 0.025% BASE	N021066 002	Oct 19, 2006	Dec	CAHN
-----	---	----------	----------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

	+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
--	---	-------------	--------	-------------	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D 1MG/7.5ML

A091292 001	May 20, 2011	May	NEWA
-------------	--------------	-----	------

LORATADINE

TABLET; ORAL

LORATADINE

MYLAN 10MG

A078447 001	Aug 12, 2011	Aug	NEWA
-------------	--------------	-----	------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT 1 COMBINATION PACK

>A>	+	INSIGHT PHARMS	2%,1.2GM	N021308 001	Jun 29, 2001	Dec	CAHN
-----	---	----------------	----------	-------------	--------------	-----	------

>D>	+	JOHNSON AND JOHNSON	2%,1.2GM	N021308 001	Jun 29, 2001	Dec	CAHN
-----	---	---------------------	----------	-------------	--------------	-----	------

MONISTAT 7 COMBINATION PACK

>A>	+	INSIGHT PHARMS	2%,100MG	N020288 002	Apr 26, 1993	Dec	CAHN
-----	---	----------------	----------	-------------	--------------	-----	------

>D>	+	JOHNSON AND JOHNSON	2%,100MG	N020288 002	Apr 26, 1993	Dec	CAHN
-----	---	---------------------	----------	-------------	--------------	-----	------

MONISTAT-3 COMBINATION PACK

>A>	+	INSIGHT PHARMS	2%,200MG	N020670 002	Apr 16, 1996	Dec	CAHN
-----	---	----------------	----------	-------------	--------------	-----	------

>D>	+	JOHNSON AND JOHNSON	2%,200MG	N020670 002	Apr 16, 1996	Dec	CAHN
-----	---	---------------------	----------	-------------	--------------	-----	------

M-ZOLE 7 DUAL PACK

@ ACTAVIS MID ATLANTIC 2%,100MG

A074586 001	Jul 17, 1997	Aug	DISC
-------------	--------------	-----	------

CREAM; TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

>A>		INSIGHT PHARMS	2%,4%	N021261 003	Jun 17, 2003	Dec	CAHN
-----	--	----------------	-------	-------------	--------------	-----	------

>D>		JOHNSON AND JOHNSON	2%,4%	N021261 003	Jun 17, 2003	Dec	CAHN
-----	--	---------------------	-------	-------------	--------------	-----	------

MONISTAT 3 COMBINATION PACK (PREFILLED)

>A>	+	INSIGHT PHARMS	2%,4%	N021261 001	Feb 02, 2001	Dec	CAHN
-----	---	----------------	-------	-------------	--------------	-----	------

>D>	+	JOHNSON AND JOHNSON	2%,4%	N021261 001	Feb 02, 2001	Dec	CAHN
-----	---	---------------------	-------	-------------	--------------	-----	------

CREAM; VAGINAL

MONISTAT 3

>A>	+	INSIGHT PHARMS	4%	N020827 001	Mar 30, 1998	Dec	CAHN
-----	---	----------------	----	-------------	--------------	-----	------

>D>	+	JOHNSON AND JOHNSON	4%	N020827 001	Mar 30, 1998	Dec	CAHN
-----	---	---------------------	----	-------------	--------------	-----	------

MONISTAT 7

>A>	+	INSIGHT PHARMS	2%	N017450 002	Feb 15, 1991	Dec	CAHN
-----	---	----------------	----	-------------	--------------	-----	------

>D>	+	JOHNSON AND JOHNSON	2%	N017450 002	Feb 15, 1991	Dec	CAHN
-----	---	---------------------	----	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

MONISTAT 7

>A>	+	INSIGHT PHARMS	100MG	N018520 002	Feb 15, 1991	Dec	CAHN
>D>	+	JOHNSON AND JOHNSON	100MG	N018520 002	Feb 15, 1991	Dec	CAHN

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL

PERRIGO ISRAEL	5%	A091344 001	Apr 28, 2011	Apr	NEWA
----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

THEROXIDIL

EI INC	2%	A078176 001	Nov 09, 2007	Oct	CAHN
	5%	A076239 001	Aug 24, 2004	Oct	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

GRANULES INDIA	EQ 200MG BASE	A091353 001	Sep 20, 2011	Sep	NEWA
MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
RANBAXY LABS LTD	EQ 200MG BASE	A091183 001	May 20, 2011	May	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	A091349 001	Jul 20, 2011	Jul	NEWA
	EQ 4MG BASE	A091354 001	Jul 20, 2011	Jul	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID OTC

+	MSD CONSUMER	20MG;1.1GM	N022281 001	Dec 01, 2009	Sep	CAHN
---	--------------	------------	-------------	--------------	-----	------

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

+	BAYER HLTHCARE	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000	Aug	CAHN
---	----------------	------------------	-------------	--------------	-----	------

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX	65MG	N018664 002	May 12, 2011	Apr	NEWA
-------	------	-------------	--------------	-----	------

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+	NIAGARA PHARMS	98.3%	N022305 001	Sep 01, 2011	Sep	NEWA
---	----------------	-------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN	EQ 75MG BASE	A075497 001	Jan 14, 2000	Feb	CAHN
PERRIGO R AND D	EQ 150MG BASE	A091429 001	May 11, 2011	Apr	NEWA
	EQ 150MG BASE	A091429 002	May 11, 2011	Apr	NEWA
SVADS HOLDINGS SA	EQ 150MG BASE	A200536 001	Jun 28, 2011	Jun	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2011

NO DECEMBER 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N022502 001	7998467	May 31, 2028	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	>A> 8080537	Jul 18, 2027	U-1078			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N021747 001	5405084	Apr 11, 2012	DP		NP	Oct 07, 2014
	5472143	Sep 29, 2013	DP			
	5497944	Mar 12, 2013	DP			
	5662271	Sep 02, 2014	DP			
	5911851	Sep 29, 2013	DP			
	5964416	Oct 04, 2016	DP			
	6007676	Sep 29, 2013	DP			
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6503362	Sep 29, 2013	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N021762 001	5994329	Jul 17, 2018	U-647	Y		
<u>ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE</u>						
A079013 001					PC	Jan 14, 2012
<u>ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE</u>						
A079014 001					PC	Jan 14, 2012
<u>ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE</u>						
A079054 001					PC	Jan 14, 2012
<u>ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE</u>						
A079056 001					PC	Jan 14, 2012
<u>ALFUZOSIN HYDROCHLORIDE - ALFUZOSIN HYDROCHLORIDE</u>						
A079057 001					PC	Jan 14, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	001				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	002				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	003				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	004				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	001	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	002	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	003	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	004	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	005	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775	001	5250542	Mar 29, 2016	DS DP U-878		
<u>AMBRISENTAN - LETAIRIS</u>						
N022081	001	RE42462	Oct 07, 2015	DS		
<u>AMBRISENTAN - LETAIRIS</u>						
N022081	002	RE42462	Oct 07, 2015	DS		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381	005				PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381	006				PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303	001	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303	006	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303	002	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303	004	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014
<u>ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM</u>						
A076477 001					PC	May 28, 2012
<u>ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM</u>						
A076477 002					PC	May 28, 2012
<u>ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM</u>						
A076477 003					PC	May 28, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM - ATORVASTATIN CALCIUM</u>						
A076477	004				PC	May 28, 2012
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022203	001 >A> 8071073	Jun 04, 2028	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N022371	001 >A> 8071073	Jun 04, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N200796	001 5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N200796	002 5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331	001				>A> NCE >A> NC	Feb 25, 2016 Dec 20, 2014
<u>AZITHROMYCIN - ZMAX</u>						
N050797	001 7887844	Feb 14, 2024	DP			
<u>AZTREONAM - CAYSTON</u>						
N050814	001				ODE	Feb 22, 2017
<u>BIMATOPROST - LATISSE</u>						
N022369	001 8017655	Nov 27, 2012	DS DP			
	8038988	Aug 25, 2023	DP			
<u>BIMATOPROST - LUMIGAN</u>						
N021275	001 8017655	Nov 27, 2012	DS DP			
<u>BIMATOPROST - LUMIGAN</u>						
N022184	001 8017655	Nov 27, 2012	DS DP			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873	001 5196404	Aug 13, 2012	DS DP U-1040			
	5196404*PED	Feb 13, 2013				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258	001 7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
	7772178	Nov 11, 2027	DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021262	001 5424078	Jun 13, 2012		Y		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N021770	001 5424078	Jun 13, 2012	DP	Y		
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N020866	001 >A> 7888310	Jul 25, 2023	U-976			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	7967011	Aug 11, 2021	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001					NP	Oct 28, 2014
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002					NP	Oct 28, 2014
<u>BUPRENORPHINE; NALOXONE - SUBOXONE</u>						
N022410 001	8017150	Sep 10, 2023	DP			
<u>BUPRENORPHINE; NALOXONE - SUBOXONE</u>						
N022410 002	8017150	Sep 10, 2023	DP			
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N022497 001	7674479	Jun 25, 2027	DP			
<u>CARBAMAZEPINE - CARBAMAZEPINE</u>						
A076697 003					PC	Nov 16, 2011
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5326570	Jul 23, 2011	U-215			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N022562 001					ODE	Mar 18, 2017
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CICLOPIROX - LOPROX</u>						
N020519 001	7026337	Nov 21, 2016	U-714			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	7981909	Sep 16, 2017	U-1162			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CLOBAZAM - ONFI</u>						
N202067 001					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N202067 002					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N202067 003					NCE ODE	Oct 21, 2016 Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N021644 001	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61 PED	May 06, 2014 Nov 06, 2014
	4847265*PED	May 17, 2012				
	5576328	Jan 31, 2014		U-432	Y	
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61 PED	May 06, 2014 Nov 06, 2014
	4847265*PED	May 17, 2012				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029		U-1116		
	7915269	Feb 17, 2029		U-1007		
	7935731	Dec 03, 2028		U-1116		
	7964647	Oct 06, 2028		U-1007		
	7964648	Feb 17, 2029		U-1161		
	7981938	Oct 06, 2028		U-1166		
	>A> 8093296	Oct 06, 2028		U-1007		
	>A> 8093297	Oct 06, 2028		U-1161		
	>A> 8093298	Oct 06, 2028		U-1116		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N008372 008					ODE	Oct 15, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027	U-1179		ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027	U-1179		ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7879349	Jun 01, 2024	DP U-1152			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 001	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 002	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
<u>DALFAMPRIDINE - AMPYRA</u>						
N022250 001	8007826	May 26, 2027	U-1030			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 001	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8003673	Sep 04, 2028	U-1180			
	8058238	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			>A> NPP	Dec 16, 2014
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			>A> PED	Jun 16, 2015
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-903		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			>A> NPP	Dec 16, 2014
	6037157	Jun 26, 2016	U-935		>A> NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			>A> PED	Jun 16, 2015
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-903		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		>A> NPP	Dec 16, 2014
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		>A> PED	Jun 16, 2015
	6248775*PED	Feb 13, 2015			PED	Jun 13, 2014
	6335460	Aug 25, 2012	DS DP U-935		PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-903		PED	Apr 21, 2012
	6335460*PED	Feb 25, 2013			PED	Dec 23, 2011
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			>A> NPP	Dec 16, 2014
	6248775	Aug 13, 2014	DS		NCE	Jun 23, 2011
	6248775*PED	Feb 13, 2015			>A> PED	Jun 16, 2015
	6335460	Aug 25, 2012	DS DP U-935		PED	Jun 13, 2014
	6335460*PED	Feb 25, 2013			PED	Jun 18, 2012
	6703403	Jun 26, 2016	U-935		PED	Dec 23, 2011
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			>A> NPP	Dec 16, 2014
	6248775	Aug 13, 2014	DS		NCE	Jun 23, 2011
	6248775*PED	Feb 13, 2015			>A> PED	Jun 16, 2015
	6335460	Aug 25, 2012	DS DP U-935		PED	Jun 13, 2014
	6335460*PED	Feb 25, 2013			PED	Jun 18, 2012
	6703403	Jun 26, 2016	U-935		PED	Dec 23, 2011
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001					>A> NDF	Dec 16, 2014
					>A> PED	Jun 16, 2015
<u>DASATINIB - SPRYCEL</u>						
N021986 005	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
<u>DASATINIB - SPRYCEL</u>						
N021986 006	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N021825	001				NCE ODE	Oct 14, 2016 Oct 14, 2018
<u>DEXAMETHASONE - OZURDEX</u>						
N022315	001	>A> 6726918	Oct 20, 2020	DP U-1205	ODE	Sep 24, 2017
		>A> 6726918	Oct 20, 2020	DP U-1204		
		>A> 6899717	Nov 01, 2023	U-1206		
		>A> 7033605	Oct 20, 2020	DP		
		>A> 7767223	Nov 28, 2021	DP		
		>A> 8034366	Jan 09, 2023	DP U-1205		
		>A> 8034366	Jan 09, 2023	DP U-1204		
		>A> 8034370	Jan 09, 2023	DP		
		>A> 8043628	Oct 20, 2020	DP U-1205		
		>A> 8063031	Oct 20, 2020	DP		
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802	007	5837284	Dec 04, 2015	DP	D-121 M-80	Oct 23, 2012 Oct 17, 2011
		5908850	Dec 04, 2015	DP U-678		
		6228398	Nov 01, 2019	DP U-676		
		6355656	Dec 04, 2015	DP		
		6528530	Dec 04, 2015	DP		
		6635284	Dec 04, 2015	DP U-677		
		6730325	Nov 01, 2019	DP U-676		
		7431944	Dec 04, 2015	DP		
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802	008	5837284	Dec 04, 2015	DP	D-121 M-80	Oct 23, 2012 Oct 17, 2011
		5908850	Dec 04, 2015	DP U-678		
		6228398	Nov 01, 2019	DP U-676		
		6355656	Dec 04, 2015	DP		
		6528530	Dec 04, 2015	DP		
		6635284	Dec 04, 2015	DP U-677		
		6730325	Nov 01, 2019	DP U-676		
		7431944	Dec 04, 2015	DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202	001	7884095	Feb 24, 2029	U-1111		
		7939518	Feb 24, 2029	U-980		
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005	001	5929048	Jun 17, 2014	U-402		
		5985850	Aug 11, 2015	DP		
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252	001	6133251	Oct 25, 2016	DP U-828	Y	
		6133251	Oct 25, 2016	DP U-112	Y	
		6133251	Oct 25, 2016	DP U-1	Y	
		6884793	Oct 25, 2016	DP	Y	
		>A> 8071577	May 13, 2026	DP U-1		
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212	001	6114319	May 18, 2019	DP		
<u>DORIPENEM - DORIBAX</u>						
N022106	001	5317016	Jun 05, 2015	DS DP U-282		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2012	DS DP U-992			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5922695	Jul 25, 2017	DS U-750			
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP U-750			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-750			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-750			
	6043230*PED	Jan 25, 2018				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
	8052993	Aug 01, 2027	DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			
	8052994	Aug 01, 2027	DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
	8062665	Aug 01, 2027	DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	6280959	Oct 30, 2018	DS DP U-930		NCE	Nov 20, 2013
	7160870	Dec 08, 2021	DS DP U-930		ODE	Nov 20, 2015
	7332481	May 24, 2021	U-930			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-930			
	7790704	May 24, 2021	U-930			
	7795293	May 21, 2023	U-930			
	>A> 8071129	Aug 01, 2027	DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS		U-257	
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP		U-257	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP			
	5977089*PED	Jan 25, 2018			U-257	
	6043230	Jul 25, 2017			U-257	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-257	
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP		U-257	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS		U-248	
	5922695	Jul 25, 2017	DS		U-541	
	5922695	Jul 25, 2017	DS		U-1170	
	5922695*PED	Jan 25, 2018				
	5935946	Jul 25, 2017	DS DP		U-1170	
	5935946	Jul 25, 2017	DS DP		U-248	
	5935946	Jul 25, 2017	DS DP		U-541	
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP		U-541	
	5977089	Jul 25, 2017	DS DP		U-248	
	5977089	Jul 25, 2017	DS DP		U-1170	
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	DP		U-1170	
	6043230	Jul 25, 2017	DP		U-248	
	6043230	Jul 25, 2017	DP		U-541	
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020			U-541	
	6642245	Nov 04, 2020			U-1170	
	6642245	Nov 04, 2020			U-248	
<u>EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE</u>						
A090870 001					PC	Oct 29, 2011
<u>EPINEPHRINE - EPIPEN</u>						
N019430 001	8048035	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N019430 002	8048035	Sep 11, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	>A> 5690960	Nov 25, 2014	DP U-729		NPP	Feb 27, 2011
	>A> 5690960	Nov 25, 2014	DP U-773		PED	Aug 27, 2011
	>A> 5690960	Nov 25, 2014	DP U-1207			
	>A> 5690960*PED	May 25, 2015				
	>A> 5714504	Feb 03, 2015	DP U-1207			
	>A> 5714504	Feb 03, 2015	DP U-729			
	>A> 5714504	Feb 03, 2015	DP U-773			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5900424	May 04, 2016	DS U-773			
	>A> 5900424	May 04, 2016	DS U-729			
	>A> 5900424	May 04, 2016	DS U-1207			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1207			
	>A> 6369085	May 25, 2018	DS DP U-729			
	>A> 6369085	May 25, 2018	DS DP U-773			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1207			
	>A> 6428810	Nov 03, 2019	DP U-729			
	>A> 6428810	Nov 03, 2019	DP U-773			
	>A> 6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	>A> 5690960	Nov 25, 2014	DP U-729		NPP	Feb 27, 2011
	>A> 5690960	Nov 25, 2014	DP U-773		PED	Aug 27, 2011
	>A> 5690960	Nov 25, 2014	DP U-1207			
	>A> 5690960*PED	May 25, 2015				
	>A> 5714504	Feb 03, 2015	DP U-1207			
	>A> 5714504	Feb 03, 2015	DP U-729			
	>A> 5714504	Feb 03, 2015	DP U-773			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5900424	May 04, 2016	DS U-773			
	>A> 5900424	May 04, 2016	DS U-729			
	>A> 5900424	May 04, 2016	DS U-1207			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1207			
	>A> 6369085	May 25, 2018	DS DP U-729			
	>A> 6369085	May 25, 2018	DS DP U-773			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1207			
	>A> 6428810	Nov 03, 2019	DP U-729			
	>A> 6428810	Nov 03, 2019	DP U-773			
	>A> 6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001					M-86 PED	Jun 18, 2012 Dec 18, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
A078965 001					PC	Sep 21, 2011
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019				
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Dec 13, 2020	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					ODE	May 05, 2018
					ODE	Oct 29, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-638 ODE ODE	May 05, 2014 May 05, 2018 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019			I-638 NCE ODE ODE	May 05, 2014 Mar 30, 2014 May 05, 2018 Oct 29, 2017
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016		U-653		
	5424286	Dec 01, 2016		U-1108		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016		U-653		
	5424286	Dec 01, 2016		U-1108		
<u>EZETIMIBE - ZETIA</u>						
N021445 001	5846966	Sep 21, 2013		U-474		
	5846966	Sep 21, 2013		U-473		
	5846966	Sep 21, 2013		U-1172		
	7612058	Jan 25, 2022		U-1173		
	7612058	Jan 25, 2022		U-1027		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-1173			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZOGABINE - POTIGA</u>						
N022345 001					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 002					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 003					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 004					NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-98	Jan 31, 2014
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001	8067033	Jul 18, 2026	DP		NC	Apr 23, 2014
	8067451	Jul 18, 2026	DP U-1196			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 007	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N020872 006	5578610	Nov 26, 2013	DS DP			U-1160
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015		DP		
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015		DP		
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017				U-1160
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015		DP		
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012				U-1160
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012				U-1160
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS			U-1160
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N021909 003	5578610	Nov 26, 2013	DS DP			U-1158
	5738872	Feb 28, 2015		DP		
	6037353	Mar 14, 2017				U-1158
	6187791	May 11, 2012				U-1158
	6399632	May 11, 2012				U-1158
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N201373 002	5578610	Nov 26, 2013	DS DP			U-1157
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017				U-1157
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012				U-1157
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012				U-1157
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION									
N020786 002	5578610	Nov	26, 2013	DS	DP	U-1159			
	5578610*PED	May	26, 2014						
	5855912	Feb	28, 2015		DP				
	5855912*PED	Aug	28, 2015						
	6037353	Mar	14, 2017			U-1159			
	6037353*PED	Sep	14, 2017			U-138			
	6039974	Jul	31, 2018		DP				
	6113942	Feb	28, 2015		DP				
	6113942*PED	Aug	28, 2015						
	6187791	May	11, 2012			U-1159			
	6187791*PED	Nov	11, 2012			U-138			
	6399632	May	11, 2012			U-1159			
	6399632*PED	Nov	11, 2012			U-468			
	7135571	May	18, 2014	DS		U-1159			
	7135571*PED	Nov	18, 2014						
	7138524	May	18, 2014	DS					
	7138524*PED	Nov	18, 2014						
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION									
N021704 002	5578610	Nov	26, 2013	DS	DP	U-1159			
	5578610*PED	May	26, 2014						
	6037353	Mar	14, 2017			U-1159			
	6037353*PED	Sep	14, 2017						
	6187791	May	11, 2012			U-1159			
	6187791*PED	Nov	11, 2012						
	6399632	May	11, 2012			U-1159			
	6399632*PED	Nov	11, 2012						
	6613357	Dec	25, 2020		DP	U-1159			
	7138524	May	18, 2014	DS					
	7138524*PED	Nov	18, 2014						
	RE39069	May	29, 2018		DP				
FIDAXOMICIN - DIFICID									
N201699 001	7378508	Jul	31, 2027	DS	DP		NCE	May	27, 2016
	7863249	Jul	31, 2027	DS	DP				
	7906489	Mar	04, 2027			U-319			
FINGOLIMOD - GILENYA									
N022527 001							M-106	Jul	20, 2014
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA									
N021112 001	7915243	Mar	22, 2026		DP				
	7939516	May	04, 2025		DP				
FLUTICASONE PROPIONATE - FLOVENT HFA									
N021433 001	6315173	Dec	23, 2017		DP				
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ									
N021211 001	7446090	Aug	23, 2019		DP		D-133	Aug	22, 2014
	7563763	Aug	23, 2019			U-993			
	7563763	Aug	23, 2019			U-1183			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	7446090	Aug 23, 2019	DP		D-133	Aug 22, 2014
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001	>A> 6436989	Dec 24, 2017	DS DP U-257			
	>A> 6436989*PED	Jun 24, 2018				
	>A> 6514953	Jul 15, 2019	DS DP U-257			
	>A> 6514953*PED	Jan 15, 2020				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001	>A> 6436989	Dec 24, 2017	DS DP U-257			
	>A> 6436989*PED	Jun 24, 2018				
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 001	5691336	Mar 04, 2019	DS DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5691336	Mar 04, 2019	DS DP			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Aug 07, 2018	DS DP U-945			
	6872838	Aug 07, 2018	DS			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
<u>GABAPENTIN - GABAPENTIN</u>						
A078974 001					PC	Aug 22, 2011
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
	8026279	Nov 10, 2016	DS DP			
	8048917	Nov 06, 2022	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	>A> 6818787	Nov 06, 2022	DS DP		>A> NCE	Apr 06, 2016
	>A> 8026279	Nov 10, 2016	DS DP			
	>A> 8048917	Nov 06, 2022	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
	8017105	May 26, 2015	DS			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
	8017105	May 26, 2015	DS			
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 001					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 002					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A079183 001					PC	May 14, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 001	>A> 8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N021925 002	>A> 8071130	Jun 08, 2028	DP			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 003					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004					M-102	Apr 29, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004					I-635	Feb 25, 2014
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N022058 001	8062652	Jun 16, 2026	U-1197			
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N022076 001	7981877	Jan 23, 2025	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N022150 001	5648333	Jul 15, 2014	DS DP U-1187		NCE ODE	Aug 25, 2016 Aug 25, 2018
<u>ILOPERIDONE - FANAPT</u>						
N022192 001	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 002	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 003	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 004	RE39198	Nov 15, 2016	DS DP U-971			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N022192 005	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 006	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N022192 007	RE39198	Nov 15, 2016	DS DP U-971			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					I-636	Mar 24, 2014
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002					NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015			U-1125	
	5776894	Jul 07, 2015	DS DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	7918833	Sep 23, 2027	DP			
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001					NCE	Jan 14, 2016
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958		PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-959		NCE	Oct 16, 2012
	6670384*PED	Jul 23, 2022			PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958		PED	Apr 16, 2013
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>KETOCONAZOLE - KETOCONAZOLE</u>						
A091550 001					PC	Feb 21, 2012
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338	May 24, 2027	U-1181			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 001					>A> I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 002					>A> I-644	Apr 15, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 003					>A> I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 004					>A> I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 005					>A> I-644	Apr 25, 2014
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N022115 006					>A> I-644	Apr 25, 2014
					>A> I-622	Jan 29, 2013
					>A> NDF	May 29, 2012
					>A> PED	Nov 29, 2012
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005					>A> ODE	Jun 29, 2013
					>A> ODE	Dec 27, 2012
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 003	6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 002					M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 005					M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 006					M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 007	5575987	Sep 02, 2013	DP		NP	Aug 15, 2014
	5631020	May 20, 2014	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N020263 008	5480656	Jan 02, 2013	DP		NP	Aug 15, 2014
	5575987	Sep 02, 2013	DP			
	5631020	May 20, 2014	DP			
	5643607	Jul 01, 2013	DP			
	5716640	Sep 02, 2013	DP			
	6036976	Dec 13, 2016	DP			
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091093 001					PC	Mar 10, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091093	002				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091261	002				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091285	001				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091285	002				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091291	002				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091399	001				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091399	002				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091430	001				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091430	002				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091557	001				PC	Mar 10, 2012
<u>LEVETIRACETAM - LEVETIRACETAM</u>						
A091557	002				PC	Mar 10, 2012
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140	001				I-637 ODE	Apr 29, 2014 Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140	002	6500829	Dec 31, 2019	DS DP	I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140	003	6500829	Dec 31, 2019	DS DP	I-637 ODE ODE	Apr 29, 2014 Apr 29, 2018 Mar 07, 2015
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280	001	6303661	Apr 24, 2017	U-774	NCE	May 02, 2016
		6890898	Feb 02, 2019	U-493		
		7078381	Feb 02, 2019	U-493		
		7407955	Aug 12, 2023	DS DP		
		7459428	Feb 02, 2019	U-493		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906	001	8025899	Sep 26, 2027	DP		
		8025899*PED	Mar 26, 2028			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906	002	8025899	Sep 26, 2027	DP		
		8025899*PED	Mar 26, 2028			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738	001				NDF PED	Apr 15, 2014 Oct 15, 2014
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249	001	6080428	May 27, 2017	U-1133		
		6080428	May 27, 2017	U-1134		
		6080428	May 27, 2017	U-447		
		6080428	May 27, 2017	U-1132		
		6129930	Sep 20, 2013	DP U-1132		
		6129930	Sep 20, 2013	DP U-1133		
		6129930	Sep 20, 2013	DP U-1134		
		6129930	Sep 20, 2013	DP U-448		
		6469035	Mar 15, 2018	U-768		
		6469035	Mar 15, 2018	U-1129		
		6469035	Mar 15, 2018	U-1130		
		6469035	Mar 15, 2018	U-1131		
		6676967	Sep 20, 2013	U-1133		
		6676967	Sep 20, 2013	U-1134		
		6676967	Sep 20, 2013	U-548		
		6676967	Sep 20, 2013	U-1132		
		6746691	Sep 20, 2013	DP U-586		
		7011848	Sep 20, 2013	U-1135		
		7011848	Sep 20, 2013	U-1136		
		7011848	Sep 20, 2013	U-1137		
		7011848	Sep 20, 2013	U-712		
		7998506	Sep 20, 2013	U-1137		
		7998506	Sep 20, 2013	U-1135		
		7998506	Sep 20, 2013	U-1136		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1132			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1137			
	7998506	Sep 20, 2013	U-1135			
	7998506	Sep 20, 2013	U-1136			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8026393	Oct 25, 2027	DP			
	>A> 8071613	Sep 05, 2020	U-1203			
	>A> 8088934	May 18, 2021	DS			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8026393	Oct 25, 2027	DP			
	>A> 8071613	Sep 05, 2020	U-1202			
	>A> 8088934	May 18, 2021	DS			
<u>MALATHION - OVIDE</u>						
N018613 001	7977324	Aug 14, 2026	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 001	8039009	Mar 24, 2029	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 002	8039009	Mar 24, 2029	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 003	8039009	Mar 24, 2029	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N022525 004	8039009	Mar 24, 2029	U-539			
<u>MESALAMINE - LIALDA</u>						
N022000 001					I-640	Jul 14, 2014
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	7919116	Mar 20, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A090692 001					PC	Mar 28, 2012
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A090692 002					PC	Mar 28, 2012
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	6559158	Nov 03, 2017	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	6559158	Nov 03, 2017	U-1185		NCE	Apr 24, 2013
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	>A> 7790705	Jun 24, 2025	U-1078			
	>A> 7919483	Mar 07, 2027	U-1078			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001	8007830	Oct 24, 2022	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	7671070*PED	Mar 29, 2020				
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>NALTREXONE - VIVITROL</u>						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N021926 001	8022095	Aug 14, 2017	DP U-867			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 002	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 003	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 004	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N021742 005	6545040	Dec 17, 2021	DP U-3			
<u>NELARABINE - ARRANON</u>						
N021877 001	5424295	Jun 13, 2017	DS DP			
<u>NEPAFENAC - NEVANAC</u>						
N021862 001	>A> 8071648	Dec 02, 2025	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1138			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7998506	Sep 20, 2013	U-1141			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6676967	Sep 20, 2013	U-1139			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
	7011848	Sep 20, 2013	U-712			
	7998506	Sep 20, 2013	U-1138			
	7998506	Sep 20, 2013	U-1139			
	7998506	Sep 20, 2013	U-1140			
	7998506	Sep 20, 2013	U-1141			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-862			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-1150			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-862			
	7998506	Sep 20, 2013	U-1151			
	7998506	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
NIACIN; SIMVASTATIN - SIMCOR								
N022078 004	6080428	May	27, 2017	U-862				
	6080428	May	27, 2017	U-1134				
	6080428	May	27, 2017	U-1132				
	6469035	Mar	15, 2018	U-863				
	6469035	Mar	15, 2018	U-1149				
	6469035	Mar	15, 2018	U-1129				
	6676967	Sep	20, 2013	U-862				
	6676967	Sep	20, 2013	U-1134				
	6676967	Sep	20, 2013	U-1132				
	7011848	Sep	20, 2013	U-862				
	7011848	Sep	20, 2013	U-1151				
	7011848	Sep	20, 2013	U-1150				
	7998506	Sep	20, 2013	U-1151				
	7998506	Sep	20, 2013	U-1150				
NIACIN; SIMVASTATIN - SIMCOR								
N022078 005	6080428	May	27, 2017	U-862				
	6080428	May	27, 2017	U-1134				
	6080428	May	27, 2017	U-1132				
	6469035	Mar	15, 2018	U-863				
	6469035	Mar	15, 2018	U-1149				
	6469035	Mar	15, 2018	U-1129				
	6676967	Sep	20, 2013	U-862				
	6676967	Sep	20, 2013	U-1134				
	6676967	Sep	20, 2013	U-1132				
	7011848	Sep	20, 2013	U-862				
	7011848	Sep	20, 2013	U-1151				
	7011848	Sep	20, 2013	U-1150				
	7998506	Sep	20, 2013	U-1151				
	7998506	Sep	20, 2013	U-1150				
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA								
N022068 002	7169791	Jul	04, 2023	DS DP U-836		I-627 NCE ODE	Jun Oct Oct	17, 2014 29, 2012 29, 2014
NITROGLYCERIN - RECTIV								
N021359 001	7189761	May	27, 2014	DP U-1198		NP	Jun	21, 2014
OLANZAPINE - OLANZAPINE								
A076000 001						>A> PC	Apr	21, 2012
OLANZAPINE - OLANZAPINE								
A076000 002						>A> PC	Apr	21, 2012
OLANZAPINE - OLANZAPINE								
A076000 003						>A> PC	Apr	21, 2012
OLANZAPINE - OLANZAPINE								
A076000 004						>A> PC	Apr	21, 2012
OLANZAPINE - OLANZAPINE								
A076000 005						>A> PC	Apr	21, 2012
OLANZAPINE - OLANZAPINE								
A076133 002						>A> PC	Apr	21, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086	001				NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086	002				NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086	003				NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086	004				NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861	001	7977376	Feb 02, 2023	DP		
		7977376*PED	Aug 02, 2023	DP		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	001	5952375	Feb 27, 2015	DS DP		
		5952375*PED	Aug 27, 2015			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	002	5952375	Feb 27, 2015	DS DP		
		5952375*PED	Aug 27, 2015			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087	003	5952375	Feb 27, 2015	DS DP		
		5952375*PED	Aug 27, 2015			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246	001	5763483	Dec 27, 2016	DS	U-376	
		5763483	Dec 27, 2016	DS	U-1113	
		5952375	Feb 27, 2015	DS DP		
		5952375*PED	Aug 27, 2015			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246	002	5763483	Dec 27, 2016	DS DP	U-1113	
		5763483*PED	Jun 27, 2017			
		5866601	Feb 02, 2016	DS DP		
		5866601*PED	Aug 02, 2016			
		5952375	Feb 27, 2015	DS DP		
		5952375*PED	Aug 27, 2015			
<u>OXYBUTYNIN - ANTUROL</u>						
N202513	001				>A> NP	Dec 07, 2014
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080	001	7201920	Mar 16, 2025	DP		
		7510726	Nov 26, 2023	DP		
		7981439	Nov 26, 2023	DP		
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080	002	7201920	Mar 16, 2025	DP		
		7510726	Nov 26, 2023	DP		
		7981439	Nov 26, 2023	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	>A> 8075872	Nov 20, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	>A> 8075872	Nov 20, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	>A> 8075872	Nov 20, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	>A> 8075872	Nov 20, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	>A> 8075872	Nov 20, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	>A> 8075872	Nov 20, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	>A> 8075872	Nov 20, 2023	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005	5254556	Oct 27, 2012	DS DP U-543			
	5254556*PED	Apr 27, 2013				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	7947724	Jan 30, 2024		DP		
	7947725	Jan 30, 2024		DP		
	7960424	Jan 30, 2024		DP		
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	7947724	Jan 30, 2024		DP		
	7947725	Jan 30, 2024		DP		
	7960424	Jan 30, 2024		DP		
<u>PARICALCITOL - ZEMPLAR</u>						
N020819 001	5597815	Jul 13, 2015		U-1195		
	5597815*PED	Jan 13, 2016				
<u>PARICALCITOL - ZEMPLAR</u>						
N020819 002	5597815	Jul 13, 2015		U-1195		
	5597815*PED	Jan 13, 2016				
<u>PARICALCITOL - ZEMPLAR</u>						
N021606 001	5597815	Jul 13, 2015		U-1195		
	5597815*PED	Jan 13, 2016				
<u>PARICALCITOL - ZEMPLAR</u>						
N021606 002	5597815	Jul 13, 2015		U-1195		
	5597815*PED	Jan 13, 2016				
<u>PARICALCITOL - ZEMPLAR</u>						
N021606 003	5597815	Jul 13, 2015		U-1195		
	5597815*PED	Jan 13, 2016				
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427 001					PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013		DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 001	6149938	Jul 23, 2018		DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 002	6149938	Jul 23, 2018		DP		
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023		DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 006	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 007	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 001	5288726	Apr 14, 2017	DS DP U-991			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N022307 002	5288726	Apr 14, 2017	DS DP U-991			
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N020815 001	8030330	Mar 10, 2017	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP		>A> NPP	Dec 21, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001					>A> NDF	Dec 21, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002					>A> NDF	Dec 21, 2014
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP	Y		
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	>A> 6403567	Apr 10, 2022	DS DP U-869			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIBAVIRIN - COPEGUS</u>						
N021511 001					NPP	Aug 09, 2014
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			
<u>RITONAVIR - NORVIR</u>						
N020659 001	5635523	Jul 30, 2013	U-190			
	5635523*PED	Jan 30, 2014				
	5674882	Jul 30, 2013	U-688			
	5674882*PED	Jan 30, 2014				
<u>RITONAVIR - NORVIR</u>						
N020945 001	5635523	Jul 30, 2013	U-347			
	5635523*PED	Jan 30, 2014				
	5674882	Jul 30, 2013	U-895			
	5674882*PED	Jan 30, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>RITONAVIR - NORVIR</u>								
N022417 001	5635523	Jul	30, 2013	U-688				
	5635523*PED	Jan	30, 2014					
	5674882	Jul	30, 2013	U-688				
	5674882*PED	Jan	30, 2014					
<u>RIVAROXABAN - XARELTO</u>								
N022406 001	7157456	Feb	08, 2021	DS DP		NCE	Jul	01, 2016
	7585860	Dec	11, 2020	DS				
	7592339	Dec	11, 2020	U-1167				
<u>RIVAROXABAN - XARELTO</u>								
N202439 001	7157456	Feb	08, 2021	DS DP		I-643	Nov	04, 2014
	7585860	Dec	11, 2020	DS		NCE	Jul	01, 2016
	7592339	Dec	11, 2020	U-1200				
	7592339	Dec	11, 2020	U-1167				
<u>RIVAROXABAN - XARELTO</u>								
N202439 002	7157456	Feb	08, 2021	DS DP		I-643	Nov	04, 2014
	7585860	Dec	11, 2020	DS		NCE	Jul	01, 2016
	7592339	Dec	11, 2020	U-1200				
	7592339	Dec	11, 2020	U-1167				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>								
N020864 001	>A> 5298520	Jun	29, 2012	DS DP U-240		>A> NPP	Dec	15, 2014
	5298520*PED	Dec	29, 2012			>A> PED	Jun	15, 2015
	5602162	Feb	11, 2014		Y			
	5602162*PED	Aug	11, 2014					
<u>RIZATRIPTAN BENZOATE - MAXALT</u>								
N020864 002	>A> 5298520	Jun	29, 2012	DS DP U-240		>A> NPP	Dec	15, 2014
	5298520*PED	Dec	29, 2012			>A> PED	Jun	15, 2015
	5602162	Feb	11, 2014		Y			
	5602162*PED	Aug	11, 2014					
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>								
N020865 001	5298520	Jun	29, 2012	DS DP U-240		>A> NPP	Dec	15, 2014
	5298520*PED	Dec	29, 2012			>A> PED	Jun	15, 2015
	>A> 5457895	Oct	01, 2013	DP				
	5457895*PED	Apr	01, 2014					
	5602162	Feb	11, 2014	U-240	Y			
	5602162*PED	Aug	11, 2014					
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>								
N020865 002	5298520	Jun	29, 2012	DS DP U-240		>A> NPP	Dec	15, 2014
	5298520*PED	Dec	29, 2012			>A> PED	Jun	15, 2015
	>A> 5457895	Oct	01, 2013	DP				
	5457895*PED	Apr	01, 2014					
	5602162	Feb	11, 2014	U-240	Y			
	5602162*PED	Aug	11, 2014					
<u>ROFLUMILAST - DALIRESP</u>								
N022522 001	5712298	Jan	27, 2015	DS DP U-1115		NCE	Feb	28, 2016
<u>ROMIDEPSIN - ISTODAX</u>								
N022393 001	4977138	Jul	06, 2012	DS DP		ODE	Jun	16, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	7927624	Dec 02, 2021	DP U-20			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	7030152	Apr 02, 2018	U-1032			
	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 005	7030152*PED	Oct 02, 2018				
	7964614	Apr 02, 2018	U-1032			
	7964614*PED	Oct 02, 2018				
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	6740669	Nov 14, 2022	DS DP			
	>A> 8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	6740669	Nov 14, 2022	DS DP			
	>A> 8076362	Jun 08, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	6740669	Nov 14, 2022	DS DP			
	>A> 8076362	Jun 08, 2018	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 001	7598257	Dec 24, 2027	DS DP U-1201		NCE ODE	Nov 16, 2016 Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 002	7598257	Dec 24, 2027	DS DP U-1201		NCE ODE	Nov 16, 2016 Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 003	7598257	Dec 24, 2027	DS DP U-1201		NCE ODE	Nov 16, 2016 Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 004	7598257	Dec 24, 2027	DS DP U-1201		NCE ODE	Nov 16, 2016 Nov 16, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N202192 005	7598257	Dec 24, 2027	DS DP U-1201		NCE ODE	Nov 16, 2016 Nov 16, 2018
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	7947681	Nov 17, 2024		U-1156		
	8003126	Nov 16, 2025				
	8067416	Nov 17, 2024		U-989		
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	7951400	Nov 30, 2028	DP		>A> M-108	Dec 16, 2013
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	7951400	Nov 30, 2028	DP		>A> M-108	Dec 16, 2013
<u>SEVELAMER CARBONATE - RENVELA</u>						
N022127 001	7985418	Oct 27, 2025	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	6303661	Apr 24, 2017		U-1188		
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019		U-1191		
	6890898	Feb 02, 2019		U-1190		
	6890898	Feb 02, 2019		U-1189		
	7078381	Feb 02, 2019		U-1188		
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
<u>SINECATECHINS - VEREGEN</u>						
N021902 001	7858662	Oct 02, 2026	DP U-172			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N201444 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7897623	Jan 12, 2020	DP			
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>TADALAFIL - CIALIS</u>						
N021368 001	6140329	Jul 11, 2016	DP U-155		I-642	Oct 07, 2014
	6140329	Jul 11, 2016	DP U-1184		I-641	Oct 07, 2014
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
<u>TADALAFIL - CIALIS</u>						
N021368 002					I-642	Oct 07, 2014
					I-641	Oct 07, 2014
<u>TADALAFIL - CIALIS</u>						
N021368 003					I-642	Oct 07, 2014
					I-641	Oct 07, 2014
<u>TADALAFIL - CIALIS</u>						
N021368 004					I-642	Oct 07, 2014
					I-641	Oct 07, 2014
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 001	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> 8075872	Nov 20, 2023	DP			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> 8075872	Nov 20, 2023	DP			
	RE39593	Aug 05, 2022	DS DP U-1178			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> 8075872	Nov 20, 2023	DP			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> 8075872	Nov 20, 2023	DP			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	6071970	Jun 06, 2017	U-1178		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178		NCE	Nov 20, 2013
	>A> 8075872	Nov 20, 2023	DP			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N019882 001	5573748	Nov 12, 2013	DP			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001	>A> 7820671	Feb 25, 2025	DS DP		NCE	May 23, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TELMISARTAN - MICARDIS</u>						
N020850 002	7998953	Jun 06, 2020	U-1177			
	8003679	Oct 06, 2022	U-1176			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	8026276	Jan 20, 2026	DP			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-250		I-569	Aug 11, 2011
	5922695	Jul 25, 2017	DS U-256		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-250		PED	Feb 11, 2012
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 003					NS	Oct 20, 2014
<u>TESTOSTERONE - ANDRODERM</u>						
N020489 004					NS	Oct 20, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
<u>TESTOSTERONE - AXIRON</u>						
N022504 001	8071075	Feb 19, 2017	DP U-1103			
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>TICAGRELOR - BRILINTA</u>						
N022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 001	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 002	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N021745 003	7988998	Oct 27, 2023	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 001	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 002	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 003	7999007	Mar 29, 2029	DP U-1174			
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
N021272 004	7999007	Mar 29, 2029	DP U-1174			
<u>TRIAMCINOLONE ACETONIDE - NASACORT AQ</u>						
N020468 001	7977045	Jul 03, 2016	DP U-896			
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	>A> 8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Sep 23, 2017	DS DP			
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	>A> 8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Sep 23, 2017	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001					M-105	Jul 22, 2014
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002					M-105	Jul 22, 2014
<u>VEMURAFENIB - ZELBORAF</u>						
N020429 001	7504509	Oct 22, 2026	DS DP		NCE	Aug 17, 2016
	7863288	Jun 20, 2029	DS DP		ODE	Aug 17, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	7652069	Mar 04, 2023	DP			
	>A> 8067472	Mar 04, 2023	U-892			
	RE38506	Nov 29, 2012	DS DP			
<u>ZILEUTON - ZYFLO CR</u>						
N022052 001	>A> 6183778	Sep 21, 2013	DP			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
	8052987	Mar 19, 2024	U-1199			
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	4939130	Sep 02, 2012	DS DP U-53			
	4939130*PED	Mar 02, 2013				
	7932241	Feb 05, 2028	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>